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ABSTRACT  
   
A variety of studies have shown that the tendency toward nicotine dependence has 
a genetic component. The work described in this thesis addresses three separate 
questions: i) are there unidentified SNPs in the nicotinic receptors or other genes that 
contribute to the risk for nicotine dependence; ii) is there evidence of ongoing selection at 
nicotinic receptor loci; and, iii) since nicotine dependence is unlikely to be the phenotype 
undergoing selection, is a positive effect on memory or cognition the selected phenotype. 
I first undertook a genome-wide association scan of imputed data using samples from the 
Collaborative Study of the Genetics of Nicotine Dependence (COGEND). A novel 
association was found between nicotine dependence and SNPs at 13q31. The genes at this 
newly associated locus on chromosome 13 encode a group of micro-RNAs and a member 
of the glypican gene family. These are among the first findings to implicate a non-
candidate gene in risk for nicotine dependence. I applied several complimentary methods 
to sequence data from the 1000 Genomes Project to test for evidence of selection at the 
nicotinic receptor loci. I found strong evidence for selection for alleles in the nicotinic 
receptor cluster on chromosome 8 that confer risk of nicotine dependence. I then used the 
dataset from the Collaborative Studies on the Genetics of Alcoholism (COGA) and 
looked for an association between neuropsychological phenotypes and SNPs conferring 
risk of nicotine dependence. One SNP passed multiple test correction for association with 
WAIS digit symbol score. This SNP is not itself associated with nicotine dependence but 
is in reasonable (r2 = 0.75) LD with SNPs that are associated with nicotine dependence. 
These data suggest at best, a weak correlation between nicotine dependence and any of 
the tested cognitive phenotypes. Given the reproducible finding of an inverse relationship 
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between SNPs associated with risk for nicotine dependence and cocaine dependence, I 
hypothesize that the apparently detrimental phenotype of nicotine dependence may confer 
decreased risk for cocaine dependence. As cocaine use impairs the positive rewards 
associated with social interactions, reducing the risk of cocaine addiction may be 
beneficial to both the individual and the group. 
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CHAPTER 1 
INTRODUCTION 
THE PUBLIC HEALTH IMPACT OF TOBACCO USE ACROSS POPULATIONS 
 Drug addiction is a pervasive problem across cultures and is both an economic 
and psychological struggle for the individuals and families involved. Today, tobacco use 
and the diseases resulting from its use are the number one cause of preventable deaths in 
the United States, accounting for approximately one out of every five deaths annually 
(Garrett, 2009).  In fact, tobacco use is the single largest preventable cause of death and 
disease in the world today (WHO, 2011).  Recent studies estimate that 6 million people 
die due to tobacco related illnesses every year and this figure will increase to 8.3 million 
deaths by 2030, possibly even increasing to 1 billion deaths in the 21st century (Mathers, 
2012). 
 The health impact of smoking takes many forms.  More people die from lung 
cancer each year than from any other type of cancer (ACS, 2009).  It is estimated that 15-
30% of lung cancer cases are linked to smoking, although smoking can cause cancer 
almost anywhere in the body (CDC, 2013). Even among those who quit smoking, there is 
an elevated risk of lung cancer, although this risk is less than in those who do not quit 
(Huang et al., 2008).  Smoking also increases risk of stroke and coronary heart disease.  
For women, smoking can make it more difficult to conceive, and increase the risk of 
preterm birth, low birth weight and stillbirth, although it also affects men’s sperm (CDC, 
2013).  Smoking affects things like bone density, teeth and gum health, and make 
diabetes harder to control (CDC, 2013). Chronic obstructive pulmonary disease (COPD), 
a serious lung disease often caused by smoking, is also among the leading causes of death 
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(N. L. Saccone, Culverhouse, et al., 2010).  People who begin smoking when they are 
young are at higher risk of smoking related complications in middle age, and almost half 
of adolescents who initiate tobacco use will likely die from causes related to tobacco use 
(Arora, Mathur, & Singh, 2013).  For children exposed to tobacco smoke in utero either 
through maternal smoking or second hand smoke, there is a risk of increased respiratory 
complications and decreased lung function, as well as increased risk of cancers and heart 
disease (Svanes et al., 2004). 
 The World Health Organization reports a wide distribution of smoking rates 
across nations.  For example, Senegal has only a 4.6% rate of adult smoking, and Haiti 
only 9.7%, while Argentina has a rate of 40.4% and Turkey has a rate of 44% (WHO, 
2011).  Regionally, as of 2004, 3% of all deaths in Africa were attributable to tobacco, 
while 16% of all deaths in European countries were attributable to tobacco (Mathers, 
2012). 
 Tobacco burden is increasing disproportionately in low and middle-income 
countries.  The WHO estimates that within a few decades, more than 80% of tobacco-
related deaths will occur in the developing world (Mathers, 2012).  This increase in the 
developing world is due, in part, to consumption of both cigarettes and smokeless forms 
of tobacco.  For example in Mumbai, India, 56% of women chew tobacco (Mackay, 
2002) while only approximately 6% of adults, both men and women, smoke cigarettes 
(Mitchell, 2011).  The increased prevalence of smokeless tobacco in India relative to 
cigarettes is due to cultural reasons.  The most common form of smokeless tobacco use in 
India is betel quid chewing.  Betel quid chewing is an ancient practice that has always 
been a part of religious, social, and cultural rituals.  Originally, betel quid consisted of 
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betel leaf, pieces of areca nut, a few drops of lime (calcium hydroxide), several 
condiments, sweetening, and flavoring agents.  After tobacco was introduced in India in 
the 17th century, it became an ingredient of the betel quid. Because it is associated with a 
socially accepted practice, smokeless tobacco use became widespread  (NCI, 2010).   
Rates of dependence are different between smokers and users of chewing tobacco.  
Among smokers, ~22% are not addicted, ~33% show moderate symptoms of addiction, 
and ~44% show high levels of addiction (Bierut et al., 2007).  With smokeless tobacco, 
rates of subjective dependence based on questionnaires seem similar to those of smoking, 
with the notable difference that smokeless tobacco users found their habit more enjoyable 
than smokers, and rated enforced abstinence as more unpleasant (Jarvis, 1991).  Thus it is 
clear that cultural and ethnic differences play a role in the use and likely the dependence 
on nicotine. 
 In addition to cultural traditions, the wide variety of smoking and smokeless 
tobacco products available in low and middle-income countries make tobacco a very 
accessible commodity for adolescents.  This leads to a high rate of smoking in the young.  
Approximately 80,000−100,000 adolescents initiate smoking every day and the WHO 
estimates that 25% of smokers had their first cigarette before age 10 (Mackay, 2002)  
Some children begin as young as 6 years of age as documented in a study in India (Arora 
et al., 2013).   
 Approximately 1 billion men worldwide are smokers, though this number is 
slowly declining (Mackay, 2002).  Among male smokers, 35% live in developed 
countries and 50% live in developing countries.  Approximately 250 million women 
smoke or about 1 out of every 5 smokers worldwide (Mackay, 2002).  Among women, 
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smoking is declining in developed countries but it is still increasing in developing 
countries.  This is due in part to the tobacco industry promoting certain brands 
specifically to women through images of slimness or sophistication (Mackay, 2002).  The 
effects of these trends have become apparent in low and middle-income countries where 
one study found a much smaller than expected difference in the prevalence of smoking 
between boys and girls in India (Babar et al., 2010).   
 In the United States, there are significant ethnic differences in the rates of 
cigarette smoking.  American Indians have the highest rate of smoking of any ethnic or 
minority group.  American Indian males have a smoking rate of 42.4%, and American 
Indian females have a smoking rate of 42%. Among youth 12-17 years old, the rates of 
smoking are highest among American Indian females (17.8%), followed by American 
Indian males (16.7%), white females (12.4%), and white males (11.3%).  Among black 
youth, the values are 5.6% for females and 6.1% for males, indicating that on average, 
white youth smoke more than black youth and females smoke more than males.  By 
adulthood, these trends are reversed so that by cohort, there are higher rates of smoking 
in males than females and higher rates in blacks than whites. Other at risk groups include 
persons of low socio-economic status, persons with mental health and substance abuse 
issues, the gay/lesbian/transgender community, and persons living in the South and 
Midwest United States (Garrett, 2009). 
 As will be discussed below, the observed population and ethnic differences in 
rates of smoking and addiction can be partially explained by genetic differences. The fact 
that smoking is so prevalent and that it is highly comorbid with other disorders such as 
mental illness, heart disease and lung cancer, places a heavy health burden on the 
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community, particularly among poorer communities.  Not surprisingly, cessation rates 
also vary by ethnicity. In a 2010 survey, 68% of current smokers expressed a desire to 
quit, and 52.4% had made a quit attempt in the past year.  People over 65 had less desire 
to quit (53.8%) than those under 65 (70.2%). When broken down by ethnicity, blacks had 
the most interest in quitting (75.6%), followed by whites (69.1%), then persons of other 
or mixed race (62.5%), and lastly Hispanics (61.0%) (Malarcher, 2011). Overall this 
same survey showed that a recent cessation was most prevalent in whites (6%) than 
blacks (3.3%). Thus, although blacks had a higher rate of a desire to quit, they have lower 
rates of cessation.  Illustrating just how difficult it is to quit smoking when addicted, one 
study found that pregnant women with the minor allele at rs1051730, a SNP in the 
CHRNA5-A3-B4 cluster, in have an increased likelihood of continuing to smoke during 
pregnancy, a time when most women are more likely to quit than any other time in their 
lives (Freathy et al., 2009).  Since so many more people try to quit than actually succeed, 
there is a definite need for intervention programs focused both on prevention and 
treatment.  It is therefore important to understand the genetic basis for nicotine 
dependence to aid in population specific treatment and prevention programs. 
 
EVIDENCE FOR A GENETIC BASIS FOR ADDICTION 
 A variety of approaches have been used to demonstrate that addiction, to any of a 
number of substances, has a genetically heritable basis.  These approaches range from 
traditional family or twin studies to more molecularly-based studies that employ 
population genetics and genome sequencing to identify susceptibility loci.  The 
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application of these different approaches to studies of the genetic basis of addiction are 
discussed below. 
Family/Twin/Adoption studies of addiction.  Differences in any trait must be 
due to either genetic or environmental factors or both. Family studies are one way in 
which the relative contributions of genes and environment to phenotypic variability can 
be measured.  The idea behind family studies is that trait similarities among relatives 
(typically parent/offspring or between siblings) must be due to shared genes or 
environment.   By comparing the phenotypic similarities across relatives with varying 
degrees of relatedness, the relative contribution of genes and environment to the 
phenotype can be inferred.  
 Family studies have shown significantly higher rates of drug abuse among 
siblings (especially those with affected parents) than in the general population.   
Merikangas et al. (Merikangas et al., 1998) interviewed drug-dependent individuals and 
their first-degree relatives.  They found an 8-fold increase in the risk of drug dependence 
among the relatives of drug-dependent individuals compared to controls, indicating that 
family history represents a major risk factor for developing substance dependence.  This 
familial aggregation applies to both generalized substance abuse as well as specific drugs 
(Gelernter & Kranzler, 2010).  For example, one study found that the rates of alcohol, 
tobacco, marijuana and cocaine dependence were increased in the siblings of alcoholics 
as compared to controls (Bierut et al., 1998).   The authors concluded that these 
dependencies are familial and that they are due to both common and specific additive 
factors.  This means that these individuals have a genetically increased risk for substance 
dependence in general but also have an increased susceptibility to addiction to a specific 
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substance.   Although family studies are consistent with the idea of a genetic component 
in addiction phenotypes, they cannot fully disentangle genetics from environment. 
 Unlike family studies, twin and adoption studies can distinguish between the 
effects of genes and environment on phenotypes.  A common study design is to compare 
identical and fraternal twins reared together.  Identical (monozygotic) twins share all of 
their genes and the same family environment.  Fraternal (dizygotic) twins share half of 
their genetic inheritance, but like monozygotic twins, they share the same family 
environment.   Therefore, if monzygotic twins are phenotypically more similar for the 
trait of interest than dizygotic twins, it can be assumed that this is due to the fact that 
monozygotic twins share twice as much genetic material as dizygotic twins.  The 
heritability of a phenotype can be estimated from the difference between the correlation 
of the monozygotic twins with the phenotype and the correlation of the dizygotic twins 
with the phenotype (Nagoshi, 2011). 
 Supporting the findings from family studies, twin studies have found that 
addiction has a genetic basis.  As far back as 1958, it was reported in a German 
population, that the concordance for smoking was significantly higher in monozygotic 
male twin pairs than in dizygotic male twin pairs (Fisher, 1958).  This finding was 
subsequently replicated in twin studies in Finland and Sweden (Kaprio et al., 1982), the 
United States ((Carmelli, Swan, Robinette, & Fabsitz, 1990; Edwards, Austin, & Jarvik, 
1995; Kendler et al., 1999), and Australia (Heath et al., 1993).  
 Twin studies with larger sample sizes have found significant genetic influences on 
specific aspects of smoking behavior.   For example, (Heath & Martin, 1993) found that 
53% of the variance in smoking persistence, defined as whether or not a smoker quits 
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smoking, was accounted for by genetic factors.  In that same cohort, age of initiation was 
also strongly influenced by genetic factors (Heath, Kirk, Meyer, & Martin, 1999).  A 
meta-analysis of several twin studies also identified a role for genetics in the initiation of 
smoking but found a smaller role for genetics on dependence in females than in males 
(M. D. Li, Cheng, Ma, & Swan, 2003).  As was true in the family studies, twin studies 
have found evidence for a genetic basis for multiple substance abuse or dependency.  
Tsuang et al. (Tsuang et al., 1998) found that among 3372 male twin pairs, abuse of one 
drug was associated with a significant increase in abuse of other drugs than in the general 
population.  Twin studies are useful because they can provide an estimate of the 
heritability of a phenotype, however they are still unable to adequately separate the 
effects of genetics and environment.  To do this, one must use adoption studies. 
 Adoption studies attempt to compare the phenotypic similarities of biological 
parents and their adopted-away children with the phenotypic similarities of adoptive 
parents and their adopted children.  Adoption studies may also compare the phenotypic 
similarities between sibling pairs of which one is adopted and the other is not (Nagoshi, 
2011).   In theory, adoption studies should be able to separate the effects of genetics on 
phenotype from those of shared environment.   
 As with family and twin studies, the results from twin and adoption studies 
support the idea that genetics plays a large role in substance abuse and dependence.  For 
example, King et al. (King et al., 2009) found that the biological children of alcoholics 
had greater rates of alcoholism than the adopted children of alcoholics.  An adoption 
study by Osler et al. (Osler, Holst, Prescott, & Sorensen, 2001) found that the main 
genetic influence on smoking behavior in adult adoptees was within the same generation 
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(i.e. most significant between adopted adults and their biological siblings).  While these 
studies support a role for genetics in addictive behavior, the size of that contribution 
varies in different studies. For nicotine dependence, estimates of heritability have varied 
from 44-72% (Carmelli et al., 1990; Lessov, Swan, Ring, Khroyan, & Lerman, 2004). 
Phenotypes.  There are multiple phenotypes commonly used in the genetic 
studies of nicotine dependence.  The main phenotype is the Fagerström Test of Nicotine 
Dependence (FTND) score.  This questionnaire contains 6 questions, including two 
questions that are out of three points each, for a total possible score of 10 (Figure 1) 
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991). 
 
 Figure 1.  FTND questionnaire.  Note that items 1 (time to first cigarette) and 4 
(cigarettes per day) are worth up to 3 points each. 
 
 FTND score can be used either as an ordinal or dichotomous (case/control) variable.  
Typically a score of 4 or above is counted as a case, and under 4 as a control.   
Importantly, items 1 (time to first cigarette in the morning) and 4 (cigarettes per day) are 
Name:____________________________________              Date:_______________ 
 
 
Fagerstrom Test for Nicotine Dependence (FTND) 
 
 
 0 1 2 3 
1.  How soon after you wake up do 










2.  Do you find it difficult to refrain 
     from smoking in places where 
     it is forbidden, e.g., in church, 











3.  Which cigarette would you hate 
     most to give up? 





4.  How many cigarettes/day do 
     you smoke?  
 
 









5.  Do you smoke more frequently 
     during the first hours of waking 










6.  Do you smoke if you are so ill 
     that you are in bed most of the  
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the two three point questions on the test, and cigarettes per day (CPD) is also often used 
in several studies as the primary phenotype when FTND data are not available.  A person 
is given a CPD score of 0 if they smoke 0-10 cigarettes per day, a score of 1 for 11-20 
cigarettes, 2 for 21-30 cigarettes, and a 3 for over 30 cigarettes per day. 
Table 1.   
DSM-IV dependence criteria 
 
 Another measure of nicotine dependence sometimes used is the DSM-IV criteria.  
Criterion 1 Tolerance, as defined by either of the following:  a) a need for markedly 
increased amounts of the substance to achieve intoxication or the 
designed effect, or b) markedly diminished effect with continued use of 
the same amount of the substance 
Criterion 2 Withdrawal, as manifested by either of the following:  a) the 
characteristic withdrawal syndrome for the substance, or b) the same (or 
a closely related) substance is taken to relieve or avoid withdrawal 
symptoms (4 or more of the following:  depressed or dysphoric mood; 
insomnia; irritability, frustration or anger; anxiety; difficulty 
concentrating; worry or impatience; decreased heart rate, increased 
appetite or weight gain) 
Criterion 3 The substance is often taken in larger amounts or over a longer period 
than was intended 
Criterion 4 There is a persistent desire or unsuccessful efforts to cut down or control 
substance use. 
Criterion 5 A great deal of time is spent in activities necessary to obtain the 
substance, use the substance or recover from its effects 
Criterion 6 Important social, occupational or recreational activities are given up or 
reduced because of substance use. 
Criterion 7 The substance use is continued despite knowledge of having a persistent 
or recurrent physical or psychological problem that is likely to have 
been caused or exacerbated by the substance, 
Specifications With physiological dependence.  This specification should be used when 
substance dependence is accompanied by evidence of tolerance 
(Criterion 1) or withdrawal (Criterion 2) 
Without physiological dependence.  This specification should be used 
when there is no evidence of tolerance (Criterion 1) or withdrawal 
(Criterion 2).  In these subjects substance dependence is characterized 
by a pattern of compulsive use (at least 3 of Criteria 3-7) 
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Dependence is indicated by the presence of 3 or more of the 7 criteria within 12 months 
(Table 1).  Like the FTND, these criteria can either be used as ordinal or dichotomous 
values. When used as ordinal values, this is what is known as DSM-IV symptom count.  
Overall, FTND score is the most comprehensive phenotype, since it includes CPD and 
was designed specifically for nicotine dependence, whereas the DSM-IV criteria are the 
same for all drugs of abuse (cocaine, alcohol, opium, etc.). 
 Candidate Gene Studies.  Once it has been determined that a trait of interest can 
be partially explained by genetic differences between individuals, i.e. that it is heritable, 
the next step is to determine which genes and in particular which genetic variants in or 
near those genes alter an individual’s disease risk.  One approach for identifying 
susceptibility genes is the candidate gene approach.  In these studies, the researcher uses 
knowledge of the pathogenesis of a disease or the likely biological mechanisms 
underlying a trait to select genes that are likely to be associated with the phenotypic 
trait(s) being measured.  For example, the cholinergic nicotinic receptors (CHRNs) were 
chosen for the list of candidate genes for nicotine dependence studies as they are the 
major receptors for nicotine in the central nervous system.  Similarly, drug metabolism 
genes such as CYP2A6 and ADH2 are candidates for nicotine and alcohol dependence 
respectively because of their roles in the metabolism of these drugs.  
 Once a list of genes is created, genotyping is performed on a set of known single 
nucleotide polymorphisms (SNPs) in the genes of interest.  SNPs are single base changes 
in DNA sequence that have previously been identified as genetic variants in a particular 
region in the genome.  SNPs that are in or near the chosen candidate genes are selected 
for sequencing under the assumption that these variants are most likely to affect gene 
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function or alter gene expression or be correlated with SNPs that do.  If there are many 
SNPs in these regions often only one of several highly correlated SNPs will be chosen for 
genotyping.  SNPs are the most abundant form of variation, although there are other types 
such as insertions and deletions (indels), repeats, and copy number variants (CNVs) that 
can be important as well.  Follow-up sequencing of promising candidate genes can 
narrow down the causative SNP(s) as well.  For example, Yu et al. (Yu et al., 2006) 
followed up a study identifying DOPA decarbolayse (DDC) on chromosome 7 by 
genotyping several SNPs in the gene and finding an association with a particular SNP and 
FTND score.  They sequenced this region and discovered that this SNP is in the same 
intron as an intronic splicing enhancer for a neuronal isoform lacking exons 10-15. 
 Candidate gene studies are useful because they facilitate comparison across 
populations by allowing investigators to determine if the same variants are seen within 
and between populations.  They allow for genotyping large numbers of individuals with 
few SNPs to analyze.  In a candidate gene study using FTND as the phenotype, Ma et al. 
(Ma, Payne, Nussbaum, & Li, 2010)analyzed 25 SNPs in the glutamate receptor gene 
(GRIN3A), which regulates ion flow in the brain, using a total of 2,037 individuals from 
602 nuclear families.   They found two SNPs in the pooled European-American and 
African American sample significant after multiple test correction, and one SNP that was 
significant only in the European-American sample.  These data, among other candidate 
gene studies indicate ethnic differences in the genetic basis for nicotine addiction. 
 The candidate gene approach has intrinsic limitations because the studies are 
biased by prior knowledge of the physiological role of the candidate genes in relation to 
the phenotype.  If the biology of the phenotype is not fully understood, it is possible to 
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unintentionally omit genes that are important in explaining the genetics of that 
phenotype.  Therefore, unbiased approaches such as genome-wide linkage and 
association scans have been developed to uncover unpredictable relationships. 
 Linkage Studies of Addiction.  Linkage studies are a genome-wide and unbiased 
method of determining genetic regions contributing to a trait.  In a linkage study, each 
individual is assessed for presence or absence of the phenotype of interest as well as 
presence or absence of genetic markers (DNA sequence that is known to vary in size or 
sequence) with known locations.  The main goal is to link the phenotype with a genetic 
marker close to the disease gene.  If the phenotype of interest consistently co-occurs with 
a particular allele of a genetic marker in a family, then those two traits are not 
independently assorting and must be close to each other on the same chromosome 
(Nagoshi 2011).  Using the primary phenotype of FTND score, Swan et al. (Swan et al., 
2006) discovered a linkage peak on chromosome 6, whose support interval is very close 
to the opioid receptor OPRM1, and includes mitogen-activated protein kinase 4 
(MAP3K4) and lysophosphatidic acid acyltransferase, delta (LPAAT-delta), both 
previously described candidate genes for nicotine dependence (P. F. Sullivan et al., 
2004).  In a study of  368 Dutch sibling pairs, using the phenotype of age at first 
cigarette, Vink et al. (Vink, Posthuma, Neale, Eline Slagboom, & Boomsma, 2006) 
discovered a linkage peak on chromosome 5 encompassing the  dopamine receptor 1 
(DRD1), a known candidate gene for smoking. In a study of 634 pedigrees totaling 2,881 
people, Gelernter et al. (Gelernter et al., 2007) completed a genome-wide linkage scan 
and discovered a risk locus for nicotine dependence on chromosome 5 on the basis of 
FTND score in the region of peptidylglycine alpha-amidating monooxygenase (PAM) and 
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cocaine and amphetamine regulated transcript (CART).  Interestingly, the association 
found by Gelernter et al. (2007) was significant in their African-American sample 
(p=0.001) but not in their European-American sample.  These are just a few examples of 
the many linkage studies on nicotine dependence.  However, an even more precise non-
biased method is the genome-wide association scan. 
 The Power of GWAS Studies.  A genome-wide association scan (GWAS) takes 
advantage of linkage disequilibrium in a population to detect all common single 
nucleotide variations in an individual.   If a SNP on the GWAS chip is associated with a 
disease phenotype in your sample, it could be because that SNP is causing the disease, or 
more likely, the SNP is in linkage disequilibrium with the functional SNP causing the 
disease.  As mentioned previously, linkage disequilibrium is the tendency for two or 
more alleles to be inherited together more often than expected by chance, due to reduced 
genetic recombination (or distance) between them. A GWAS compares DNA variation at 
millions of SNPs in individuals that do (affected) or do not (unaffected) exhibit the trait 
of interest.  The frequency of each SNP is then compared between affected and 
unaffected individuals to determine if there is a significant association between genotype 
and phenotype. Alternatively, quantitative traits may be examined to test for association 
between genotype and the levels of the quantitative trait. 
 To genotype the large number of genetic variants spread out across the genome, 
genotyping microarrays were invented which allow one to genotype millions of SNPs 
simultaneously.  The microarrays are glass slides with immobilized pieces of DNA 
complementary to the DNA immediately 5’ of the SNP position.  The individuals’ DNA 
is hybridized to the microarray and the immobilized DNA probe is extended one base 
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using nucleotides, each of which has a unique fluorescent dye, using the individuals DNA 
as the template.  An individual’s genotype can then be determined based on the 
fluorescent signal at each position on the array.   
 The SNPs on the array are selected such that the majority of common SNPs 
(frequency > 5%) in the genome are either genotyped or in high linkage disequilibrium 
with a genotyped SNP (Visscher, Brown, McCarthy, & Yang, 2012).  The association 
between genotypes obtained from the array and the trait of interest is then determined.  
For example, if one allele of a SNP is found more often in affected individuals than 
unaffected individuals, then it is associated with the disease phenotype.  The p-values that 
are generally accepted for a genome-wide significant association in a GWAS are 
 < 5x10-8.  This is equal to 0.05/1,000,000.  A value of 0.05 is the p-value for significance 
of 1 SNP.   It is divided by 1,000,000 (the standard Bonferroni correction) because it is 
conservatively estimated that there are 1,000,000 independent regions of linkage 
disequilibrium in the genome. This makes the number of samples needed to achieve 
significance large. 
 GWAS have been used to identify novel genetic variants associated with many 
disease phenotypes.  For example, Ripke et al. (Ripke et al., 2013) performed a GWAS 
for schizophrenia and then meta-analyzed their results with those of other GWAS.  They 
were able to identify 13 novel loci genome-wide significantly associated with 
schizophrenia.  In a two-stage meta-analysis of GWAS for Alzheimer’s disease, Lambert 
et al. (Lambert et al., 2013) were able to identify 11 novel loci associated with the disease 
at the genome-wide significant level. Thus, these examples demonstrate that GWAS are 
useful for identifying SNPs associated with the disease phenotype that otherwise would 
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not have been considered.   
 GWAS are largely a discovery tool and are not necessarily meant to capture all 
possible information.  Rather they can be used to give hints as to what genes might be 
important for the trait of interest.  GWAS identify loci which may contain a single gene 
or many genes depending on LD. Recent studies using pathway analyses or co-regulation 
analyses have demonstrated that GWAS genes fall into distinct pathways, providing 
biological insight into the disease even if the functional variant is not identified.  By 
combining family and twin studies with candidate gene studies and GWAS, significant 
progress has been made in identifying genetic factors that contribute to addictive 
behavior in general and to addiction to specific substances in particular.   
 
GENETICS OF NICOTINE DEPENDENCE 
 Candidate gene studies.  The most comprehensive candidate gene study of 
nicotine dependence is that of Saccone et al. (S. F. Saccone et al., 2007).  Here, over 300 
candidate genes and 3713 SNPs were examined in 1050 cases and 879 controls.  The 
strongest association with FTND was a SNP in CHRNB3 (p=9.4x10-5).  Multiple SNPs in 
the CHRNB3-A6 and CHRNA5-A3-B4 clusters were among the top hits, including the on-
synonymous change, rs16969968.  The other two genes with p-values of less than 0.001 
in this study were the potassium inwardly rectifying channel 6 (KCNJ6) and gamma-
aminobutyric acid receptor a4 (GABRA4). 
Because of the enhancing role nicotine has on the actions of dopamine, several 
candidate gene studies have focused on dopamine receptors.  Most drugs of abuse act on 
the mesolimbic dopaminergic neurons in the brains of humans and many other mammals. 
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The neurotransmitter dopamine is involved in neural activity related to motivation, 
emotion, food intake, liking, learning, wanting and cognition.   Activation and 
reinforcement of this system is a necessary part of drug abuse (Koob, 1996).  The 
dopaminergic system is therefore crucial to addiction and it is hypothesized that 
mutations in these pathways are associated with risk for dependence on multiple drugs, 
including nicotine. 
 There are two main dopamine receptor subtypes, DRD1-like and DRD2-like 
receptors.  Linkage scans have associated the DRD1 region with cigarette consumption 
(N. L. Saccone, Neuman, Saccone, & Rice, 2003) and age of initiation in a study of 
Dutch twin and sibling pairs (Vink et al., 2006).  Furthermore, two DRD1 
polymorphisms, A48G (DdeI aka rs4532) and T1403C (rs686), have been associated with 
heavy smoking behavior and high scores on the Fagerstrom Test for Nicotine 
Dependence in a pooled sample of 2037 participants from the United States of African-
American or European-American origins (Huang et al., 2008).  Thus, DRD1 appears to 
be associated with smoking behavior and nicotine addiction. 
 DRD2 is associated with pleasure, and has specifically been called a “reward 
gene” (Blum et al., 2011).  The most studied polymorphism in the DRD2 region is 
TaqIA, a C >T substitution (rs1800497) on chromosome 11q22–q23.  This SNP has been 
associated with pathological gambling, overeating, schizophrenia, heroin addiction, 
nicotine dependence, alcoholism, and other psychiatric disorders (Comings et al., 1996; 
Epstein et al., 2007; Monakhov, Golimbet, Abramova, Kaleda, & Karpov, 2008; Noble et 
al., 1998; Smith, Watson, Gates, Ball, & Foxcroft, 2008; Xu et al., 2004).  This SNP was 
originally thought to be in the 3’ untranslated region of DRD2, but has more recently 
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been shown to be located in exon 8 of a neighboring gene (10 kb downstream of the 
DRD2 gene), named ANKK1 (ankyrin repeat and kinase domain containing 1) (Blum et 
al., 2011).  The SNP causes a nonsynonymous coding change (Glu713Lys) that can affect 
DRD2 receptor expression and synthesis of dopamine in the brain. Confirming the 
relevance of ANKK1 in nicotine dependence, Huang et al. (Huang et al., 2009) found a 
significant correlation with nicotine dependence and a second non-synonymous 
functional SNP (rs2734849) in the ANKK1 gene. This correlation was seen only in 
African-American and not European-American smokers, again implying ethnic 
differences in the genetic basis for nicotine addiction.   The A1 allele was also associated 
with a higher consumption of heroin in Spanish individuals, particularly males (Perez de 
los Cobos et al., 2007) as well as increased levels of craving after heroin exposure in 
Chinese individuals (Y. Li et al., 2006). However, despite some promising results, DRD2 
has not been well replicated over time. 
 Several studies link the DRD2 gene to specific smoking related phenotypes.  As 
early as 1996, Taq1A had been implicated as a risk factor for smoking, as one group 
found a significantly higher portion of A1 alleles in smokers than non-smokers (p=10-8) 
(Comings et al., 1996).  Frequencies of A1 and the more 5’ B1 alleles have been 
associated with age of smoking initiation and fewer attempts to quit (Spitz et al., 1998).  
The Taq1A polymorphism has been associated with smoking progression in adolescents, 
especially among those with depressive symptoms (Audrain-McGovern, Lerman, 
Wileyto, Rodriguez, & Shields, 2004).  Genotype status at a DRD2 intron 2 simple 
tandem repeat was related to cigarettes per day (P=0.035) and heaviness of smoking 
index (P=0.049) (Vandenbergh et al. 2007).  Two common DRD2 haplotypes were 
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associated with the quantity of smoking and drinking in a sample of alcoholics who were 
habitual smokers (Preuss, Zill, Koller, Bondy, & Sokya, 2007).  A significant association 
between TaqA1 genotype and maximum duration of quit time among male Egyptian 
smokers has been reported (Radwan et al., 2007).  Together, these findings suggest that 
although there are mixed results with association in this region, that the dopaminergic 
pathway is important to addiction.  These genes are likely associated with dependencies 
to several different drugs and probably confer a general predisposition to addiction, rather 
than addiction to a particular substance. It is curious that GWAS do not seem to pick up 
any association with nicotine dependence in the DRD genes.  Perhaps they do have a 
nominally significant p-value, but it is not mentioned because it does not pass genome-
wide significance, or perhaps the effect of DRD genotypes is too downstream of the 
effect of nicotine to change how nicotine is perceived and thus change a person's 
likelihood of becoming addicted to it. 
 GWAS Studies.  Several genetic variants that modify susceptibility or resistance 
to nicotine dependence have been identified by GWAS (Berrettini et al., 2008; Bierut et 
al., 2007; Thorgeirsson et al., 2008).  Perhaps not surprisingly, the loci identified by 
GWAS as associated with nicotine addiction mainly include genes encoding neuronal 
cholinergic nicotinic receptors (CHRNs) and nicotine metabolizing genes.   
 Neuronal cholinergic nicotinic receptors (CHRNs) are a heterogeneous class of 
cation (positively charged) channels expressed in the central and peripheral nervous 
system.  There are 11 neuronal CHRN genes, each of which encodes a receptor 
subunit.  The neuronally expressed nicotinic receptors consist of combinations of alpha 
and beta subunits, encoded in humans by 8 alpha (α2-α 7, α9-α10) and 3 beta (β2-β4) 
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genes (Bierut, 2009).  These subunits form homo- or hetero-pentameric subtypes, which 
are present in various regions throughout the nervous system. To form a receptor, five 
subunits must be combined within the cell and the specific combination of these subunits 
defines the receptor subtype.   
 In the body, the opening of these channels is controlled by the endogenous ligand, 
acetylcholine, a chemical produced by neurons to activate other nearby neurons.  
Nicotine, the major psychoactive chemical present in tobacco smoke is a chemical 
present in the environment that can also stimulate the opening of these nicotinic 
acetylcholine receptor ion channels  (Gotti et al., 2007)Nicotine has differing effects on 
the brain depending on the receptor subtype and location.  For example, when nicotine is 
bound to α3ß4 receptors in the medial habenula and interpeduncular nucleus, there is a 
higher sensitivity to the aversive effects of nicotine.  By contrast, α4ß2 receptors in the 
ventral tegmental area play a major role in nicotine self-administration in mice (Frahm et 
al., 2011).   
 A number of GWAS studies have been performed that demonstrate an association 
between the nicotinic receptors and smoking.  The strongest association between 
nicotinic receptors and nicotine addiction is a non-synonymous change (rs16969968, 
D398N) in the gene encoding the α5 subunit of the nicotinic receptor (CHRNA5) on 
chromosome 15 (Bierut et al., 2008; N. L. Saccone et al., 2009; S. F. Saccone et al., 
2007; Spitz, Amos, Dong, Lin, & Wu, 2008; Thorgeirsson et al., 2008; Weiss et al., 
2008).  When cells are made to express nicotinic receptors containing the minor allele 
form of this SNP (398N), agonists induce less channel opening and cell activation than in 
cells that express receptors containing the major allele (398D).  Thus, this SNP results in 
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a significant functional change in the behavior of this ion channel, causing more nicotine 
to be needed in individuals with the minor allele to produce the same effect.  
 The SNP rs16969968 is highly associated with CPD (OR = 1.9, p = 5.96 e-31) (N. 
L. Saccone, Schwantes-An, et al., 2010).  The association between rs16969968 and 
smoking behavior has been replicated in several studies and across several populations.  
Interestingly, the minor allele (meaning the less common base pair at this SNP) of 
rs16969968 is present at a frequency of 37% in European populations, but is almost 
absent in African populations.  Although it is rare in African-Americans, the odds ratio is 
similar to that of European-Americans, further increasing the confidence in its effect on 
nicotine dependence (Bierut et al., 2008).  While the association of SNP rs6969968 with 
nicotine addiction is highly significant, it does not explain a large percentage of the 
overall heritability of nicotine dependence.  In fact, it accounts for less than 5% of the 
variance observed in nicotine dependence (Bierut, 2011).  This suggests that other loci 
also contribute to a susceptibility to nicotine addiction.   
 Interestingly, with regard to cocaine dependence, it has been shown that the 
chromosome 15 variant in the CHRNA5 nicotinic receptor, rs16969968, that influences 
the development of nicotine dependence, independently contributes to cocaine 
dependence as well. In a European-American sample, the minor allele of this variant 
increased the risk for nicotine dependence, but decreased risk for cocaine dependence 
(Grucza et al., 2008).  The reason for this reversed effect has been suggested to be 
because nicotinic receptors are involved in both excitatory and inhibitory modulation of 
dopamine-medicated reward pathways (Bierut, 2011).  The fact that variants can affect 
multiple substance dependencies and in different directions underscores the complexity in 
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investigating these behavioral phenotypes due to the comorbidity that is so common with 
substance abuse.   
 Chromosome 8 represents another target for studies of nicotine addiction because 
the genes encoding the ß3 (CHRNB3) and α6 (CHRNA6) nicotinic receptor subunits 
reside there.  The nicotinic receptor gene cluster on chromosome 8 that includes the 
nicotinic receptor subunit gene cluster CHRNB3-CHRNA6 is correlated with smoking 
behavior.  The same GWAS that identified the association between nicotine addiction 
and the CHRNA5 risk allele also identified several SNPs in high linkage disequilibrium 
around the gene CHRNB3 (S. F. Saccone et al., 2007).  Associations were later found 
with 3 SNPs in CHRNB3, including the one previously identified by Saccone et al. 2007 
(Hoft et al., 2009; Zeiger et al., 2008).  A SNP in CHRNA6 was also found to be 
associated with nicotine dependence (Hoft et al., 2009).  These results indicate that there 
are genes on chromosome 8 that are promising targets for discovering some of the 
missing heritability for nicotine dependence.  
 Adding support for the necessity of further study of this region, a SNP tagging a 
region of linkage disequilibrium was discovered in the CHRNB3-A6 region (N. L. 
Saccone et al., 2009).  Subsequent follow-up produced evidence for two distinct regions 
of association: one within CHRNB3 and the other in a nearby non-genic region upstream 
of the B3-A6 cluster (N. L. Saccone, Culverhouse, et al., 2010). A separate GWAS 
discovered additional correlations between nicotine dependence and the CHRN cluster on 
chromosome 8, as well as the nicotine metabolizing gene, CYP2A6 on chromosome 19 
(Thorgeirsson et al., 2010).  This region showed genome-wide significant association 
with nicotine dependence (rs6474412 p = 1.4 e-8) (Thorgeirsson et al., 2010).  These 
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results have been replicated and additional variants discovered (Rice et al., 2012).  
Although a few studies found no association with smoking behavior and the B3-A6 
region, this may have been due to small sample size (N=277, (Etter et al., 2009); N=485, 
(Keskitalo-Vuokko et al., 2011).  Together, these findings strongly implicate the nicotinic 
cholinergic receptor genes on chromosome 8 in nicotine addiction.  However, further 
study is needed to fully characterize the genetic variation this region as it relates to 
nicotine dependence.  Rare variants at this locus have also been associated with alcohol 
and cocaine dependence (Haller et al., 2013), and low-frequency variants have also been 
associated with risk for cocaine dependence (Sadler et al., 2014).  Although biological 
mechanisms in this region have been elusive, one study identified a GWAS signal of 
smoking behavior in the region to be strongly associated with changes in a DNase I 
sensitivity site in the region (Degner et al., 2012).  Most recently, a GWAS of imputed 
data using FTND discovered a genome-wide significant association near a group of 
micro-RNAs (MIR17HG) and a member of the glypican gene family (GPC5) on 
chromosome 13. Notably, the GPC5 gene is expressed mainly in the adult brain and was 
previously shown to be involved in the behavioral response to alcohol. These are among 
the first findings to implicate a non-candidate gene in risk for nicotine dependence, 
however replication to date has been difficult (unpublished data). 
 
NICOTINIC RECEPTORS IN MEMORY AND LEARNING 
 Nicotinic receptors are distributed throughout the nervous system and clearly have 
a role in attention, memory and learning.  Agonists of nicotinic receptors have been 
shown to improve, and receptor antagonists to impair, performance in cognitive tasks 
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(Dajas-Bailador & Wonnacott, 2004).  Nicotine has been shown to improve working 
memory, although reference memory is not affected by either acute or chronic nicotine 
administration (Levin & Simon, 1998).  The α4β2, α3β2, and α7 receptors in the 
hippocampus appear to be important for working memory functions and Greenwood et al. 
(Greenwood, Parasuraman, & Espeseth, 2012) found substantial evidence in the literature 
to support the hypothesis that the minor allele of rs1044396, a SNP in CHRNA4, is 
associated with the ability to focus attention very strongly on a target at the expense of all 
outside stimuli.   
 Also supporting a role of nicotine in attention, the study of Thiel et al. (Thiel, 
Zilles, & Fink, 2005) showed that nicotine enhanced the reorientation of attention in 
visuospatial tasks in a German, nonsmoking population.  Murphy & Klein (Murphy & 
Klein, 1998) also showed that nicotine enhanced visuospatial reorientation in casual 
smokers immediately after smoking a cigarette.  Studies using fMRI to examine 
behavioral performance and regional brain activity have shown altered neuronal activity 
responsible for increased attention and arousal with nicotine as compared to placebo 
(Kumari et al., 2003).  Ernst et al. (Ernst et al., 2001) found that administration of 
nicotine improved reaction time in focused attention tasks in both smokers and non-
smokers. 
 Consistent with a role of nicotine in cognition, several recent studies have 
demonstrated cognitive differences between smokers and non-smokers. Winterer et al. 
(Winterer et al., 2010) found an association between nicotine dependence risk variants in 
CHRNA5 and lower cognitive performance scores.  The authors suggested that these 
variants may increase the risk for nicotine dependence because the individuals seek out 
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nicotine for “reasons of cognitive enhancement”.  Yakir et al. (Yakir et al., 2007) 
reported that non-smokers had better performance than current smokers on cognitive tests 
involving sustained attention, control of impulsivity, and planning.  The authors 
suggested that improvement by nicotine of cognitive function in these domains might 
predispose young women who initiate cigarette smoking to maintain their smoking 
behaviors for purposes of self-medication if they had deficits in these domains.  A similar 
explanation could account for the results of Hong et al. (Hong et al., 2010) who showed 
that the rs16969968 risk allele was associated with decreased resting state functional 
connectivity of the CHRNA5 nicotinic receptor-expressing regions in the dorsal anterior 
cingulate–ventral striatum/extended amygdala circuit.  
 A study attempting to determine the association between SNPs in nicotinic 
receptors and cognitive function found association between cognitive function and 
variants in the receptors CHRNA2, A4, A5, A7, A9, A10, B2 and B3, as well as with 
several related haplotypes (Rigbi et al., 2008).  As a group, smokers performed worse 
overall than non-smokers.   However, smokers who carried a particular combination of 
genetic variants at these loci performed better than non-smokers who carried a different 
combination at these loci (Rigbi et al., 2008).  Given that nicotine improves cognition in 
the domains investigated in the study, the authors suggested that these variants would 
render a person more or less likely to smoke in accordance with the direction of effect.  
Another study found significant impairments in smokers in visual attention and cognitive 
impulsivity, regardless of smoking quantity.  The authors argued for an a priori cognitive 
deficit in smokers and suggest these deficits be considered as phenotypes for future 
research (Wagner et al., 2013).  Together, these data are consistent with the hypothesis 
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that a predisposition to nicotine dependence could be due to the effects of SNPs either in 
the nicotinic receptors or in other loci causing variability in memory and learning, for 
which other SNPs in nicotinic receptors could be attempting to compensate. 
    
THE EVOLUTION OF NICOTINE DEPENDENCE 
 Addictive drugs are habit forming because they act on brain circuits that subvert 
more natural and biologically significant rewards (Nesse & Berridge, 1997).  These 
pathways evolved in the adaptive context of inducing positive emotions in the presence 
of a fitness benefit, and negative emotions in situations where defenses may have been 
necessary.  Selective pressures in our ancestral environments were likely not on 
addiction, but rather on behaviors or characteristics that enhanced survival and 
reproductive success.    
 As discussed above, numerous studies indicate that nicotine enhances cognitive 
performance and that individuals with subtle differences in cognition or memory may be 
predisposed to addiction or become nicotine addicted in order to improve their 
performance.  Therefore, it is possible that the genes associated with nicotine addiction 
were selected for their ability to improve cognition or to counteract negative effects on 
cognition mediated by other loci.  
 Population differences in frequencies of alleles related to memory and cognition 
could answer questions about where and when these alleles arose.  For example, 
rs16969968 in CHRNA5, which is so strongly associated with nicotine dependence, is 
present at a frequency of 37% in Europeans, yet is nearly absent in Africans and Asians.   
From the frequencies of this allele in different populations worldwide, it is clear that it 
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had to have arisen after the out-of-Africa migration, due to the fact that it is at nearly zero 
percent in African populations.  Frequency distribution shows that this allele had to have 
arisen in the Middle East or Europe and followed the pattern of the peopling of the rest of 
the world (Figure 2 from (Bierut et al., 2008)).  
 It is possible that after the out of Africa migration, the rs16969968 mutation arose 
by chance in the population of humans living in Europe.  However, given the effects of 
nicotine on memory and cognition, it is also possible that the mutation conferred some 
fitness benefit related to brain function.  This would have provided a selective pressure to  
Figure 2.  Allele frequency differences of rs16969968 in different ethnic populations.  
The frequency of the A allele is the white segment of the circles in the figure. Geographic 
regions: 1.  America; 2. Africa; 3. North Africa; 4. Europe; 5. Middle East; 6. 
Central/South Asia; 7. Central/South Asia; 8. East Asia; 9. Oceania.   From (Bierut et al., 
2008). 
 
enhance its frequency in Europeans.  The addiction phenotype would have been an 
evolutionarily neutral consequence of this allele selection because the opportunity for 
prolonged use of purified drugs was absent since there were no highly concentrated 
sources of nicotine in the ancestral environment.  This phenotype would only have 
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become apparent, and problematic, in the current environment where there is ready 
access to nicotine-containing products.   
 The hypothesis that there are variants in the nicotinic receptors that are associated 
with increased memory and cognition might lead some to ask the question of why these 
allegedly beneficial variants have not reached fixation (i.e. appear at population 
frequencies of nearly 100%).  However, there are many reasons that a variant conferring 
a benefit would not reach fixation in a population.  For example, the strength of selection 
on that allele may not be strong enough to exact such a drastic frequency shift, 
particularly if other variants at the locus are not deleterious but rather neutral.  It could 
also be the case that not enough generations have passed for fixation to occur, especially 
if these beneficial variants are in linkage disequilibrium with other unknown deleterious 
polymorphisms.   
 The heritability of addiction is approximately 50%, yet the confirmed genetic 
contributions to nicotine dependence and other drug dependencies explain only a small 
fraction of this heritability.  Current explanations for the missing variance are: 1) rare 
variation not tagged on current GWAS chips; 2) many genes of small effect; and 3) non-
additive effects such as gene x gene or gene x environment interactions.  If SNPs in the 
nicotinic receptors involved in nicotine addiction can be shown to be associated with 
differences in cognitive function, this would suggest a third explanation for missing 
variance-- unnoticed linkage between phenotypes due to evolutionary reasons.     
   
CENTRAL HYPOTHESIS AND AIMS 
 The overall hypothesis I propose to test is whether specific genotypes, either 
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known or discovered by association analyses I will run, within the regions of the CHRN 
clusters on chromosomes 8 and 15 that are significantly associated with either nicotine or 
cocaine phenotypes, have actually been selected upon due to their effects on memory and 
learning.  This would mean that the primary phenotype would be these more ancient and 
evolutionarily beneficial phenotypes, and any effect on smoking or cocaine use has 
hitchhiked along with these older phenotypes.  The prevalence of maladaptive behaviors, 
namely nicotine dependence and cocaine addiction, suggests other factors may be at play. 
 In chapter 2, I discuss running a GWAS using imputed data from the 
Collaborative Genetic Study of Nicotine Dependence (COGEND) dataset and perform 
association testing using the phenotypes of case (nicotine dependent smoker) and control 
(non-dependent smoker) based on FTND scores to see whether any novel imputed SNPs 
within these CHRN clusters are associated with nicotine addiction.  Key SNPs identified 
in these analyses of the imputed data were selected for follow-up genotyping to confirm 
association.  These analyses reveal new associations, including evidence for more than 
one signal of association.   
 My third chapter discusses an in depth association analysis with the nicotinic 
cluster on chromosome 8 on which less is known about, using genotypic data from a 
GWAS of the Study of Addiction: Genetics and Environment (SAGE) dataset, to 
determine if there is any association with cocaine dependence.  The basis for this is that 
the same SNP on chromosome 15 that is most highly associated with risk for nicotine 
dependence, is also protective for cocaine dependence, so it is reasonable to suspect there 
may in fact be an association here. 
 All SNPs discovered in chapters 2 and 3, as well as previously discovered 
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associations in the regions, are the substrate for chapter 4.  In this chapter, I use three 
separate tests of natural selection on the 1000 Genomes dataset, which I group into 
European, African and Asian populations.  I predict that regions of these genes that have 
functional importance will show evidence of selection.  I also perform an association 
analysis in a dataset of approximately 500 individuals, between genotype at these SNPs, 
and performance on assessments of memory and learning.  Lastly, I will discuss these 
results in the context of potential anthropological explanations for these results.  
 In summary, this work will bring about a more detailed understanding, both 
biologically and evolutionarily, of the variation in the nicotinic receptors on 
chromosomes 8 and 15, and their relationship with drug dependence, memory and 
learning and human sociality. 	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CHAPTER 2 
COMMON VARIANTS NEAR GPC5 AFFECT RISK OF NICOTINE DEPENDENCE 
IDENTIFIED THROUGH IMPUTATION 
 
ABSTRACT 
Previous findings have demonstrated that variants in or near nicotinic receptor genes and 
the nicotine-metabolizing enzyme CYP2A6 are associated with nicotine dependence. We 
conducted genome-wide association analyses using samples from the Collaborative Study 
of the Genetics of Nicotine Dependence (COGEND) to identify novel genes involved in 
the development of nicotine dependence. In order to increase power to detect novel 
associations, we imputed genotypes from the 1000 Genomes project using the IMPUTE2 
software package. Variants at two loci were associated with nicotine dependence as 
defined by a score of >4 on the Fagerstrom Test of Nicotine Dependence (FTND). One 
group included the previously identified SNPs at 15q25 represented by rs55853698. The 
second locus is a novel association between nicotine dependence and SNPs at 13q31, 
represented by rs7995715. This association was confirmed by genotyping the top SNPs 
using Sequenom assays. We also attempted to replicate this finding in an independent 
dataset using the Study of Addiction, Genes and Environment (SAGE) dataset minus the 
overlapping COGEND individuals.  Among the genes at this newly associated locus are a 
group of micro-RNAs (MIR17HG) and a member of the glypican gene family (GPC5). 
Notably, the GPC5 gene is expressed mainly in the adult brain and was previously shown 
to be involved in the behavioral response to alcohol. These are among the first findings to 
implicate a non-candidate gene in risk for nicotine dependence, as well as the first time 
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that the known association in CHRNA5 has been linked at the genome-wide significant 
level to FTND nicotine dependence.  
INTRODUCTION 
Tobacco use and related diseases are the number one cause of preventable deaths 
in the United States, accounting for approximately one out of every five deaths annually 
(CDC, 2008).  The impact of smoking on health is very broad.  More people die from 
lung cancer each year than from any other type of cancer (ACS, 2009).  Even among 
those who quit smoking, there is an elevated risk of lung cancer, although this risk is less 
than in those who do not quit (Huang et al., 2008).  Chronic obstructive pulmonary 
disease (COPD), a serious lung disease often caused by smoking, is also among the 
leading causes of death (N. L. Saccone, Culverhouse, et al., 2010).  
Smoking rates are elevated in at risk populations such as those with mental 
illness.  In 2000, it was estimated that this population consumes 44.3% of all cigarettes in 
the country and have approximately twice the risk of becoming a smoker than other 
individuals (Lasser et al., 2000). Mentally ill individuals have a harder time quitting, and 
can attempts to quit can cause severe depression.  There is recent evidence linking 
smoking in this population to an underlying biological mechanism, especially 
schizophrenia, for which nicotine seems to normalize deficits in the CHRNA7 nicotinic 
receptor (Leonard et al., 2001).  Most recently, an epidemiological study of drug use in 
those with psychotic illness found that the odds of substance abuse are even higher, 
putting the odds ratio for smoking in this group at 4.6 (95% CI 4.3-4.9) (Hartz et al., 
2014).  
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The percentage of people in the United States living with a substance abuse 
disorder is high: 13.5% with nicotine dependence, 13% with alcohol dependence, and 
6.1% with all other drug dependencies (Grant, Hasin, Chou, Stinson, & Dawson, 2004; 
Regier et al., 1990).  Adding to the genetic complexity of these phenotypes, persons with 
substance disorders are often comorbid for multiple substance dependencies as well as 
mental illnesses.  For example, the percentage of nicotine dependence in the general 
population is 13%, compared with 30-70% in persons with mental illnesses (Hartz & 
Bierut, 2010).  This necessarily means that the genetic basis of these disorders will be 
complex, and that there will likely be variants that contribute to risk for more than one 
disorder.   
Susceptibility to drug use, abuse, and dependence has been shown by several 
studies to have a moderate to high genetic component (Bierut, 2011; J. C. Wang, Kapoor, 
& Goate, 2012).  The heritability of nicotine dependence has been estimated to be from 
44-72% (Carmelli et al., 1990; Lessov et al., 2004).  Genome-wide association scans 
(GWAS) are a powerful tool for identifying genetic loci with a wide range of effect sizes 
on traits of interest. GWAS take advantage of linkage disequilibrium in a population to 
detect all common single nucleotide variations in an individual.   If a SNP on the GWAS 
genotyping array is associated with a disease phenotype in a sample, it could be because 
that SNP is causing the disease, but more likely, that SNP is in linkage disequilibrium 
with the real SNP causing the disease.  Linkage disequilibrium is the tendency for two or 
more alleles to be inherited together more often than expected by chance, due to reduced 
genetic recombination (or distance) between them. A GWAS compares DNA variation at 
millions of SNPs in individuals that do (affected) or do not (unaffected) exhibit the trait 
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of interest.  SNP allele frequencies between affected and unaffected individuals are then 
compared to disease status or any other phenotypic data collected to determine if there is 
a significant association between genotype and phenotype. An important advantage of 
GWAS is that they do not require prior hypothesis about the underlying biological 
mechanisms of a trait. However, they do have the disadvantage of not being able to tag 
all variation in the genome, especially portions of the heritability of the trait that are 
caused by rare variants.  
Several smoking related phenotypes are commonly studied, that get at different 
aspects of nicotine dependence. The Fagerström Test for Nicotine Dependence (FTND) is 
a widely accepted quantitative measure of nicotine dependence (ND). This tool has 6 
questions including how many cigarettes are smoked per day (CPD), which is one of two 
three-point questions on the test, as well as time to first cigarette (TTF).  The highest 
score possible is a 10 indicating maximum nicotine dependence (Heatherton et al. 1991). 
FTND is therefore a more comprehensive measure of ND since it encompasses CPD, as 
well as other aspects of ND. Nevertheless, CPD is often used by itself as a measure of 
nicotine dependence, and on the FTND is broken down into 4 possible answers: 0-10, 11-
20, 21-30 and 30+ cigarettes per day. The pros of using CPD as the phenotype are that it 
is a direct measure of consumption and it is simple to collect, however the cons are that it 
is affected by cultural observations such as African-Americans smoking fewer cigarettes 
a day (Johnson, Morgan-Lopez, Breslau, Hatsukami, & Bierut, 2008). Additionally, CPD 
is affected by legislation banning smoking in places such as public buildings that has had 
a dramatic effect on smoking levels.  FTND has the benefit of including CPD, as well as 
the other questions on the test such as item 3: which cigarette would you most hate to 
	   	  	  35 
give up?  Rice et al. (Rice et al., 2012) describe an association between early morning 
smoking and the genome-wide significant bin on chromosome 8, suggesting that using 
just CPD would miss this aspect of nicotine dependence.  However the main 
disadvantage of the FTND is that because it is more complicated than just how many 
cigarettes does one smoke per day, it is likely hard to administer with perfect inter-rater 
reliability.  Compared to several of the measures of DSM-IV nicotine dependence, FTND 
seems to pick up more direct measures of addiction (CPD, TTF, desire to smoke where 
prohibited, smoking while ill), while the DSM-IV measures aspects related to quality of 
life and how smoking interferes with leading a normal life.  Perhaps the reason is that the 
DSM-IV uses the same criteria for all drug dependencies, while the FTND is specifically 
for smoking. 
GWAS have discovered several variants that modify susceptibility or resistance to 
cigarette consumption  (Berrettini et al., 2008; Bierut et al., 2007; Thorgeirsson et al., 
2010). The loci identified by GWAS as associated with cigarettes per day (CPD) include 
genes encoding neuronal cholinergic nicotinic receptors (CHRNs) and the nicotine 
metabolizing gene CYP2A6. Two regions, one containing the CHRNA5, CHRNA3 and 
CHRNB4 genes on chromosome 15 and one containing the CHRNB3 and CHRNA6 genes 
on chromosome 8 are the most replicated loci associated with nicotine dependence (N. L. 
Saccone, Culverhouse, et al., 2010; N. L. Saccone et al., 2009; S. F. Saccone et al., 2007; 
Spitz et al., 2008; Thorgeirsson et al., 2008; Thorgeirsson et al., 2010; Weiss et al., 2008). 
The strongest association (p = 5.96 x 10-31) between nicotinic receptors and nicotine 
addiction is a non-synonymous change (rs16969968, D398N) in the gene encoding the α5 
subunit of the nicotinic receptor, CHRNA5 on chromosome 15 (Bierut et al., 2008; N. L. 
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Saccone et al., 2009; S. F. Saccone et al., 2007; Spitz et al., 2008; Thorgeirsson et al., 
2008; Weiss et al., 2008).   The phenotype previously found to be associated with this 
variant at the genome-wide significant level is cigarettes per day (CPD).  The minor 
allele of this SNP has a frequency of ~30% in European-Americans but is rare in other 
populations including African-Americans. When nicotinic receptors containing the minor 
allele form of this SNP (398N), are overexpressed in cultured cells, agonists induce less 
channel opening and cell activation than in cells that express receptors containing the 
major allele (398D).  Thus, this SNP results in a significant functional change in the 
behavior of this ion channel.  Additionally, variants in CHRNA5 have been shown to alter 
the levels of expression of CHRNA5 mRNA, (J. C. Wang et al., 2009) and influence risk 
for nicotine dependence (N. L. Saccone, Culverhouse, et al., 2010). Associations with 
cigarette consumption have also been found with SNPs in or near the nicotinic receptors 
on chromosome 8 (Hoft et al., 2009; Johnson et al., 2010; Rice et al., 2012; N. L. 
Saccone, Culverhouse, et al., 2010; S. F. Saccone et al., 2007; Thorgeirsson et al., 2010; 
Zeiger et al., 2008), but the mechanism underlying the association on chromosome 8 is 
not well understood.  Lastly, the candidate gene CYP2A6, which plays a role in nicotine 
metabolism, has been associated at the genome-wide significant level with both CPD 
(Thorgeirsson et al., 2010) and COPD (Cho et al., 2012).  However, no genome-wide 
significant associations with nicotine dependence related phenotypes have been found 
outside of these genes. So far, the only association with FTND nicotine dependence has 
been the genome-wide significant association with rs1451240 near CHRNB3 described 
by Rice et al. (Rice et al., 2012). They report that FTND better captured the association 
on chromosome 8 for ND than CPD and that this held true even when comparing their 
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sample of 4200 subjects with a meta-analysis of over 75,000 subjects. They attribute part 
of this improvement with a different phenotype to the fact that African-Americans smoke 
fewer cigarettes per day than do European-Americans, so CPD would not fully capture 
ND in this group.  Their study also highlights the importance of precise phenotypes like 
FTND, which has previously been shown to be more consistent across populations than 
CPD (Johnson et al., 2008). Large-scale meta-analyses might miss associations since 
increasing sample size does not always increase power when the phenotypes are either 
imprecise or non-specific.   
 To date, no GWAS have identified non-candidate gene loci associated with 
nicotine dependence phenotypes.  We report here for the first time, a genome-wide 
significant locus on chromosome 13q31 near the glypican 5 (GPC5) gene, associated 
with FTND case control status.  The second important discovery in this study is the 
association of the known risk variant in CHRNA5 with FTND for the first time. Given the 
previous discussion of the benefits and drawbacks of the various nicotine-related 
phenotypes, it is possible that the mechanism underlying the association near GPC5 is 
one that is better captured by FTND than CPD, and that the increased power in the 
previous association in CHRNA5 supports this hypothesis. 
 
METHODS 
COGEND Dataset.  Subjects in this study have self-identified their ethnicity as 
either African-American or European-American.  Cases and controls were ascertained on 
the basis of their FTND score (maximum 10 points), where cases had scores of four and 
above and controls had scores of less than 4.  Controls also had to have smoked at least 
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100 cigarettes in their lifetime and yet not be dependent.  Subjects were all recruited from 
St. Louis and Detroit metropolitan areas.  2646 blood samples were collected for study 
purposes. The sample consists of 1936 European American individuals (995 nicotine 
dependent (ND) cases and 941 smokers with no symptoms of dependence (controls)) as 
well as 710 African Americans (461 ND cases and 249 controls).  All data was collected 
in accordance with the protocols approved by the Institutional Review Board at each 
institution involved.  Informed consent was obtained from all subjects for their DNA to 
be used in genetic studies and their phenotypic information to be shared with appropriate 
investigators. 
Phenotypes.  Subjects were placed in either the case or control category, based on 
their FTND score.  Cases were nicotine dependent individuals who scored four or higher 
on the FTND, and controls were those who had smoked at least 100 cigarettes in their 
lifetime, but had not become dependent, and whose FTND scores were less than 4.  We 
also used for comparison the ordinal traits of cigarettes per day (CPD) and time to first 
cigarette in the morning (TTF).  CPD has 4 categories; 0-10, 10-20, 20-30, and 31+.  
Time to first cigarette has 4 as well; 0-5 minutes, 6-30 minutes, 31-60 minutes, and 61+ 
minutes. 
Genotyping and Quality Control.  The GWAS SNP dataset was obtained 
partially on the Illumina Human 1M-Duo beadchip genotyping array and partially on the 
2.5 SNP genotyping array.  Those samples that were genotyped on the Illumina Human 
1M-Duo beadchip were typed by the Center for Inherited Disease Research (CIDR) at 
Johns Hopkins University.  Of the 1,049,008 SNP assay probes on the chip, 948,658 
passed the quality control process, which included investigation of hidden relatedness 
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(IBD>10%), HapMap controls, batch effects, gender/chromosomal abnormalities, HWE 
=10x-4, genotyping call rate of 97% and Mendelian error or duplication error detection.  
Additionally, there are 23,812 intensity only probes on the chip (P. Lin et al., 2011). 
Individuals typed on the Human Omni 2.5M chip, which has 2,379,514 probes, were also 
typed by CIDR.   All data was cleaned by GENEVA.  These processes are described in 
more detail in the data cleaning report freely available on the GENEVA website at 
(http://www.genevastudy.org/docs/GENEVA_Alcohol_QC_report_8Oct2008.pdf).  
Follow-up genotyping of top novel association results was done using the Sequenom 
Mass Array genotyping platform (J. C. Wang et al., 2009). All SNPs with an r2 >0.8 with 
rs7995715, and any SNP with an r2 >0.8 with the first group of SNPs were chosen for 
follow up genotyping to maximize coverage of potentially interesting LD bins. 
Imputation Quality Control.  In order to eliminate unnecessary risk of spurious 
associations that would result from the use of two different platforms, only the SNPs 
present on both genotyping platforms were considered, which consisted of 605,735 SNPs.  
This was a particularly important issue because in this case, most of the controls were 
typed on one chip and most of the cases were typed on the other.  Additionally, a minor 
allele frequency cutoff of 5%, HWE=10x-4, a chromosomal missingness cutoff of 5% and 
genotyping call rate of 97% were employed.  Relatedness was evaluated for 3rd degree or 
higher, based on IBD>10%. We identified a total of 23 2nd-3rd degree relative pairs, 
involving 12 EAs and 26 AAs.  We proceeded without excluding any subjects due to this 
lesser degree of relatedness. No 1st degree relative pairs were identified. The subjects 
were then imputed to the 1000 Genomes cosmopolitan reference panel using IMPUTE2. 
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Imputation Software. Haplotypes were pre-phased using SHAPE-IT (Delaneau, 
Marchini, & Zagury, 2012), and imputation was performed using the program IMPUTE2 
(B. Howie, Marchini, & Stephens, 2011; B. N. Howie, Donnelly, & Marchini, 2009), 
using all available reference genomes from the 1000 Genomes Project (Durbin, Altshuler, 
Abecasis, Bentley, & Consortium, 2010).  SHAPE-IT allows computational time to be 
minimized by using multi-threaded phasing. IMPUTE2 was chosen as the imputation 
program based on studies that have shown it to perform better for situations like ours in 
comparison to other programs available (Chanda et al., 2012; Ellinghaus, Schreiber, 
Franke, & Nothnagel, 2009). 
Population Stratification.  Subjects in the study had self-identified as European-
American or African-American.  Since admixture across these populations needs to be 
accounted for, we used the program EIGENSTRAT (Price et al., 2006) to calculate 
principal components.  The first two principal components were included in association 
analyses to control for population stratification. 
GWAS Association Analysis.  Genotype/phenotype association analyses were 
performed using PLINK, with the imputed genotype probabilities data from IMPUTE2 
using SNPs genotyped on both platforms and SNPs imputed from those sites. FTND 
diagnosis of nicotine dependence was the primary phenotype. Time to first cigarette and 
maximum lifetime cigarettes per day were analyzed in order to dissect the effect of 
associated SNPs on the FTND phenotype.  Logistic regression was run for the 
dichotomous trait of FTND, and linear regression for continuous traits of TTF and CPD.  
The covariates used were age at interview, sex, PC1, and PC2 for the combined sample.   
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RESULTS 
 Imputed Data.  In order to identify novel loci associated with FTND nicotine 
dependence, we performed a genome-wide association study in individuals from the 
Collaborative Study of the Genetics of Nicotine Dependence (COGEND). To increase 
power to detect novel associations, we performed imputation for all samples using phased 
haplotype data from the 1000 Genomes project as the reference. After filtering SNPs with 
minor allele frequency < 5% and genotyping or imputation call rate < 97%, we analyzed 
association data for ~2,500,000 imputed and genotyped autosomal SNPs using logistic 
regression with age at interview, sex, PC1 and PC2 as covariates.  
Mega-analysis.  We find a genome-wide significant association in the mega-
analysis of the combined sample (N=1952 EA, 709 AA) with SNPs at 15q25, represented 
by rs114205691 (OR = 1.41, 95% CI= 1.29-1.53, MAF=0.31, P = 4.35 x 10-8) and a 
novel genome-wide significant association at 13q31 in the combined sample represented 
by rs7995715 (OR=1.41, 95% CI= 1.29-1.53, MAF=0.33, P = 3.27 x 10-8), with FTND 
nicotine dependence (Figure 3).   
 
Figure 3.  Loci for susceptibility to FTND nicotine dependence detected by GWAS for 
the combined sample  (EAs and AAs). Manhattan plot of association test results of 
GWAS data showing the chromosomal position of genotyped or imputed SNPs plotted 
against −log10P. The red horizontal line represents the threshold for genome-wide 
significance (P < 5 × 10−8). 
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A regional association plot is shown for the results of the association testing near 
GPC5 (Figure 4) and near CHRNA5-A3-B4 (Figure 5), and a table with the top 50 SNPs 
from the genome-wide association analysis is shown in Appendix A. This association 
with the bin tagged by rs7995715 is also significant with the secondary phenotype of 
CPD (p=1.40 x 10-4 β=0.12) and genome-wide significant with the secondary phenotype 
of TTF (p=4.72 x 10-8, β= 0.21). Overall, there was no inflation in the association results 
as demonstrated in the QQ-plot of the combined association results (λ=1.02, SE= 
2.38x10-6) (Figure 6).   
	  	  
Figure 4.  Regional association plot for the area on chromosome 13 surrounding GPC5 	  	  
	   	  	  43 
	  	  




Figure 6.  QQ-Plot of Combined EA and AA Whole Genome Association Results. 
(λ=1.02, SE= 2.38x10-6)   
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 Of interest is that 4 genes other than the cluster of nicotinic receptors on 
chromosome 15 and the GPC5 region on chromosome 13 had SNPs that made it into the 
top 50 most significant SNPs in the genome-wide association wit FTND nicotine 
dependence (Appendix A). Perhaps the most interesting is neurotrimin (NTM) on 
chromosome 11.  This gene encodes a protein that promotes neurite outgrowth and 
adhesion, and is closely linked to opioid binding protein/cell adhesion molecule-like 
(OPCML). Polymorphisms in this gene have even been found to influence intelligence in 
the COGA dataset (Pan, Wang, & Aragam, 2011).  
 This confirms the previous association of rs16969968 at 15q25 (r2=0.9 with 
rs55853698 in HapMap CEU samples) and nicotine related behavior. However, this is the 
first time that this SNP been associated with FTND nicotine dependence at a genome-
wide significant level.  Previous studies have demonstrated genome-wide significant 
associations between this SNP and the number of cigarettes smoked per day (CPD), only 
one component of the FTND score. 
 Meta-analysis.  We performed a meta-analysis of the European-American and 
African-American samples and compared the results to the mega-analysis (Appendix A).  
The results were nearly identical to those of the mega-analysis.  The LD bin on 
chromosome 15 tagged by rs114205691 remained genome-wide significant (p=4.14 x 10-
8, β=0.71), and the LD bin on chromosome 13 tagged by rs7995715 was nearly genome-
wide significant (p=9.20 x 10-8, β=0.72). 
European-Americans.  Genome-wide association results for European-
Americans with FTND nicotine dependence still pick up the signals on chromosomes 13 
and 15, although not as strongly as in the combined sample (Figure 7).  
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Figure 7.  Loci for susceptibility to FTND nicotine dependence detected by GWAS 
among European Americans. Manhattan plot of association test results of GWAS data 
showing the chromosomal position of genotyped or imputed SNPs plotted against 
−log10P. The red horizontal line represents the threshold for genome-wide significance 
(p < 5 × 10−8). 
 
The top 50 SNPs genome-wide are included in Table 2.  Within EAs separately, the 
strongest association with FTND nicotine dependence in the GPC5 region of 
chromosome 13 is the bin tagged by rs7995715 (p=2.01x10-6, OR=1.43, 95% CI= 1.27-
1.59). However, a locus on chromosome 19 containing the gene KTD15 has three SNPs 
with more significant p-values than GPC5.  KTD15, which is expressed in the central 
nervous system, has been associated with obesity in a meta-analysis (Willer et al. 2008). 
However to date it does not appear to be associated with any psychiatric conditions. 
 With the secondary phenotype of CPD, rs7995715 is still highly associated 
(p=3.38 x 10-5, β=0.17), similarly for TTF (p=1.85 x 10-6, β=0.22). The association on 
chromosome 15 remains strong as well.  The bin tagged by rs114205691 is still the top 
hit in the association analysis with FTND nicotine dependence (p=1.32x10-6, OR=1.40, 
95% CI=1.26-1.54). Covariates used in all cases were age, sex, PC1 and PC2.  
  
	   	  	  46 
Table 2 
Top 50 SNPs in the GWAS in the European-American sample 
Genome-wide Top 50 SNPs in European-Americans from FTND Nicotine Dependence Association Analysis 
CHR Position Gene rs number A1 A2 Freq INFO OR SE P-Value 
19 34341157 KCTD15 rs10404267 C T 0.9684 0.9493 0.3442 0.2168 8.71E-07 
19 34342004 KCTD15 rs10424551 C T 0.9683 0.9482 0.3448 0.2166 8.83E-07 
19 34343918 KCTD15 rs10413064 C A 0.9682 0.9463 0.3464 0.216 9.13E-07 
13 91953042 GPC5 rs7994634 C T 0.7418 1.0408 0.6943 0.0753 1.27E-06 
19 34349137 KCTD15 rs73926943 C T 0.9675 0.9407 0.3564 0.2132 1.30E-06 
13 91952459 GPC5 rs9301726 T C 0.7417 1.0403 0.6945 0.0753 1.30E-06 
15 78901113 CHRNA3-A5-B4 rs114205691 C T 0.6456 1.0039 0.7139 0.0697 1.32E-06 
15 78898932 CHRNA3-A5-B4 rs55676755 C G 0.6468 1.0033 0.7141 0.0698 1.39E-06 
13 91953719 GPC5 rs1332216 T C 0.7421 1.0418 0.6966 0.0753 1.56E-06 
13 91954199 GPC5 rs10161911 C T 0.7413 1.0394 0.6967 0.0753 1.57E-06 
13 91955192 GPC5 rs9523299 G A 0.7423 1.0436 0.697 0.0752 1.59E-06 
15 78906177 CHRNA3-A5-B4 rs146009840 A T 0.6472 1.0026 0.7153 0.0698 1.59E-06 
19 34340136 KCTD15 rs10421416 G T 0.9691 0.9538 0.3529 0.2175 1.68E-06 
19 34340137 KCTD15 rs10423005 C T 0.9691 0.9537 0.3529 0.2175 1.68E-06 
13 91957035 GPC5 rs7335045 A G 0.7423 1.0422 0.6975 0.0753 1.69E-06 
13 91956188 GPC5 rs9589183 C T 0.7423 1.0424 0.6976 0.0752 1.71E-06 
13 91956038 GPC5 rs7989842 G T 0.7423 1.0425 0.6977 0.0752 1.71E-06 
13 91953721 GPC5 rs1332217 T G 0.7417 1.0406 0.6976 0.0753 1.72E-06 
13 91965134 GPC5 rs9515908 C T 0.7501 0.9802 0.6872 0.0784 1.73E-06 
13 91955287 GPC5 chr13:91955287:I A AT 0.7423 1.0426 0.6978 0.0752 1.73E-06 
15 78867482 CHRNA3-A5-B4 rs17486278 A C 0.6465 1.0055 0.7171 0.0697 1.80E-06 
13 91949562 GPC5 rs9515905 A G 0.7417 1.039 0.698 0.0753 1.82E-06 
13 91949444 GPC5 rs9523296 G A 0.7417 1.0389 0.6981 0.0753 1.83E-06 
13 91950114 GPC5 rs7986895 C A 0.7416 1.0385 0.6982 0.0753 1.86E-06 
15 78882925 CHRNA3-A5-B4 rs16969968 G A 0.6482 1.0079 0.7175 0.0696 1.86E-06 
13 91963080 GPC5 rs1475655 A T 0.7503 0.9823 0.6884 0.0783 1.88E-06 
13 91952853 GPC5 chr13:91952853:D CA C 0.7423 1.0423 0.6987 0.0752 1.89E-06 
13 91940278 GPC5 rs28620036 C T 0.76 0.9996 0.6875 0.0788 1.95E-06 
13 91948047 GPC5 rs9523295 G A 0.7416 1.038 0.6989 0.0753 1.98E-06 
13 91955562 GPC5 rs7995715 T G 0.7399 1.0426 0.7002 0.075 2.01E-06 
13 91950403 GPC5 rs9515906 G C 0.7479 1.0313 0.6962 0.0762 2.03E-06 
13 91946788 GPC5 rs12708388 C T 0.7415 1.0372 0.6992 0.0753 2.05E-06 
13 91946343 GPC5 rs12867738 G A 0.7415 1.0368 0.6994 0.0754 2.08E-06 
13 91946092 GPC5 rs9515904 G T 0.7414 1.0366 0.6994 0.0754 2.10E-06 
13 91945089 GPC5 rs9523293 C T 0.7414 1.0359 0.6996 0.0754 2.14E-06 
13 91942919 GPC5 rs34165267 C T 0.7414 1.0357 0.6996 0.0754 2.15E-06 
13 91942808 GPC5 rs35921784 T C 0.7414 1.0357 0.6996 0.0754 2.16E-06 
13 91941936 GPC5 rs9583908 T C 0.7414 1.0357 0.6996 0.0754 2.16E-06 
13 91940083 GPC5 rs7984992 T C 0.7414 1.0356 0.6997 0.0754 2.17E-06 
13 91940484 GPC5 rs7994469 G A 0.7414 1.0356 0.6997 0.0754 2.17E-06 
15 78886947 CHRNA3-A5-B4 rs4887067 G A 0.6479 1.0069 0.719 0.0697 2.17E-06 
13 91940169 GPC5 rs7985179 T A 0.7414 1.0356 0.6997 0.0754 2.17E-06 
15 78886198 CHRNA3-A5-B4 rs8192482 C T 0.6479 1.0069 0.719 0.0697 2.17E-06 
13 91939270 GPC5 rs9583907 C T 0.7414 1.0355 0.6997 0.0754 2.17E-06 
15 78894339 CHRNA3-A5-B4 rs1051730 G A 0.6469 1.0038 0.7189 0.0697 2.20E-06 
15 78868636 CHRNA3-A5-B4 rs72740964 G A 0.6485 1.006 0.7191 0.0697 2.24E-06 
15 78922638 CHRNA3-A5-B4 rs2869548 G A 0.617 0.9761 0.7202 0.0694 2.27E-06 
15 78849034 CHRNA3-A5-B4 rs58365910 T C 0.6394 1.0026 0.7202 0.0694 2.28E-06 
15 78857939 CHRNA3-A5-B4 rs55853698 T G 0.6436 0.9999 0.7193 0.0697 2.29E-06 
15 78862453 CHRNA3-A5-B4 rs7172118 C A 0.648 1.0026 0.7192 0.0698 2.35E-06 
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African-Americans.  Within AAs separately, the strongest association with 
FTND nicotine dependence in the GPC5 region of chromosome 13 is not the bin tagged 
by rs7995715, although this SNP is still marginally significant (p= 0.01, OR=1.33, 95% 
CI=1.09-1.57).  The gene that dominates the top fifty genome-wide significant results 
with FTND nicotine dependence is PLXNA2 (Table 3 and Figure 8 for Manhattan plot). 
This gene is a semaphorin co-receptor that is expressed during nervous system 
development, and has been found at elevated levels in patients with schizophrenia 
(Eastwood, Law, Everall, & Harrison, 2003). A GWAS of schizophrenia resulted in 
several SNPs in this gene associated with disease status (Mah et al., 2006).  One group 
found an association between a SNP in this gene and anxiety, depression, neuroticism 
and psychological distress (Wray et al., 2007). It would make sense that this gene is also 
associated with addiction phenotypes, since addiction is highly comorbid with other 
psychiatric disorders. Interestingly, the GWAS study was in European-Americans, yet we 
find association with variants in PLXNA2 and FTND nicotine dependence predominantly 
in African- Americans.  
 
Figure 8.  Loci for susceptibility to FTND nicotine dependence detected by GWAS 
among African Americans. Manhattan plot of association test results of GWAS data 
showing the chromosomal position of genotyped or imputed SNPs plotted against 
−log10P. The red horizontal line represents the threshold for genome-wide significance 
(p < 5 × 10−8). 
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Table 3 
 
Top 50 SNPs in the GWAS in the African-American sample 
Genome-wide Top 50 SNPs in African-Americans from FTND Nicotine Dependence Association Analysis 
CHR Position Gene rs number A1 A2 Freq INFO OR SE P-Value 
1 208909872 PLXNA2 rs11119123 G T 0.6294 0.9785 0.5157 0.1269 1.80E-07 
1 208904565 PLXNA2 chr1:208904565:D GATAA G 0.6227 0.9705 0.5188 0.1267 2.23E-07 
1 208905388 PLXNA2 rs73090281 A G 0.623 0.9707 0.519 0.1267 2.27E-07 
1 208905914 PLXNA2 rs75097667 C T 0.6232 0.971 0.5192 0.1267 2.31E-07 
1 208906343 PLXNA2 rs2297940 G A 0.6233 0.9712 0.5194 0.1267 2.33E-07 
1 208907775 PLXNA2 rs11119122 C T 0.6211 0.9646 0.5274 0.1266 4.31E-07 
1 208913341 PLXNA2 rs12063346 T C 0.6341 0.9668 0.5279 0.1277 5.61E-07 
7 33543550 BBS9 rs2392241 G A 0.1266 0.9966 0.4246 0.1712 5.67E-07 
8 5443069 CSMD1 rs11776337 G A 0.8926 0.991 2.5085 0.1843 6.03E-07 
1 208874955 PLXNA2 chr1:208874955:D CAGCT C 0.5573 0.9289 1.8505 0.1233 6.04E-07 
8 5443259 CSMD1 rs11787025 A T 0.8888 0.9626 2.5042 0.1841 6.18E-07 
8 5444800 CSMD1 rs7815374 A G 0.892 0.9877 2.5013 0.1842 6.47E-07 
1 208881060 PLXNA2 rs189457972 G A 0.6126 0.8835 0.5174 0.1327 6.82E-07 
1 208912269 PLXNA2 rs61434781 A T 0.6239 0.9703 0.5344 0.1262 6.94E-07 
1 208882605 PLXNA2 rs73088247 A G 0.5662 0.9653 0.542 0.1234 6.98E-07 
1 208885796 PLXNA2 rs6540486 G A 0.5956 0.9476 0.5345 0.1265 7.43E-07 
1 208903281 PLXNA2 rs2275912 G T 0.6372 0.9626 0.5305 0.1284 7.88E-07 
8 5443046 CSMD1 rs11774009 T C 0.8919 0.9892 2.4739 0.1838 8.27E-07 
1 17552875 PLXNA2 rs2977290 A G 0.34 0.9413 0.5387 0.1256 8.42E-07 
1 208897416 PLXNA2 rs1166879 C T 0.5334 0.9998 1.7847 0.1177 8.51E-07 
8 5441318 CSMD1 rs2408064 A G 0.8928 0.9907 2.4771 0.1843 8.61E-07 
1 208912736 PLXNA2 rs12062092 T C 0.6318 0.9463 0.5311 0.1286 8.62E-07 
1 208907024 PLXNA2 rs6669474 C A 0.6176 0.9683 0.5389 0.1257 8.71E-07 
1 208906804 PLXNA2 rs2297941 A G 0.6175 0.9681 0.5389 0.1257 8.73E-07 
1 208905917 PLXNA2 rs1166882 C T 0.5267 0.9734 1.796 0.1192 8.93E-07 
7 129555243 UBE2H rs141050514 G A 0.9502 0.6538 4.9996 0.3276 8.98E-07 
1 208888351 PLXNA2 rs1770207 C T 0.578 0.9546 1.8191 0.1218 9.04E-07 
1 208881174 PLXNA2 rs138249513 G A 0.5846 0.9362 0.5387 0.1266 1.02E-06 
1 208885801 PLXNA2 rs6540487 T C 0.5851 0.9444 0.5409 0.126 1.08E-06 
1 208876405 PLXNA2 rs12081558 T C 0.5648 0.9617 0.5471 0.1237 1.09E-06 
8 5444781 CSMD1 rs7831116 G A 0.8931 0.9899 2.4529 0.1846 1.17E-06 
1 208880999 PLXNA2 rs112296483 A G 0.6159 0.8745 0.5237 0.1331 1.18E-06 
1 208879549 PLXNA2 chr1:208879549:D CAA C 0.5838 0.9391 0.5423 0.1263 1.26E-06 
7 33549368 BBS9 rs6972695 G C 0.1327 1.0127 0.4459 0.1668 1.28E-06 
1 208881463 PLXNA2 rs148752960 T C 0.5744 0.9477 0.5484 0.1247 1.44E-06 
1 208877502 PLXNA2 rs144386006 C T 0.5991 0.9101 0.5375 0.1292 1.55E-06 
2 131637355 AK127124 chr2:131637355:I T TA 0.9468 0.8888 3.6251 0.2684 1.60E-06 
7 33546619 BBS9 rs2392243 G A 0.133 1.0193 0.451 0.166 1.60E-06 
8 5445144 CSMD1 rs67617814 G C 0.8939 0.991 2.4253 0.1849 1.66E-06 
7 90674192 CDK14 rs962281 C T 0.8435 1.0193 2.0918 0.1546 1.79E-06 
10 133808669 BNIP3 rs11146478 T G 0.6216 0.9022 0.5351 0.1311 1.83E-06 
8 5454722 CSMD1 rs4875594 C T 0.8071 0.8839 2.0981 0.1556 1.90E-06 
7 129543199 UBE2H rs17559441 C G 0.9554 0.69 4.9778 0.3373 1.95E-06 
8 5435605 CSMD1 rs4875588 A G 0.9109 0.9721 2.6245 0.2034 2.10E-06 
8 5441053 CSMD1 rs4875593 G A 0.9017 0.9925 2.4725 0.1913 2.22E-06 
1 208886608 PLXNA2 rs73090226 A G 0.5772 0.9546 0.555 0.1245 2.25E-06 
1 208887322 PLXNA2 rs11811442 C T 0.5793 0.9571 0.5558 0.1246 2.43E-06 
1 208886470 PLXNA2 rs17013108 A G 0.5794 0.9575 0.556 0.1246 2.45E-06 
1 208886512 PLXNA2 chr1:208886512:D CT C 0.5794 0.9575 0.556 0.1246 2.45E-06 
1 208886536 PLXNA2 chr1:208886536:I A AT 0.5794 0.9575 0.556 0.1246 2.45E-06 
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However, with the phenotype of CPD, rs7995715 in AAs alone is not at all 
significant (p=0.95, β=0.00).  This is interesting because this could be why the signal on 
chromosome 8 was not picked up in a large meta-analysis using CPD, but was picked up 
as GWS using FTND nicotine dependence as the phenotype (Rice et al., 2012).  Lastly 
with TTF, rs7995715 is again more significant (p=0.02, β=0.17).  The association on 
chromosome 15 with FTND nicotine dependence is high although not as strong as in 
European-Americans (p=8.83x10-3, OR=1.5, 95% CI= 1.2-1.8 in AAs). Again, covariates 
used in all cases were age, sex, PC1 and PC2.  For full regional results for the combined 
sample as well as separate samples, refer to Table 4 for FTND nicotine dependence near 
GPC5, Table 5 for CPD near GPC5, Table 6 for TTF near GPC5, and Table 7 for FTND 
nicotine dependence near CHRNA5-A3-B4.  
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Table 4 
 
Top 30 SNPs in the GPC5 region associated with FTND nicotine dependence 
 
   FTND-Combined Sample FTND - EAs Only FTND - AAs Only 
SNP A1 A2 Freq OR SE P-Value Freq OR SE P-Value Freq OR SE P-Value 
rs7995715 T G 0.68 0.71 0.06 3.27E-08 0.74 0.70 0.08 2.01E-06 0.50 0.75 0.12 1.27E-02 
rs9515908 C T 0.71 0.71 0.07 1.96E-07 0.75 0.69 0.08 1.73E-06 0.59 0.79 0.12 4.65E-02 
rs9523295 G A 0.70 0.72 0.06 2.15E-07 0.74 0.70 0.08 1.98E-06 0.60 0.80 0.12 4.74E-02 
rs9523288 C T 0.82 0.67 0.08 2.15E-07 0.86 0.69 0.10 7.92E-05 0.69 0.67 0.13 2.51E-03 
rs67147421 A C 0.82 0.67 0.08 2.17E-07 0.86 0.69 0.10 1.24E-04 0.70 0.66 0.13 1.54E-03 
rs9523289 G A 0.81 0.67 0.08 2.26E-07 0.86 0.68 0.10 6.10E-05 0.69 0.68 0.13 3.51E-03 
rs9301726 T C 0.70 0.72 0.06 2.28E-07 0.74 0.69 0.08 1.30E-06 0.59 0.81 0.11 6.80E-02 
rs7994634 C T 0.70 0.72 0.06 2.28E-07 0.74 0.69 0.08 1.27E-06 0.59 0.81 0.11 6.91E-02 
rs7986895 C A 0.70 0.72 0.06 2.31E-07 0.74 0.70 0.08 1.86E-06 0.59 0.80 0.11 5.31E-02 
rs7335045 A G 0.70 0.72 0.06 2.35E-07 0.74 0.70 0.08 1.69E-06 0.59 0.81 0.11 5.93E-02 
rs9589183 C T 0.70 0.72 0.06 2.38E-07 0.74 0.70 0.08 1.71E-06 0.59 0.81 0.11 5.93E-02 
rs7989842 G T 0.70 0.72 0.06 2.38E-07 0.74 0.70 0.08 1.71E-06 0.59 0.81 0.11 5.93E-02 
rs9523299 G A 0.70 0.72 0.06 2.42E-07 0.74 0.70 0.08 1.59E-06 0.59 0.81 0.11 6.00E-02 
rs1475655 A T 0.71 0.72 0.06 2.60E-07 0.75 0.69 0.08 1.88E-06 0.60 0.80 0.12 5.68E-02 
rs9523296 G A 0.70 0.72 0.06 2.77E-07 0.74 0.70 0.08 1.83E-06 0.59 0.81 0.11 6.24E-02 
chr13: 
91955287:I A AT 0.70 0.73 0.06 3.05E-07 0.74 0.70 0.08 1.73E-06 0.59 0.81 0.11 6.93E-02 
chr13: 
91952853:D CA C 0.70 0.73 0.06 4.15E-07 0.74 0.70 0.08 1.89E-06 0.59 0.82 0.11 8.36E-02 
rs1332216 T C 0.67 0.73 0.06 4.57E-07 0.74 0.70 0.08 1.56E-06 0.49 0.83 0.11 1.11E-01 
rs73599638 G A 0.82 0.68 0.08 5.06E-07 0.86 0.70 0.10 1.61E-04 0.69 0.68 0.13 3.03E-03 
rs10161911 C T 0.69 0.73 0.06 5.41E-07 0.74 0.70 0.08 1.57E-06 0.54 0.84 0.11 1.18E-01 
rs1332217 T G 0.68 0.73 0.06 6.63E-07 0.74 0.70 0.08 1.72E-06 0.50 0.84 0.11 1.29E-01 
rs9515905 A G 0.69 0.74 0.06 8.87E-07 0.74 0.70 0.08 1.82E-06 0.57 0.85 0.11 1.50E-01 
rs9515906 G C 0.69 0.74 0.06 1.06E-06 0.75 0.70 0.08 2.03E-06 0.53 0.85 0.11 1.52E-01 
rs68126334 C T 0.82 0.69 0.08 1.39E-06 0.86 0.69 0.10 1.08E-04 0.69 0.72 0.13 1.25E-02 
rs59920274 C G 0.80 0.70 0.08 2.36E-06 0.86 0.69 0.10 1.21E-04 0.64 0.74 0.12 1.46E-02 
rs9583905 T A 0.81 0.70 0.08 3.43E-06 0.86 0.69 0.10 1.16E-04 0.67 0.75 0.13 2.71E-02 
rs7994469 G A 0.72 0.75 0.06 3.50E-06 0.74 0.70 0.08 2.17E-06 0.65 0.89 0.12 3.19E-01 
rs9583907 C T 0.72 0.75 0.06 3.76E-06 0.74 0.70 0.08 2.17E-06 0.65 0.89 0.12 3.24E-01 
rs9523293 C T 0.72 0.75 0.06 3.77E-06 0.74 0.70 0.08 2.14E-06 0.65 0.89 0.12 3.27E-01 
rs34165267 C T 0.72 0.75 0.06 3.79E-06 0.74 0.70 0.08 2.15E-06 0.65 0.89 0.12 3.27E-01 
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Table 5 
 
Top 30 SNPs in the GPC5 region associated with cigarettes per day (CPD) 
 
   CPD - Combined Sample CPD - EAs Only CPD - AAs Only 
SNP A1 A2 Freq BETA SE P-Value Freq BETA SE P-Value Freq BETA SE P-Value 
rs1475655 A T 0.71 -0.14 0.03 4.09E-05 0.75 -0.18 0.04 1.18E-05 0.60 -0.02 0.05 6.60E-01 
rs9523299 G A 0.70 -0.13 0.03 8.23E-05 0.74 -0.17 0.04 3.27E-05 0.59 -0.02 0.05 6.41E-01 
rs7994634 C T 0.70 -0.13 0.03 8.57E-05 0.74 -0.17 0.04 3.31E-05 0.59 -0.02 0.05 6.65E-01 
rs9301726 T C 0.70 -0.13 0.03 8.66E-05 0.74 -0.17 0.04 3.35E-05 0.59 -0.02 0.05 6.65E-01 
rs7986895 C A 0.70 -0.13 0.03 9.19E-05 0.74 -0.17 0.04 4.29E-05 0.59 -0.03 0.05 6.14E-01 
rs12561118 T C 0.90 0.23 0.06 9.43E-05 0.87 0.24 0.07 2.01E-04 0.97 0.02 0.18 9.06E-01 
chr13: 
91955287:I A AT 0.70 -0.13 0.03 9.44E-05 0.74 -0.17 0.04 3.65E-05 0.59 -0.02 0.05 6.67E-01 
rs9523295 G A 0.70 -0.13 0.03 1.04E-04 0.74 -0.17 0.04 4.45E-05 0.60 -0.02 0.05 6.42E-01 
rs9523296 G A 0.70 -0.13 0.03 1.07E-04 0.74 -0.17 0.04 4.25E-05 0.59 -0.02 0.05 6.72E-01 
chr13: 
91952853:D CA C 0.70 -0.12 0.03 1.09E-04 0.74 -0.16 0.04 4.53E-05 0.59 -0.02 0.05 6.64E-01 
rs7335045 A G 0.70 -0.12 0.03 1.14E-04 0.74 -0.17 0.04 3.61E-05 0.59 -0.02 0.05 7.50E-01 
rs9589183 C T 0.70 -0.12 0.03 1.15E-04 0.74 -0.17 0.04 3.62E-05 0.59 -0.02 0.05 7.50E-01 
rs7989842 G T 0.70 -0.12 0.03 1.15E-04 0.74 -0.17 0.04 3.63E-05 0.59 -0.02 0.05 7.50E-01 
rs9515908 C T 0.71 -0.13 0.03 1.17E-04 0.75 -0.18 0.04 1.11E-05 0.59 0.01 0.05 8.93E-01 
rs7995715 T G 0.68 -0.12 0.03 1.40E-04 0.74 -0.17 0.04 3.38E-05 0.50 0.00 0.05 9.49E-01 
rs9523293 C T 0.72 -0.12 0.03 3.94E-04 0.74 -0.16 0.04 4.61E-05 0.65 0.01 0.05 8.48E-01 
rs34165267 C T 0.72 -0.12 0.03 3.94E-04 0.74 -0.16 0.04 4.62E-05 0.65 0.01 0.05 8.49E-01 
rs9583907 C T 0.72 -0.12 0.03 3.99E-04 0.74 -0.16 0.04 4.64E-05 0.65 0.01 0.05 8.47E-01 
rs7994469 G A 0.72 -0.12 0.03 4.07E-04 0.74 -0.16 0.04 4.64E-05 0.65 0.01 0.05 8.12E-01 
rs12873378 T A 0.69 -0.13 0.04 4.20E-04 0.73 -0.15 0.05 2.12E-03 0.59 -0.10 0.06 8.23E-02 
rs7985179 T A 0.72 -0.11 0.03 4.22E-04 0.74 -0.16 0.04 4.64E-05 0.65 0.01 0.05 8.14E-01 
rs7984992 T C 0.72 -0.11 0.03 4.26E-04 0.74 -0.16 0.04 4.64E-05 0.65 0.01 0.05 8.10E-01 
rs9583908 T C 0.72 -0.11 0.03 4.26E-04 0.74 -0.16 0.04 4.63E-05 0.65 0.01 0.05 8.10E-01 
rs12867738 G A 0.71 -0.11 0.03 4.43E-04 0.74 -0.16 0.04 4.56E-05 0.61 0.01 0.05 7.89E-01 
rs12708388 C T 0.71 -0.11 0.03 4.60E-04 0.74 -0.16 0.04 4.52E-05 0.64 0.02 0.05 7.64E-01 
rs9515905 A G 0.69 -0.11 0.03 4.96E-04 0.74 -0.17 0.04 4.24E-05 0.57 0.02 0.05 7.00E-01 
rs10161911 C T 0.69 -0.11 0.03 5.12E-04 0.74 -0.17 0.04 3.72E-05 0.54 0.02 0.05 6.41E-01 
rs1332217 T G 0.68 -0.11 0.03 5.60E-04 0.74 -0.17 0.04 4.24E-05 0.50 0.03 0.05 6.22E-01 
rs1332216 T C 0.67 -0.11 0.03 7.13E-04 0.74 -0.17 0.04 3.83E-05 0.49 0.04 0.05 4.90E-01 
rs9515906 G C 0.69 -0.11 0.03 9.12E-04 0.75 -0.16 0.04 8.83E-05 0.53 0.02 0.05 6.86E-01 
 
Data shown for the combined sample and EAs/AAs alone. Table sorted by p-value in the 
combined sample. 
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Table 6 
 
Top 30 SNPs in the GPC5 region associated with time to first cigarette (TTF) 
 
   TTF - Combined Sample TTF - EAs Only TTF - AAs Only 
SNP A1 A2 Freq BETA SE P-Value Freq BETA SE P-Value Freq BETA SE P-Value 
rs7995715 T G 0.68 -0.21 0.04 4.72E-08 0.74 -0.22 0.05 1.85E-06 0.50 -0.17 0.07 1.83E-02 
rs1475655 A T 0.71 -0.22 0.04 5.27E-08 0.75 -0.23 0.05 1.24E-06 0.60 -0.17 0.07 2.05E-02 
rs9515908 C T 0.71 -0.22 0.04 6.28E-08 0.75 -0.23 0.05 1.14E-06 0.59 -0.17 0.07 2.41E-02 
rs9523289 G A 0.81 -0.26 0.05 6.46E-08 0.86 -0.23 0.06 9.34E-05 0.69 -0.27 0.08 6.38E-04 
rs9523295 G A 0.70 -0.21 0.04 8.01E-08 0.74 -0.22 0.05 1.69E-06 0.60 -0.16 0.07 2.24E-02 
rs7994634 C T 0.70 -0.21 0.04 8.44E-08 0.74 -0.23 0.05 1.03E-06 0.59 -0.15 0.07 3.41E-02 
rs9301726 T C 0.70 -0.21 0.04 8.47E-08 0.74 -0.23 0.05 1.05E-06 0.59 -0.15 0.07 3.36E-02 
rs7335045 A G 0.70 -0.21 0.04 8.59E-08 0.74 -0.22 0.05 1.38E-06 0.59 -0.16 0.07 2.86E-02 
rs9589183 C T 0.70 -0.21 0.04 8.67E-08 0.74 -0.22 0.05 1.39E-06 0.59 -0.16 0.07 2.86E-02 
rs7989842 G T 0.70 -0.21 0.04 8.69E-08 0.74 -0.22 0.05 1.40E-06 0.59 -0.16 0.07 2.86E-02 
rs9523299 G A 0.70 -0.21 0.04 9.36E-08 0.74 -0.22 0.05 1.29E-06 0.59 -0.15 0.07 3.04E-02 
rs7986895 C A 0.70 -0.21 0.04 9.64E-08 0.74 -0.22 0.05 1.59E-06 0.59 -0.16 0.07 2.71E-02 
rs9523296 G A 0.70 -0.21 0.04 1.13E-07 0.74 -0.22 0.05 1.57E-06 0.59 -0.15 0.07 3.17E-02 
chr13:91955287:I A AT 0.70 -0.21 0.04 1.15E-07 0.74 -0.22 0.05 1.41E-06 0.59 -0.15 0.07 3.45E-02 
chr13:91952853:D CA C 0.70 -0.21 0.04 1.33E-07 0.74 -0.22 0.05 1.78E-06 0.59 -0.15 0.07 3.26E-02 
rs9523288 C T 0.82 -0.25 0.05 1.40E-07 0.86 -0.22 0.06 1.68E-04 0.69 -0.27 0.08 7.50E-04 
rs67147421 A C 0.82 -0.25 0.05 1.72E-07 0.86 -0.22 0.06 2.45E-04 0.70 -0.27 0.08 6.14E-04 
rs73599638 G A 0.82 -0.24 0.05 3.89E-07 0.86 -0.21 0.06 3.65E-04 0.69 -0.26 0.08 9.84E-04 
rs10161911 C T 0.69 -0.20 0.04 3.90E-07 0.74 -0.22 0.05 1.37E-06 0.54 -0.12 0.07 9.54E-02 
rs9515905 A G 0.69 -0.20 0.04 4.35E-07 0.74 -0.22 0.05 1.56E-06 0.57 -0.12 0.07 9.25E-02 
rs1332216 T C 0.67 -0.20 0.04 4.44E-07 0.74 -0.22 0.05 1.34E-06 0.49 -0.12 0.07 1.09E-01 
rs1332217 T G 0.68 -0.19 0.04 6.70E-07 0.74 -0.22 0.05 1.48E-06 0.50 -0.11 0.07 1.29E-01 
rs68126334 C T 0.82 -0.23 0.05 7.97E-07 0.86 -0.22 0.06 2.20E-04 0.69 -0.23 0.08 3.73E-03 
rs9515906 G C 0.69 -0.19 0.04 1.59E-06 0.75 -0.22 0.05 3.36E-06 0.53 -0.11 0.07 1.38E-01 
rs9583905 T A 0.81 -0.23 0.05 1.64E-06 0.86 -0.22 0.06 2.38E-04 0.67 -0.21 0.08 7.16E-03 
rs9301724 C T 0.80 -0.22 0.05 1.72E-06 0.85 -0.21 0.06 2.12E-04 0.67 -0.21 0.08 7.81E-03 
rs9523293 C T 0.72 -0.18 0.04 2.58E-06 0.74 -0.22 0.05 1.81E-06 0.65 -0.08 0.07 2.50E-01 
rs34165267 C T 0.72 -0.18 0.04 2.60E-06 0.74 -0.22 0.05 1.82E-06 0.65 -0.08 0.07 2.50E-01 
rs9583907 C T 0.72 -0.18 0.04 2.61E-06 0.74 -0.22 0.05 1.83E-06 0.65 -0.08 0.07 2.50E-01 
rs59920274 C G 0.80 -0.22 0.05 2.92E-06 0.86 -0.22 0.06 2.40E-04 0.64 -0.20 0.08 9.36E-03 
 
The data shown are for the combined sample and EAs and AAs alone.  The table is sorted 
by p-value in the combined sample. 
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Table 7 
 
Top 30 SNPs in the CHRNA5-A3-B4 region associated with FTND nicotine dependence 
 
   FTND - Combined Sample FTND - EAs Only FTND - AAs Only 
SNP A1 A2 Freq OR SE P-Value Freq OR SE P-Value Freq OR SE P-Value 
chr15: 
78874842:D AG A 0.73 0.69 0.07 2.93E-08 0.67 0.72 0.07 4.87E-06 0.89 0.43 0.22 1.31E-04 
rs114205691 C T 0.69 0.71 0.06 4.35E-08 0.65 0.71 0.07 1.32E-06 0.82 0.67 0.15 8.83E-03 
rs17486278 A C 0.67 0.72 0.06 4.91E-08 0.65 0.72 0.07 1.80E-06 0.72 0.72 0.13 9.28E-03 
rs147499554 C T 0.73 0.69 0.07 5.33E-08 0.68 0.72 0.07 6.91E-06 0.86 0.52 0.19 5.31E-04 
rs141518190 A G 0.73 0.69 0.07 5.33E-08 0.68 0.72 0.07 6.91E-06 0.86 0.52 0.19 5.31E-04 
rs2036527 G A 0.68 0.72 0.06 7.54E-08 0.64 0.72 0.07 2.96E-06 0.78 0.68 0.14 5.36E-03 
rs16969968 G A 0.73 0.70 0.07 7.82E-08 0.65 0.72 0.07 1.86E-06 0.94 0.43 0.29 3.31E-03 
rs55781567 C G 0.67 0.72 0.06 9.70E-08 0.64 0.72 0.07 2.66E-06 0.74 0.72 0.13 1.29E-02 
rs55676755 C G 0.70 0.71 0.06 9.74E-08 0.65 0.71 0.07 1.39E-06 0.83 0.70 0.16 2.34E-02 
rs11633958 C T 0.73 0.70 0.07 9.95E-08 0.65 0.72 0.07 2.35E-06 0.94 0.44 0.28 3.73E-03 
rs8192482 C T 0.73 0.70 0.07 1.03E-07 0.65 0.72 0.07 2.17E-06 0.94 0.43 0.29 3.96E-03 
rs4887067 G A 0.73 0.70 0.07 1.03E-07 0.65 0.72 0.07 2.17E-06 0.94 0.43 0.29 3.97E-03 
rs55853698 T G 0.72 0.70 0.07 1.08E-07 0.64 0.72 0.07 2.29E-06 0.92 0.53 0.23 5.87E-03 
rs17487223 C T 0.69 0.71 0.07 1.21E-07 0.62 0.72 0.07 3.08E-06 0.89 0.58 0.21 1.07E-02 
rs72740955 C T 0.71 0.71 0.06 1.29E-07 0.64 0.72 0.07 3.54E-06 0.88 0.60 0.18 5.71E-03 
rs140330585 G A 0.71 0.71 0.06 1.36E-07 0.65 0.72 0.07 3.13E-06 0.87 0.63 0.18 1.11E-02 
rs2869548 G A 0.70 0.70 0.07 1.48E-07 0.62 0.72 0.07 2.27E-06 0.94 0.46 0.29 6.30E-03 
rs17486195 A G 0.71 0.71 0.06 1.52E-07 0.65 0.72 0.07 2.42E-06 0.88 0.65 0.18 1.63E-02 
rs7172118 C A 0.71 0.71 0.06 1.74E-07 0.65 0.72 0.07 2.35E-06 0.89 0.64 0.19 1.62E-02 
rs1051730 G A 0.71 0.72 0.06 2.18E-07 0.65 0.72 0.07 2.20E-06 0.88 0.66 0.18 2.28E-02 
rs951266 G A 0.71 0.71 0.06 2.21E-07 0.65 0.72 0.07 2.65E-06 0.89 0.64 0.19 1.82E-02 
rs56077333 C A 0.70 0.72 0.06 2.24E-07 0.66 0.72 0.07 6.55E-06 0.82 0.66 0.16 7.79E-03 
rs7180002 A T 0.71 0.72 0.06 2.25E-07 0.65 0.72 0.07 2.71E-06 0.89 0.64 0.19 1.84E-02 
rs8031948 G T 0.70 0.72 0.06 2.46E-07 0.65 0.73 0.07 8.71E-06 0.85 0.64 0.17 8.41E-03 
rs56390833 C A 0.71 0.72 0.06 2.67E-07 0.65 0.72 0.07 3.10E-06 0.89 0.64 0.19 1.88E-02 
rs138544659 T G 0.73 0.70 0.07 2.84E-07 0.69 0.73 0.07 1.84E-05 0.87 0.54 0.19 1.37E-03 
rs147144681 C T 0.71 0.71 0.07 3.18E-07 0.66 0.72 0.07 4.24E-06 0.85 0.67 0.17 1.78E-02 
rs72740964 G A 0.72 0.71 0.07 3.38E-07 0.65 0.72 0.07 2.24E-06 0.93 0.59 0.25 3.28E-02 
rs58365910 T C 0.67 0.73 0.06 3.75E-07 0.64 0.72 0.07 2.28E-06 0.75 0.76 0.13 4.01E-02 
rs146009840 A T 0.72 0.71 0.07 4.16E-07 0.65 0.72 0.07 1.59E-06 0.93 0.64 0.24 6.80E-02 
 
Data shown for the combined sample and EAs/AAs alone. Table sorted by p-value in the 
combined sample. 
 
Genotype Confirmation.  Using the Sequenom platform, we performed follow-
up genotyping on 28 SNPs in the region of the novel GPC5 signal (Table 8).  All SNPs 
with an r2 >0.8 with rs7995715, and any SNP with an r2 >0.8 with the first group of SNPs 
were chosen for follow up genotyping. We confirm the results from the imputed data of a 
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GWS signal near GPC5 associated with nicotine dependence phenotypes. In a logistic 
analysis on chromosome 13, rs9515908 (r2= 0.96 with rs7995715) had an N=2614; p-
value = 8.42 x 10-8 and OR=1.4 with the phenotype of FTND nicotine dependence.  
Table 8 
Results from the follow-up genotyping of SNPs in LD with rs7995715 
Sequenom Genotyping Confirmation 
CHR SNP BP N Freq OR P-Value 
13 rs9515908 91965134 2614 0.30 1.40 8.42E-08 
13 rs7995715 91955562 2567 0.32 1.39 1.28E-07 
13 rs9523295 91948047 2565 0.29 1.39 1.75E-07 
13 rs7994634 91953042 2613 0.30 1.38 2.38E-07 
13 rs9523296 91949444 2604 0.30 1.38 2.60E-07 
13 rs9523299 91955192 2614 0.30 1.38 3.30E-07 
13 rs9301726 91952459 2612 0.30 1.38 3.49E-07 
13 rs1475655 91963080 2607 0.29 1.37 5.73E-07 
13 rs9515905 91949562 2491 0.30 1.36 1.55E-06 
13 rs7139676 91970313 2611 0.29 1.32 9.40E-06 
13 rs869544 91956987 2606 0.49 0.78 1.44E-05 
13 rs78375372 91976200 2612 0.12 0.83 0.03625 
13 rs74357547 92027055 2611 0.03 0.78 0.1375 
13 rs16945778 91978780 2609 0.18 0.91 0.1881 
13 rs9634624 92029241 2611 0.22 0.93 0.3163 
13 rs7332464 92065093 2606 0.18 1.08 0.3563 
13 rs72640378 92106136 2613 0.01 0.75 0.361 
13 rs17556509 91995570 2610 0.07 0.91 0.4026 
13 rs74622835 92058305 2612 0.07 0.93 0.4742 
13 rs7325427 91930464 2613 0.05 0.90 0.4897 
13 rs9556077 91945836 2581 0.15 0.95 0.493 
13 rs9589195 91974565 2614 0.09 1.07 0.4959 
13 rs9556074 91904181 2611 0.00 1.35 0.5288 
13 rs12232047 91928228 2612 0.00 1.31 0.5921 
13 rs9589196 91974740 2600 0.43 0.98 0.7133 
13 rs7324710 92085325 2597 0.14 1.03 0.7254 
13 rs79977572 92095067 2613 0.04 0.95 0.7509 
13 rs7318578 92005469 2612 0.35 0.99 0.8457 
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Replication Datasets.  We have attempted to replicate these findings in 
independent datasets.  The first of which was in the SAGE dataset, subtracting those 
individuals that overlap between SAGE and COGEND.  However with the phenotype of 
FTND nicotine dependence we could not replicate the results from the COGEND dataset 
for either chromosome 13 or chromosome 15.  In European-Americans, the p-value for 
rs7995715 was 0.08, OR=1.40, 95% CI=1.02-1.78; in African-Americans p=0.94, 
OR=1.01, 95% CI=0.67-1.39; meta-analysis p=0.12, OR=1.22. For rs114205691, in 
European-Americans, the p-value was 0.73, OR=1.06, 95% CI= 0.70-1.42; in African-
Americans p=0.57, OR=1.14, 95% CI= 0.70-1.58; meta-analysis p=0.93, OR=1.10.  
There was 62% power to detect an association with a p-value less than 0.05 in the COGA 
dataset and a power of 47% in the SAGE-COGEND dataset.  See Table 9 for full results.  
We also examined differing CPD thresholds to see if a different phenotype was more able 
to detect an association.  No matter what the threshold, no SNP in LD with either 
rs7995715 or rs114205691 was significant.  
 We also attempted replication in the individuals in the COGA dataset that are not 
in SAGE.  However rs7995715 was not typed in the COGA dataset. The only two SNPs 
in COGA that are in high LD with rs7995715 that were genotyped in COGA are 
rs9523299 (r2=1) and rs9583907 (r2=1).  We examined both SNPs with the phenotypes of 
CPD as an ordinal trait and dichotomous over 20 CPD vs under 20 CPD.  In both cases 
for both SNPs, neither was significant (0.20<p<0.82, -0.78< β<0.00). 
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Table 9 
Results of SAGE minus COGEND replication attempt for the top SNPs on chromosomes 
13 and 15 
 










FTND_DX     EA 0.08 1.40 0.73 1.06 
AA 0.94 1.01 0.57 1.14 
Meta 0.93 1.10 0.20 1.18 
     CPD Over 20/Under 
10     
EA 0.94 1.02 0.61 1.13 
AA 0.65 1.10 0.79 1.07 
Meta 0.76 1.06 0.58 1.10 
     CPD Over 20/Under 
20     
EA 0.62 1.07 0.61 1.06 
AA 0.88 1.03 0.73 1.08 
Meta 0.75 1.04 0.77 1.03 
     CPD Over 30/Under 
10     
EA 0.87 1.05 0.83 1.06 
AA 0.26 1.11 0.53 1.20 
Meta 0.69 1.08 0.56 1.12 
     CPD Over 30/Under 
30     
EA 0.33 1.16 0.80 1.03 
AA 0.86 1.04 0.73 1.09 
Meta 0.36 1.12 0.95 1.01 
 
DISCUSSION 
 We report here the largest GWAS for FTND nicotine dependence resulting in 
two genome-wide significant hits.  This is the first time that the known bin on 
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chromosome 15 has been associated with FTND nicotine dependence at the genome-wide 
significant level and this is also the first time there has been an association with nicotine 
dependence and a SNP near a non-candidate gene, in this case GPC5 on chromosome 13.   
Both associations with FTND nicotine dependence are clearly detected in the combined 
analysis as well as the meta-analysis (Appendix A). The signal on chromosome 15 is 
much stronger in European-Americans (p=1.32x10-6, OR=1.4, 95% CI= 1.33-1.47) than 
African-Americans (p=8.83x10-3, OR=1.5, 95% CI=1.2-1.8), partially due to the larger 
EA sample size, however it should be noted that the point estimate of the odds ratios are 
similar even though the p-values are different.  The lower p-value in African-Americans 
is also due to the fact that it has been shown that CPD is not as effective a measure of 
addiction in African-Americans, and CPD is a large component of FTND score. In this 
dataset, CPD in African-Americans is not significantly associated with rs7995715 
(p=0.95, β=0.00), concurring with previous work showing that FTND nicotine 
dependence can succeed where CPD failed in picking up this association (Rice et al. 
2012).  However for the signal on chromosome 13, in addition to FTND nicotine 
dependence, TTF is also genome-wide significant in the combined sample (p=4.72 x 10-8, 
β=-0.21), suggesting that it may be picking up on some aspect of craving that is important 
to the biology of this association at GPC5 that CPD does not pick up as strongly (p=1.40 
x 10-4, β=-0.12). 
 The glypican gene family contains 6 members (GPC1 to GPC6).  This gene 
family is composed of heparin sulphate proteoglycans (HSPGs). GPC5 variants have 
been associated with several types of tumors including lymphomas, neurological tumors, 
and breast tumors (Y. Li & Yang, 2011).  The GPC5 gene contains eight exons encoding 
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572 amino acids and spans a region of 1.47 Mb (Zheng et al., 2012).  In a GWAS of 
never smokers rs2352028/rs2352029 were identified as associated with lung cancer (Y. 
Li et al., 2010), although the p-value of 5.94 x 10−6 was not genome-wide significant. 
Although this has yet to be replicated, Zheng et al. (Zheng et al., 2012) reported a 
nominal p-value of 0.04 in a Han-Chinese population when a recessive model was 
assumed, as well as when cases were narrowed down to only those patients with 
adenocarcinoma.  In a GWAS of alcohol dependence, several SNPs within GPC5 have 
been associated with AD (top hit rs148154304, p=7.80x10-6, Dr. Amy Adkins, personal 
communication).  
 These results are encouraging in that smoking-related phenotypes have been 
previously significantly associated with genotypes in this gene region.  If common gene 
family of the glypicans is any indication of common function, the fact that both GPC4 
and GPC6 have been associated with the psychiatric conditions of attention deficit 
hyperactivity disorder (Lesch et al., 2008) and neuroticism (Calboli et al., 2010) 
respectively is also encouraging, due to the comorbidity of psychiatric conditions. 
Although we have only imputed from ~600,000 SNPs, we have found a new 
genome-wide significant association, as well as replicated a previous association.  
Imputation can be problematic, and result in misleading or spurious associations in some 
cases due to insufficient filtering or improperly combined platforms. However in this 
case, we have taken the most conservative approach possible in that we only used the 
intersection of these two platforms, discarding ~2 million SNPs in the process.  This is 
preferable to simply combining the two datasets, as this incurs many problems of its own, 
including spurious associations that result from a SNP only having been genotyped on 
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one or the other platform, or from having two separate populations imputed together.  We 
also filtered the SNPs with MAF less than 5% and genotyping or imputed call rate of 
97% or higher.  Because of this, we are confident in our results, as well as because the Q-
Q plots show no inflation after removal of the two genome-wide significant SNPs. 
 Although we were not able to replicate our results within either SAGE (without 
COGEND) or in all of COGA, this lack of replication could reflect differences in 
ascertainment of the samples or differences in phenotype: Only the COGEND study has 
FTND measured. In the other studies we relied on CPD which shows a weaker 
association even in the original dataset. We dichotomized the CPD categories to 
approximate the FTND categories but this may not be entirely accurate in samples like 
COGA that have multigenerational families and thus the CPD corresponding to a 
particular FTND may be difference across generations.  Additionally, the lack of 
replication could be due to poor controls.  For example just because a person does not 
smoke many cigarettes a day does not mean they are not addicted to nicotine. A more 
powerful replication sample would be one that has measured FTND nicotine dependence 
and that was ascertained in a similar manner to the discovery dataset.  
Importantly, we also show that although large sample sizes are useful when using the 
GWAS approach, they are not necessary if precise phenotypes are used.  Here we had a 
sample size of less than 3,000; however we have discovered previously unknown 
addiction associations by using a uniformly collected dichotomous phenotype. It is our 
hope that with this new information, new pathways involved in addiction will be studied 
and will lead to novel strategies for cessation therapy and initiation prevention. Like all 
approaches, imputation and GWAS have limitations, including the inability to detect rare 
	   	  	  60 
variants. But if performed carefully and interpreted conservatively, imputation has its 
place in association analyses.  GWAS can identify genes involved in underlying 
pathways, which is promising for increasing our understanding of the biology of 
addiction and addictive behavior.  In the future, we would like to re-genotype all of the 
samples on the 2.5M chip to increase the number of SNPs from which to impute, as this 
may lead to additional discoveries of loci associated with nicotine dependence.	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CHAPTER 3 
LOW FREQUENCY AND COMMON VARIANTS NEAR CHRNB3-CHRNA6 ARE 
ASSOCIATED WITH MULTIPLE SUBSTANCE DEPENDENCIES 
ABSTRACT 
Drug and alcohol dependence are pervasive problems that affect millions of 
individuals across the world every year. Numerous studies have demonstrated the 
presence of drug specific and multi-drug genetic influences. One such genetic factor, the 
CHRNA3-B4-A5 nicotinic receptor gene cluster on chromosome 15, was recently 
identified as a locus contributing to alcohol, cocaine and nicotine dependence, each 
independently of the other. Similarly, our group recently demonstrated an association 
between rare coding variants in CHRNB3 with alcohol and cocaine dependence without 
an effect on nicotine dependence while common variants within the CHRNB3-A6 gene 
cluster have been associated with cigarette consumption in several genome-wide 
association studies. These data suggest that other genetic variants in or near nicotinic 
receptor genes may play a role in one or more of these substance dependencies. 
Generally, these receptors represent intriguing candidate genes for the study of cocaine 
and alcohol dependence because nicotinic receptors are thought to be involved in 
generalized addiction pathways in addition to nicotine specific pathways.  Using 
genotypic data from a GWAS of the Study of Addiction: Genetics and Environment 
(SAGE) dataset including 1976 European-Americans, we tested for association of 
CHRNB3-A6 SNPs with DSM-5 cocaine use disorder and DSM-5 alcohol use disorder.  
Multiple SNPs in the region were significantly associated with increased risk of cocaine 
use disorder, but none were significantly associated with alcohol use disorder after 
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multiple test correction.  Further, inclusion of the most significant SNP as a covariate in a 
linear regression model provided evidence for an additional independent signal within 
this locus for DSM-5 cocaine use disorder, in European Americans. Interestingly, the 
SNPs associated with increased risk for cocaine use disorder, are also associated with 
decreased risk for nicotine dependence in this dataset. When the previously identified 
nicotine dependence risk variant (rs1451240) is included in the model, the newly 
identified SNPs remain associated with DSM-5 cocaine use disorder but are no longer 
associated with nicotine dependence, suggesting that the SNPs in this region affecting 
risk for these two disorders are at least partially independent and that the CHRNB3-A6 
locus contains multiple variants affecting risk for vulnerability to cocaine and nicotine 
dependence. This locus is the second nicotinic receptor gene cluster containing SNPs that 
show opposing directions of effect for nicotine and cocaine dependence risk.  
 
INTRODUCTION 
 Differences in any trait must be due to either genetic or environmental factors or 
both, and addiction is no exception.  From twin studies, we have found that different 
substances have common and specific genetic liabilities.  Numerous twin studies indicate 
a high degree of overlap among genetic factors influencing the liability to a variety of 
substance use disorders (Kendler, Myers, & Prescott, 2007; Tsuang, Bar, Harley, & 
Lyons, 2001).  Genomic studies have also suggested that there are genetic loci that have 
substance-specific effects but also that loci exist that affect risk for the development of 
dependence on multiple substances (see (J. C. Wang et al., 2012) for review).  Loci that 
have been largely implicated to specifically influence a single substance use disorder 
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include those that exert metabolic influence on the substance of abuse. For instance, 
SNPs in cytochrome P450 2A6 (CYP2A6), the gene encoding the major nicotine-
metabolizing enzyme, affect cigarette consumption (Mwenifumbo & Tyndale, 2009; 
Thorgeirsson et al., 2010) and a SNP in the Alcohol Dehydrogenase 1B (ADH1B) gene 
affects levels of alcohol consumption (Bierut et al., 2012) and risk for alcohol 
dependence (J. C. Wang et al., 2012) via regulation of conversion of alcohol to 
acetaldehyde.   
On the other hand, there are numerous examples of receptor encoding loci whose 
effects extend across multiple substance dependence phenotypes (Sherva et al., 2010). 
One such example is the SNP rs16969968 (D398N) in the cholinergic nicotinic receptor 
subunit α5 (CHRNA5) that both increases nicotine dependence risk and decreases cocaine 
dependence risk (Sherva et al., 2010).  The minor allele of this SNP is the most 
significant and widely replicated variant associated with cigarette consumption and is 
also associated with protection against cocaine dependence (Consortium, 2010; Grucza et 
al., 2008; Thorgeirsson et al., 2010).  The protective effect of rs16969968 with CD has 
been replicated in both European and African-Americans (Sherva et al., 2010).  The same 
study also found that another SNP in CHRNA5 (rs684513) is associated with risk for 
cocaine dependence in African-Americans (OR=1.43, P=0.0004).  
 In fact, prior studies of the nicotinic receptors on chromosomes 8 and 15 show 
that variants within or near these receptors are associated with nicotine (Grucza et al., 
2008; S. F. Saccone et al., 2007), alcohol (Haller et al., 2013), and cocaine dependencies 
(Haller et al., 2013).  In addition, a cluster of nicotinic receptors on chromosome 8 
including CHRNA6-B3 was also previously shown to reduce risk for nicotine-related 
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phenotypes in several GWAS of nicotine dependence and cigarettes smoked per day 
(Hoft et al., 2009; Mwenifumbo & Tyndale, 2009; Rice et al., 2012; N. L. Saccone, 
Culverhouse, et al., 2010; N. L. Saccone et al., 2009; S. F. Saccone et al., 2007; 
Thorgeirsson et al., 2010; Zeiger et al., 2008). The role of these specific SNPs in the 
etiology of other drug dependencies remains unexplored but several rare variants in 
CHRNB3 have been associated with increased risk for both cocaine and alcohol 
dependence (Haller et al., 2013).  Together, these results suggest that nicotinic receptors 
are good candidate genes for susceptibility to multiple substance dependence 
vulnerability and that investigation of the role of common and low frequency variants 
within the CHRNB3-A6 locus in drug dependence is warranted. 
Drug addiction is a pervasive problem across cultures and is both an economic 
and psychological burden for the individuals and families involved.  Susceptibility to 
drug use, abuse, and dependence has been shown by several studies to have a moderate to 
high genetic component (Goldman, Oroszi, & Ducci, 2005; J. C. Wang et al., 2012).  The 
one year point prevalence, or the proportion of people possessing a phenotype within a 
one year timeframe, for substance use disorders in the USA, excluding nicotine has been 
estimated to be 9.35% (Goldman et al., 2005). The heritability of cocaine dependence 
(CD) has been estimated from twin studies to be 63-79% (Grucza et al. 2008), and that of 
alcohol dependence (AD) has been estimated to be 40-60% (J. C. Wang et al., 2012).  
However as it is common for an individual to have a dependence on more than one drug, 
as well as to have comorbidity with mental disorders (Goldman et al., 2005), the loci 
associated with one substance, have a greater chance of also being associated with 
multiple substances and other psychiatric disorders. 
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 In this study, we describe a novel association between DSM-5 cocaine use 
disorder and genotyped SNPs (~24kb) upstream of the CHRNB3 transcription start site 
that contains the locus previously discovered to be genome-wide significant with nicotine 
dependence. We show that these SNPs remain significant after adjusting for genotype at 
the SNP previously reported to be associated with nicotine dependence in GWAS, 
suggesting that the cocaine association is not simply due to the nicotine association.   
 
METHODS 
Samples.  Subjects were members of the Study of Addiction: Genetics and 
Environment (SAGE) dataset, part of the Gene Environment Association Studies 
(GENEVA) program of the National Institutes of Health (NIH) Genes, Environment, and 
Health Initiative (Laurie et al., 2010).  SAGE was designed to study alcohol dependence, 
and as a result is composed largely of unrelated alcohol-dependent cases (n = 1048) and 
non-alcohol-dependent control subjects (n = 928). The SAGE dataset was ascertained 
from 3 large substance dependence datasets: the Collaborative Genetic Study of Nicotine 
Dependence (COGEND), the Collaborative Study on the Genetics of Alcoholism 
(COGA) and the Family Study of Cocaine Dependence (FSCD) (Bierut et al., 2010).  For 
the purpose of the current analyses, there were 1976 European-Americans as defined both 
by self-report and principal components from the GWAS data (See Table 10 for a 
summary of comorbidity within the sample). 
The DSM-5 was published on May 18, 2013, and supersedes the DSM-IV text 
revision published in 2000.  In the DSM-5, the DSM-IV criteria cocaine abuse and 
cocaine dependence have been combined into a single cocaine use disorder.  Cocaine use  
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Table 10 
 















disorder is now divided into mild (2-3 criteria), moderate (4-5 criteria) and severe (6 or 
more criteria).  A further difference is that whereas in the DSM-IV, cocaine abuse 
diagnostic criteria required only one symptom, in the DSM-5 diagnostic criteria, a 
diagnosis of mild cocaine use disorder requires at least two criteria to be met.  Lastly, the 
DSM-IV recurrent legal problems criterion for cocaine abuse was replaced with the new 
criterion of craving (Hasin et al., 2013).  These same changes are also true for the 
 
 COGEND COGA FSCD Total 
ND Cases 189 429 196 814 
ND Controls 892 172 98 1162 
     
AUD Cases 769 483 273 1525 
AUD Controls 312 118 21 451 
     
CUD Cases 76 212 218 506 
CUD Controls 1005 389 76 1470 
     
ND, AUD 184 373 189 746 
ND, CUD 54 170 173 397 
ND, AUD, CUD 54 170 168 392 
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phenotype of alcohol use disorder.  We recoded DSM-IV values in SAGE to DSM-5 for 
both cocaine and alcohol use, since we examine both phenotypes in our analyses. 
COGEND Sample.  COGEND was designed as a community based case–control 
study of nicotine dependence. COGEND contains current smokers with nicotine 
dependence defined by a Fagerstrom Test for Nicotine Dependence (FTND) score > 4 
(maximum score of 10) and non-nicotine dependent subjects who had smoked at least 
100 cigarettes and had a lifetime FTND score of zero or one. All subjects were 
ascertained from Detroit and St Louis. Out of the 53,000 subjects who were screened by 
telephone, 2,800 were interviewed in person and approximately 2,700 donated blood 
samples for genetic studies (Rice et al. 2012). 
COGA Sample.  Out of more than 11,000 subjects who participated in COGA, a 
case-control series of unrelated individuals was selected for SAGE. COGA recruited 
subjects in Hartford, Connecticut; Indianapolis, Indiana; Iowa City, Iowa; New York 
City, New York; San Diego, California; St Louis, Missouri; and Washington, DC. For 
inclusion in SAGE, cases had to meet lifetime criteria for DSM-IV alcohol dependence, 
the majority of cases were recruited from alcoholism treatment centers. Control subjects, 
were both biologically unrelated to cases, and had consumed alcohol but never 
experienced any significant alcohol or drug-related problems, according to the Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA) (Rice et al., 2012). 
FSCD Sample.  Subjects in the FSCD were specifically recruited for cocaine use 
from chemical dependency treatment units in the greater St Louis metropolitan area. The 
Missouri Family Registry identified community-based control subjects and matched them 
by age, race, gender and residential zip code. Controls were biologically unrelated 
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individuals from the same communities who consumed alcohol, but had no lifetime 
history of dependence on any substance.  
 Genotyping and quality control.  All DNA samples were genotyped on the 
Illumina Human 1M-Duo beadchip by the Center for Inherited Disease Research (CIDR) 
at Johns Hopkins University. After thorough genotype quality control process, 948,758 of 
the 1,049,008 genotyped SNPs were available for genetic analysis.  Sixty-five of these 
genotyped SNPs fell within the region containing the CHRNA6 and CHRNB3 genes on 
chromosome 8. Of the 65, only SNPs with a minor allele frequency (MAF) >1% and a 
genotyping call rate >0.98 were considered (47 SNPs). Full details regarding the quality 
control procedures are provided in the data cleaning report posted on the GENEVA 
website 
(http://www.genevastudy.org/docs/GENEVA_Alcohol_QC_report_8Oct2008.pdf) and in 
related publications (Bierut et al., 2010; Laurie et al., 2010). 
Phenotypes.  FTND nicotine dependence for all members of the SAGE dataset 
was calculated by adding together all point totals from the FTND questionnaire. Here we 
used an FTND score of 4 or above as a case (N=814) and below 0-3 as a control 
(N=1162).  Alcohol use disorder for all members of the SAGE dataset was measured 
using the DSM-5 criteria (Hasin et al., 2013).  As outlined in the manual, 11 criteria (3 
abuse, 7 dependence and craving) were combined and alcohol use disorder was scored as 
the endorsement of 2 or more of these 11 criteria (N=1525). Unaffected individuals met 
zero or one of the DSM-5 criteria (N=451).  Cocaine use disorder for all members of the 
SAGE dataset was measured using the same DSM-5 criteria.  As outlined in the manual, 
11 criteria (3 abuse, 7 dependence and craving) were combined and cocaine use disorder 
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was scored as the endorsement of 2 or more of these 11 criteria (N=506). Unaffected 
individuals met zero or one of the DSM-5 criteria (N=1470). 
Statistical Analyses.  All analyses were performed on genotyped data.  Association 
analyses were conducted in PLINK (Purcell et al. 2007) for SNPs in the region on 
chromosome 8 encoding the α6 and β3 subunits of nicotinic receptors (42,600,000 kb to 
42,800,000 kb).  Logistic regression with DSM-5 cocaine use disorder as the dependent 
variable was performed. Covariates included were age at interview as a continuous 
variable, gender, study, maximum lifetime FTND score (0-10, based on the Fagerström 
Test of Nicotine Dependence) to control for smoking status, and DSM-5 alcohol use 
disorder.  Study was coded using two dummy variables (yes/no for two of the three 
studies) in order to control for differences in ascertainment.  Haploview was run using the 
genotypes of the study population to determine the number of independent linkage 
disequilibrium (LD) bins in the region using a threshold of r2 ≥0.8.  The Bonferroni 
correction used in this study is p=0.002 (0.05/22), as the number of LD bins in the region 
examined is 22.  A conditional analysis was conducted including allele dosage for the top 
associated SNP as a covariate in the logistic model.   
In a case/control division of subjects based on presence or absence of cocaine use 
disorder, logistic regressions were run both using as controls only those who had been 
exposed to cocaine but had not become dependent (i.e. have used cocaine at least once in 
their lifetime) and all non-cocaine-dependent individuals in the sample, regardless of 
exposure status.  
To improve our understanding of observed associations, the top SNPs identified 
in the whole SAGE dataset were examined using the same models described above in 
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strata of the data defined by study (COGEND, COGA, FSCD), smoking status (FTND 
cases and FTND controls), and alcohol use disorder (DSM-5 cases and DSM-5 controls). 
A two-SNP haplotype analysis was run in R using the top SNP and the SNP tagging the 
bin previously found to be genome-wide significant with nicotine dependence 
(rs1451240) (Rice et al. 2012). This model included the covariates age, sex, study, DSM-
5 alcohol symptom count, FTND total (in the cocaine haplotypes) and DSM-5 cocaine 
use disorder (in the FTND haplotypes), and examined the association with each 
haplotype with the phenotype compared to homozygotes for the reference allele at both 
SNPs. Finally, we used conditional analyses to examine the extent of independence 
between these cocaine-associated SNPs and the previous association in the region with 
nicotine dependence tagged by rs1451240. 
 
RESULTS 
The 47 SNPs within the CHRNA6-B3 region constitute 22 LD bins using an r2 
cutoff ≥ 0.8, requiring a p-value of 0.002 after Bonferroni correction. Eleven SNPs, 
representing four LD bins met this cutoff and are associated with DSM-5 cocaine use 
disorder (Table 11). Overall, a total of thirty-one SNPs were nominally significant 
(2.34x10-4<p<4.66x10-2) in this single SNP analysis. Consistent with previous results in 
an overlapping dataset, we saw a protective effect of rs16969968 in CHRNA5 on risk for 
DSM-5 cocaine use disorder (Grucza et al., 2008).  Inclusion of rs16969968 as a 
covariate had no effect on the association of the top SNP within CHRNA6-CHRNB3, 
rs9298626 with DSM-5 cocaine use disorder.  When we run the analysis with DSM-5 
alcohol use disorder, no SNPs in the region pass the Bonferroni correction.  The most 
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significant SNP with this phenotype is rs7844566 (OR=1.64, p=0.01). With FTND 
nicotine dependence, the most highly associated SNP is rs4950 (OR=0.66, p=7.32 x 10-5),  
Table 11. 
Top Association Results for the Linear Models Run for DSM-5 Cocaine Use Disorder  
 
a SNP that tags the previously discovered GWS signal in the region. Overall, 29 SNPs 
within this region are associated with FTND nicotine dependence with a p-value equal to 
or less than 0.002.  This is consistent with previous studies showing an association in this 
SNP LD Bin bp N OR L95 U95 Freq P 
rs9298626 1 42,647,165 1970 2.618 1.568 4.372 0.04 2.34E-04 
rs7844824 1 42,672,170 1970 2.652 1.575 4.464 0.04 2.43E-04 
rs4305884 2 42,637,880 1966 2.133 1.419 3.205 0.06 2.69E-04 
rs7824160 1 42,705,413 1969 2.502 1.494 4.19 0.04 4.88E-04 
rs11986893 4 42,772,016 1971 1.564 1.216 2.011 0.2 4.92E-04 
rs7002907 1 42,702,998 1970 2.494 1.49 4.174 0.04 5.03E-04 
rs6997994 1 42,702,328 1971 2.494 1.49 4.175 0.04 5.04E-04 
rs7815274 1 42,701,740 1967 2.469 1.469 4.149 0.04 6.41E-04 
rs4952 1 42,706,222 1971 2.427 1.444 4.078 0.04 8.12E-04 
rs10107450 5 42,749,052 1969 1.504 1.178 1.918 0.22 1.04E-03 
rs1868859 2 42,634,958 1971 1.847 1.269 2.688 0.07 1.36E-03 
rs892413 3 42,733,535 1971 1.475 1.151 1.889 0.2 2.11E-03 
rs4950 6 42,671,790 1957 1.422 1.107 1.827 0.22 5.93E-03 
rs13280604 6 42,678,743 1971 1.406 1.095 1.804 0.22 7.49E-03 
rs1530848 6 42,672,065 1964 1.399 1.094 1.79 0.22 7.53E-03 
rs2196128 3 42,737,443 1971 1.374 1.083 1.744 0.23 8.83E-03 
rs6997909 6 42,679,406 1971 1.388 1.083 1.78 0.22 9.67E-03 
rs6474414 6 42,679,493 1971 1.388 1.083 1.78 0.22 9.67E-03 
rs4736835 6 42,666,190 1971 1.388 1.081 1.782 0.22 1.03E-02 
rs9298628 3 42,725,148 1968 1.376 1.078 1.756 0.21 1.04E-02 
rs6474415 6 42,682,095 1970 1.383 1.079 1.774 0.22 1.05E-02 
rs1451240 6 42,665,868 1970 1.381 1.075 1.774 0.22 1.14E-02 
rs7004381 6 42,670,318 1971 1.376 1.072 1.767 0.22 1.24E-02 
rs13273442 6 42,663,174 1970 1.376 1.071 1.767 0.22 1.25E-02 
rs1955185 6 42,668,804 1971 1.371 1.069 1.759 0.22 1.30E-02 
rs6474413 6 42,670,221 1971 1.371 1.068 1.759 0.22 1.31E-02 
rs16891620 7 42,744,820 1970 1.424 1.057 1.918 0.13 2.00E-02 
rs10958726 6 42,655,066 1971 1.342 1.043 1.726 0.21 2.20E-02 
rs6474421 12 42,776,255 1969 1.497 1.049 2.137 0.07 2.62E-02 
rs10958725 6 42,643,741 1968 1.31 1.021 1.682 0.22 3.37E-02 
rs7012713 13 42,711,460 1970 1.648 1.008 2.695 0.04 4.66E-02 
         
Bolded SNPs passed multiple test correction (p>0.002). Maximum FTND is the score from 0-10, L95 and 
U95 is the 95% confidence interval, and the frequency is in the SAGE dataset. 
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region.  (See Appendix B for the entire association results in the region with each 
substance examined). 
 
Conditional analyses suggest at least two independently associated SNPs with 
DSM-5 cocaine use disorder.  To determine whether there was evidence for multiple 
independently associated variants at this locus contributing to risk for DSM-5 cocaine use 
disorder, the most significant SNP in the region (rs9298626) was added to the model as a 
covariate.  Conditioning on rs9298626 eliminated the association with SNPs in LD bins 1 
and 2, but the association remained for SNPs in bins 4 and 5. After including rs9298626 
as a covariate, the top SNP associated with this phenotype was rs892413 (p=3.57x10-3, 
OR=1.58, CI=1.23-2.04).  
Examination of LD shows that the r2 between rs9298626 and rs892413 is low, 
suggesting that these SNPs represent independent association signals (r2 = 0.01; D’= 
0.85).  Because the minor allele frequency for rs9298626 is low, the r2 will never be high 
but the D’ indicates that the minor allele of this SNP is usually but not always on the 
background of one allele of rs892413. Neither of these SNPs is in significant LD with the 
previously identified genome-wide significant signal (rs1451240) associated with 
cigarette consumption and nicotine dependence (Rice et al., 2012; Thorgeirsson et al., 
2010) in this region (r2 = 0.14 between rs9298626 and rs1451240, r2= 0.35 between 
rs892413 and rs1451240; Figure 9), although rs9298626 is in high LD (r2 = 0.94) with 
rs4952, another SNP previously reported to be associated with nicotine dependence 
(Saccone et al. 2007). We find that rs9298626, rs892413 and rs1451240 correspond to 
different LD bins using r2=0.8 as the threshold for defining the bins (Table 11).  This is 
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consistent with recent results from our group showing, in an overlapping dataset, that the 
genome-wide significant signal in this region, tagged by rs1451240, is solely associated 
with nicotine dependence.  Taken together, this suggests that these three SNPs represent 
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Effects of cocaine exposure in the control population on association with 
rs9298626.  To determine whether there is a significant effect of lifetime cocaine 
exposure on these associations, we compared the frequency of the minor allele of 
rs9298626 in those with DSM-5 cocaine use disorder, non-exposed non-dependent 
individuals and those who were exposed to cocaine but were unaffected (N=393 with 0-1 
DSM-5 criteria), as well as those who were never exposed (N=1077). The minor allele 
frequency of rs9298626 was 9.9% among those with DSM-5 cocaine use disorder and 
5.3% among subjects who have been exposed to cocaine but did not progress to cocaine 
use disorder.  Non-exposed controls have an intermediate minor allele frequency of 7.7%, 
suggesting that both those with DSM-5 cocaine use disorder and those who were cocaine-
exposed non-dependent controls show allele frequency differences from unselected 
controls (Table 12), although the difference in frequency of rs9298626 between exposed 
but unaffected controls and unexposed controls was not significant. When control 
subjects were restricted to those who had been exposed to cocaine but were unaffected 
(n=899 vs. 1976), the significance of the association between rs9298626 and DSM-5 
cocaine use disorder was reduced but the odds ratio was unchanged (p= 3.12x10-3, 
OR=2.68, CI=1.40-5.16), supporting the role of this SNP, or another SNP in LD with 
rs9298626, in risk for DSM-5 cocaine use disorder, even after accounting for cocaine 
exposure.  We conclude that the minor allele of rs9298626 is correlated with cocaine use 
disorder, which is strengthened by the fact that there remains an association even when 
not considering unexposed individuals in the analysis. 
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Table 12 
Characteristics of the sample broken down by: DSM-5 cocaine use disorder, exposed but 
unaffected, and non-exposed unaffected 
 












Age (years)     
mean age 36 38 39 38 
<35 37% 26% 35% 34% 
35-39 28% 27% 22% 25% 
40-44 23% 35% 25% 26% 
>45 12% 12% 18% 13% 
     
Male 62% 50% 34% 44% 
Female 38% 50% 66% 56% 
     
Nicotine 
Dependence     
FTND  0,1 10% 47% 68% 49% 
FTND 2,3 12% 9% 9% 10% 
FTND>4 78% 44% 23% 41% 
     
DSM-5 Alcohol 
Use Disorder     
Case 99% 88% 37% 42% 
Control 1% 12% 63% 58% 




    
Yes 9.9% 5.3% 7.7% 7.8% 
No 90.1% 94.7% 92.3% 92.2% 
 
Stratified analysis show robustness of association with DSM-5 cocaine use 
disorder.  Because SAGE is composed of individuals from three independent studies, 
each ascertained for a different substance dependence, we performed stratified analyses 
both by study and by nicotine dependence and alcohol dependence to determine if there 
existed a subset of subjects in which the association was most pronounced. The top SNP 
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associated with DSM-5 cocaine use disorder (rs9298626) in the whole SAGE dataset was 
significantly associated with DSM-5 cocaine use disorder in the COGA subset and 
showed a trend in the same direction in the FSCD and COGEND subsets. Furthermore, 
when individuals from the whole dataset were stratified by DSM-5 alcohol use disorder, 
or FTND nicotine dependence there was evidence of association between rs9298626 and 
cocaine use disorder in both groups (Table 13).  This suggests that the observed 
associations are not an artifact of ascertainment and supports the hypothesis that this SNP 
is associated with DSM-5 cocaine use disorder and that the CHRNB3-A6 locus is robustly 
associated with DSM-5 cocaine use disorder, regardless of comorbidity or ascertainment. 
Table 13. 
 
European-American DSM-5 Cocaine Use Disorder 	   	   N	   OR	   95%	  CI	   p-­‐Value	  for	  rs9298626	  
Study	   	   	   	   	  COGEND	   1077	   1.77	   0.67-­‐4.62	   0.25	  COGA	   599	   2.62	   1.25-­‐5.52	   0.01	  FSCD	   294	   6.35	   0.67-­‐60.43	   0.11	  
Smoking	  
Status	   	   	   	   	  FTND	  Cases	   814	   2.31	   1.06-­‐5.02	   0.03	  FTND	  Controls	   1156	   2.59	   1.22-­‐5.50	   0.01	  
Alcohol	  Status	   	   	   	   	  DSM-­‐5	  Cases	   1522	   2.41	   1.46-­‐3.98	   0.0006	  DSM-­‐5	  Controls	   448	   7.05	   0.52-­‐94.60	   0.14	  Results	  of	  stratified	  analyses	  in	  these	  groups	  for	  rs9298626	  –	  controls	  included	  here	  are	  both	  those	  who	  are	  exposed	  and	  unaffected,	  as	  well	  as	  those	  who	  are	  unexposed.	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Haplotype analysis suggest functional allele responsible for association with 
DSM-5 cocaine use disorder is in high LD with rs9298626.  To further examine the 
relationship between our top variant identified for DSM-5 cocaine use disorder and the 
group of variants known to be associated with smoking, tagged by rs1451240, we 
performed haplotype-based association testing using rs9298626 and rs1451240. These 
two SNPs occur on three haplotypes that occur with a frequency >1% (Table 14).  
Table 14. 
Haplotypes observed in the SAGE GWAS European-American sample for DSM-5 cocaine 
use disorder.   
 
Haplotypes DSM-5 
Cocaine Use Disorder 
rs9298626 rs1451240 Frequency Odds Ratio p-value 
A A 0.04 3.19 1.35x10-4 
A G <0.01 9.89 0.89 
C A 0.18 1.23 0.14 
C G 0.78 - - 
The grey box indicates the major allele for that SNP. P-values are denoting significance 
of that haplotype relative to the reference haplotype.  SNPs are arranged in the order they 
occur on the chromosome. Covariates used are age, sex, study, DSM-5 alcohol symptom 
count, FTND total. 
 
We chose rs1451240 because it was found to be genome-wide significant for nicotine 
dependence in a previous study using the SAGE GWAS data (Rice et al., 2012). The 
most common haplotype, composed of the major alleles of both SNPs, has a frequency of 
78%. The haplotype associated with the highest risk for DSM-5 cocaine use disorder, has 
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a frequency of 4% and is composed of the minor alleles at both rs9298626 and rs1451240 
(OR=3.19 p= 1.35x10-4, 95% CI=1.64-4.73). A haplotype composed of the major allele at 
rs9298626 and the minor allele at rs1451240 has a frequency of 18% but was not 
associated with DSM-5 cocaine use disorder (p=0.14).  Because the frequencies and odds 
ratio of the haplotype with both minor alleles is nearly identical to that of the single SNP 
analysis for rs9298626 and the fact that the other haplotype containing the minor allele of 
rs1451240 is not associated with DSM-5 cocaine use disorder, we conclude that the 
functional allele responsible for this association is in high LD with the low frequency 
variant, rs9298626. 
Association with rs9298626 and DSM-5 cocaine use disorder is independent 
of association with nicotine dependence.  To further examine the relationship between 
nicotine dependence and DSM-5 cocaine use disorder associations in this region, we 
performed additional conditional analyses.  In a linear regression model using age, sex, 
study, DSM-5 alcohol symptom count, total FTND score and rs1451240 genotype as 
covariates, the association with DSM-5 cocaine use disorder remained significant (Table 
15).  Lastly, the DSM-5 cocaine use disorder signal remains significant when 
conditioning on the two rare variants (rs35327613 and rs149775276) recently identified 
by our group to be associated with DSM-IV alcohol and cocaine dependence symptom 
count (Haller et al., 2013). This is not surprising given that these rare missense variants 
are present on the haplotypes containing the major allele of rs9298626, whereas the 
association reported here is with the minor allele. The fact that the association with 
cocaine use disorder remains when conditioning on the genome-wide significant signal 
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with nicotine dependence in the region, suggests that the association is independent and 
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DISCUSSION 
We have shown, in genotyped data from European-Americans in the SAGE dataset, that 
there are at least two statistically independent signals associated with increased risk for DSM-5 
cocaine use disorder in the region of the CHRNB3-A6 nicotinic receptors on chromosome 8.  
Several SNPs representing the rs9298626 LD bin surpass the multiple test correction for the 
region with DSM-5 cocaine use disorder (p=0.002).  rs9298626 is also associated with reduced 
risk for nicotine dependence (OR=0.47, 95% CI= 0.30-0.76, p=1.80x10-3) in a univariate genetic 
analysis. This may be due in part to the fact that, in European ancestry populations, the minor 
allele of rs9298626 (MAF=0.04) occurs almost exclusively on the background of the more 
frequent minor allele (MAF=0.22) for the variant (rs1451240) previously reported to be genome-
wide significantly associated with nicotine dependence (Table 14). Conditioning on rs1451240 
had no effect on the association with DSM-5 cocaine use disorder (Table 15). This is not 
surprising because rs1451240 is not associated with DSM-5 cocaine use disorder in our data 
(Table 11). We find no association with DSM-5 alcohol use disorder in this dataset, which could 
indicate that the association at this locus is unique to DSM-5 cocaine use disorder and nicotine 
dependence.  However, the sample size of those with DSM-5 alcohol use disorder could also be 
too small to detect an association. 
LD bins tagged by rs9298626 and rs892413 each show association with DSM-5 cocaine 
use disorder in joint SNP analysis.  Analyses conditioning on rs9298626 reveal that rs892413 is 
independently associated with DSM-5 cocaine use disorder.  rs892413 is also associated with 
DSM-5 cocaine use disorder independent of the previously identified genome-wide significant 
association in the region with nicotine dependence (represented by rs1451240), providing 
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support for a direct effect of this SNP on higher DSM-5 cocaine use disorder risk, as opposed to 
acting through nicotine dependence risk (Tables 14 and 15).   
The LD bin containing rs9298626 also contains rs4952 and rs4953, two low frequency 
synonymous variants in CHRNB3 that have previously been reported to be associated with 
reduced risk for nicotine dependence (S. F. Saccone et al., 2007) and increased risk for bipolar 
disorder EAs (OR=1.7, 95%, CI= 1.2-2.4, p=0.001) (Hartz et al., 2011).  Interestingly the 
association of rs4952/rs4953 with cocaine use disorder is in the same direction as the association 
with bipolar disorder (risk) but in the opposite direction to the association with nicotine 
dependence (protective) suggesting that CHRNB3 variants have pleiotropic effects on substance 
use disorders and other psychiatric diseases.  Many epidemiological studies have reported the 
common co-occurrence of bipolar disorder and substance dependence (Goodwin, Zvolensky, 
Keyes, & Hasin, 2012; Kenneson, Funderburk, & Maisto, 2013; Leverich & Post, 2006).  Studies 
have also implicated shared genes with substance dependence and bipolar disorder (P. I. Lin et 
al., 2006; Post & Kalivas, 2013). It is therefore possible that the high frequency of bipolar 
disorder and substance dependence comorbidity is in part due to common underlying genetic risk 
factors such as the risk alleles in the CHRNB3-A6 locus reported here.  
Our group has previously reported that rare missense variants in CHRNB3 increase risk 
for cocaine dependence (Haller et al., 2013). The results reported here demonstrate that low 
frequency and common alleles within the CHRNB3 locus are also associated with increased risk 
of DSM-5 cocaine use disorder.  Cocaine dependence has now been associated with SNPs in two 
different nicotinic receptor gene clusters, on chromosomes 8 and 15 (Grucza et al., 2008; Haller 
et al., 2013). It is interesting, however, that the variant on chromosome 15, within CHRNA5 is 
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associated with decreased risk for cocaine dependence, while rs9298626 and other variants in the 
CHRNB3-A6 region are associated with higher (OR =2.62) risk for DSM-5 cocaine use disorder. 
Furthermore, similar to the observation on chromosome 15, the chromosome 8 locus is 
associated with opposing effects on the risk for cocaine dependence and nicotine dependence.  
The CHRNB3-A6 locus is associated with decreased risk for nicotine dependence and increased 
risk for DSM-5 cocaine use disorder. In contrast, in CHRNA5, the same variant, D398N 
(rs16969968), increases risk for nicotine dependence and decreases risk for cocaine dependence. 
Furthermore, our data suggest that different but overlapping SNPs may explain the cocaine and 
nicotine dependence associations in CHRNB3-A6 rather than a single SNP causing opposing 
effects as was seen on chromosome 15.  These results suggest that CHRNA5 and CHRNB3 
demonstrate pleiotropic effects on substance dependence risk. 
Nicotinic acetylcholine receptors (nAChR) are expressed in multiple types of neurons, 
and have been shown to modulate reward response for several substances (Grucza et al. 2008).  
For example, work in animals suggests that activation of α3β4 nAChR can increase cocaine self-
administration (Hansen & Mark, 2007).  Because comorbidity between substance dependencies 
is so high, it is plausible that these receptors could play a role in addiction to multiple substances.   
Most drugs of abuse act on the mesolimbic dopamine-containing receptors in the brains 
of humans and many other mammals.  Among other functions, this system is known to regulate 
motivation (Koob, 1996; Wise, 1996) and has similar effects across mammalian species (Tanda, 
Pontieri, & Di Chiara, 1997).  Activation and reinforcement of this system is a necessary part of 
drug abuse (Koob, 1996).  The dopaminergic system is therefore crucial to addiction, however 
other neurotransmitters besides dopamine affect the mesolimbic system, especially acetylcholine 
(Hansen & Mark, 2007).  
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The biological connection between these two systems could be related to the reversal of 
the odds ratio for rs16969968, which is protective for cocaine dependence but a risk factor for 
nicotine dependence, as well as our observation that in the CHRNB3-A6 locus on chromosome 8, 
there are variants associated with protection against nicotine dependence, in addition to variants 
associated with risk for DSM-5 cocaine use disorder and bipolar disorder.  Since the finding in 
CHRNA5 on chromosome 15 is the only association with cocaine dependence to be successfully 
replicated, it would be interesting to examine the CHRNB3-A6 region in other datasets that have 
assessed cocaine dependence phenotypes, as well as to analyze datasets of other ethnicities.  
Currently, there is no evidence that either of the variants reported here are correlated with 
SNPs that have known functional consequences. However, rs4952 and rs4953 are both 
synonymous variants in CHRNB3 and may therefore have some, as yet unknown effect on 
transcription or translation of CHRNB3 mRNA.  Overall, our findings underscore the 
comorbidity among drug dependencies and corroborate the role of nicotinic receptors in cocaine-
related phenotypes.  This study represents one of only a few to implicate specific variants in 
cocaine dependence phenotypes and the first to implicate low frequency variants within the 
CHRNB3-A6 locus in risk for DSM-5 cocaine use disorder. 
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CHAPTER 4 
EVOLUTION, NATURAL SELECTION, AND NICOTINE DEPENDENCE 
ABSTRACT  
 
Much of the evolution of human behavior remains a mystery, including how certain 
disadvantageous behaviors have become so prevalent.  Nicotine addiction is one such phenotype.  
Several loci have been implicated in nicotine related phenotypes including the nicotinic receptor 
clusters (CHRNs) on chromosomes 8 and 15, and the nicotine metabolizing gene CYP2A6.  Here 
we use 1000 Genomes sequence data from 3 populations (Africans, Asians and Europeans) to 
examine whether natural selection has occurred at these loci.   Further, we test the hypothesis 
that any selection that has occurred at these loci is not related to nicotine addiction, but rather is 
associated with cognitive phenotypes such as memory and learning. To test for selection, we 
have used multiple complimentary methods that include Tajima’s D, integrated haplotype score 
(iHS) and Ka/Ks ratio.  While each method has its own strengths and weaknesses, together they 
capture selection at multiple time-depths.  Our results from these statistics provide evidence for 
strong selection in the nicotinic receptor cluster on chromosome 8, previously found to be 
significantly associated with nicotine and cocaine dependencies.  This selection is occurring at 
certain loci associated with increased risk for nicotine dependence but decreased risk for cocaine 
dependence.  This is intriguing given recent studies that have shown that cocaine addicts have a 
dampened, and therefore maladaptive, reward response to social interaction.  This suggests the 
possibility that selection is acting to decrease risk of cocaine addiction at the expense of an 
increased risk for nicotine dependence.  We also find evidence of weaker, but still detectable 
selection, acting on the region containing the CHRNA5 nicotinic receptor gene on chromosome 
15 that is genome wide significant for risk for nicotine dependence.  To examine the possibility 
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that this selection is related to memory and learning, we performed an association in exome chip 
data from the Collaborative Studies on the Genetics of Alcoholism (COGA) dataset with 
neuropsychological phenotypes.  We find one SNP that passes multiple test correction for the 
phenotype of WAIS digit symbol.  This test captures aspects of reaction time and memory, 
suggesting that this locus is associated with both nicotine dependence and cognition. 
 
INTRODUCTION 
 Nicotine dependence is the leading cause of preventable death in the USA.  It has been 
noted that some populations experience higher levels of addiction than others but the reason for 
this is not understood.  Multiple studies have demonstrated a genetic component to nicotine 
addiction (Berrettini et al., 2008; Bierut et al., 2007; S. F. Saccone et al., 2007; Thorgeirsson et 
al., 2010) but little is known about the role of natural selection in shaping the genetic 
components of nicotine addiction.  Such knowledge could help us understand the genetic and 
behavioral nature of addiction and ultimately facilitate the design and delivery of appropriate 
interventions to reduce nicotine addiction.    
 It has been estimated that approximately 10% of the genome has been affected by linkage 
due to recent selective sweeps (Williamson et al., 2007).  However it is often difficult to 
determine the actual phenotype that was the target of selection.  This is particularly true when the 
phenotype being examined has no obvious beneficial impact or has an apparently deleterious 
effect but is nonetheless undergoing positive selection.  In this case, additional mechanisms 
and/or alternative explanations must be sought for the existence of selection on the gene of 
interest.   
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 An example of such a situation occurs in the gene for hemoglobin.  In homozygous form, 
the ‘sickle cell’ allele, HbS, drives the formation of malformed red cells, which aggregate to 
cause blockages of blood flow to numerous organs including the brain.  This results in organ 
damage and strokes, severely shortening the lifespan of the individual.  Nonetheless, the HbS 
allele is maintained in the gene pool in regions where malaria is endemic because in 
heterozygous form it provides protection against malaria (for a review see (Ashley-Koch, Yang, 
& Olney, 2000)). 
 A second example derives from a SNP in a p53 binding site in the KITLG gene.  This 
SNP has undergone positive selection in Caucasians despite its association with an increased risk 
of several types of cancer (Zeron-Medina et al., 2013).  The authors hypothesize that this is due 
to the role of KITLG in the tanning response, which provides a protective effect against UV light.  
Thus, for purposes of selection, a beneficial effect of the gene in one setting can over-ride an 
apparently deleterious effect of that gene in another context. 
The case of nicotine addiction represents a similar conundrum.  Several genetic variants 
that modify susceptibility or resistance to nicotine dependence have been identified by genome-
wide association studies (GWAS) (Berrettini et al., 2008; Bierut et al., 2007; Thorgeirsson et al., 
2010).  Perhaps not surprisingly, the loci identified in these studies mainly include genes 
encoding neuronal nicotinic cholinergic receptors (CHRNs) and a nicotine-metabolizing gene 
(CYP2A6).   
But why would nature seemingly select for this trait, especially given the fact that it is 
believed that nicotine has not been a part of our evolutionary history long enough, and in large 
enough quantities, for its effects to be visible in our genomes?  One hypothesis is that selection 
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acted on a more primary phenotype and the effect on nicotine addiction was secondary and 
incidental, a genetic phenomenon termed hitchhiking. 
 Nicotine is known to have an enhancing effect on cognitive performance. For example 
one study showed that nicotine enhanced the reorientation of attention in visuospatial tasks (Thiel 
et al., 2005).  A second study used fMRI to show that nicotine altered neuronal activity 
responsible for increased attention and arousal (Kumari et al., 2003).  Nicotinic receptors are also 
important in the functional impairments found in Alzheimer’s disease (AD), as it has been shown 
that AD patients have a reduction in nicotinic receptor binding sites (Newhouse, Potter, Kelton, 
& Corwin, 2001).  Furthermore, epidemiological evidence suggests that smokers have a 
significantly lower incidence of symptoms and diagnoses of AD and Parkinson’s disease than 
non-smokers (Fratiglioni & Wang, 2000; Tyas, 1996). With regard to genetics, Rigbi et al (Rigbi 
et al., 2008) found an association between cognitive function and variants within the genes 
encoding A2, A4, A5, A7, A9, A10, B2 and B3 nicotinic receptors, as well as with several related 
haplotypes.  More recently, Winterer et al (Winterer et al., 2010) found an association between 
risk variants for nicotine dependence in CHRNA5 and lower cognitive performance scores.  They 
suggested that these individuals would choose to use nicotine more often than non-risk allele 
carriers to overcome this lower cognitive performance. 
 Evidence from nicotinic receptor knockout mice also supports a role for these receptors 
in memory and learning, as well as anxiety levels.  CHRNA7 knockout mice have impaired 
reaction times (Hoyle, Genn, Fernandes, & Stolerman, 2006) and decreased procedural learning 
(Young, Meves, Tarantino, Caldwell, & Geyer, 2011). Interestingly, CHRNA6 knockout mice 
show that this receptor plays a role in nicotinic modulation of dopaminergic transmission. These 
knockout mice lose high-affinity binding of alpha-conotoxin-MII (αCtxMII), a compound that 
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blocks nicotine-induced dopamine release.  Combined with data showing that α3 knockout mice 
do not show changes in αCtxMII binding, this suggests that CHRNA6, and not CHRNA3, 
preferentially combines with the β2 subunit in dopaminergic neurons (Drago, McColl, Horne, 
Finkelstein, & Ross, 2003).  Based on the foregoing observations, we hypothesize that the 
nicotinic receptors may have been targets of recent selection and that this selection is related to 
the role of nicotinic receptors in memory and learning.   
Selective forces leave informative signatures in the human genome.  There are several 
tests designed to measure departures from neutrality that can be indicative of selection at a locus 
or loci that have sufficiently high linkage disequilibrium with the target site.  Each test gives the 
most accurate results when functioning within optimal parameters for variables such as time 
depth and allele frequencies.  In this chapter, three different methods were used for detecting 
natural selection at loci relevant to nicotine dependence, specifically the CHRNA5-A3-B4 region 
on chromosome 15q25 and the CHRNB3-A6 region on chromosome 8p11.  The data provide 
strong evidence for selection in the CHRNB3-A6 region and moderate evidence for selection in 
the CHRNA5-A3-B4 region.   However, there is only a modest correlation between nicotine 
dependence and score on the Wechsler Adult Intelligence Scale (WAIS) Digit Symbol test.  We 
discuss the alternate possibility that because the effects of SNPs associated with risk of nicotine 
dependence are independently associated with protection from cocaine dependence that it is the 
latter phenotype that may be driving selection.  
 
METHODS 
 To determine whether the nicotinic receptor loci are under selection, we used Tajima’s D, 
integrated haplotype score (iHS), and the ratio of nonsynonymous to synonymous substitutions 
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(Ka/Ks) to examine the landscape of natural selection at three loci previously demonstrated to 
harbor genetic variants contributing to the risk of nicotine dependence.  These tests have 
different but complementary strengths.  Tajima’s D test functions best on recently completed 
selective sweeps.  There are many variables that contribute to how far in the past a sweep can be 
detected, such as how extreme the sweep was in the first place. Both the mutation rate and the 
recombination rate affect it as well and vary widely across the genome making generalizations 
difficult.  By contrast, integrated haplotype score iHS functions best for detecting sweeps in 
progress with alleles at intermediate frequencies, mainly in the range of or after the separation of 
European, Asian and African populations, during the agricultural phase of human evolution 
(Voight, Kudaravalli, Wen, & Pritchard, 2006).   Ka/Ks can detect older selection in orthologous 
protein coding regions that has occurred between lineages. Together, these tests should be able to 
detect selection at multiple time-depths, as well as both sequence-based and haplotype-based 
selection. 
 We utilized 1000 Genomes data for Tajima’s D and iHS analyses.  The populations were 
grouped into EUR (GBR, TSI, CEU, FIN), ASN (CHS, CHB, JPT), and AFR (YRI, LWK, 
ASW).  For Ka/Ks we used Genbank reference mRNA sequences for human (hg19) and chimp 
(PanTro4) as the outgroup.  All methods were calculated for the same regions: the CHRNA5-A3-
B4 region on chromosome 15q25, the CHRNB3-A6 region on chromosome 8p11, the LCT region 
as a positive control on chromosome 2q21, and several intergenic negative control regions where 
applicable. 
Tajima’s D test.  Tajima’s D was calculated using the program Variscan (Hutter, Vilella, 
& Rozas, 2006). To run Variscan, one must input certain parameters such as how large of a 
sliding window to use, and what bp increment to move each time.  After an exploratory data 
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analysis of window size, we concluded a sliding window size of 1000 bp, and window 
increments of 100 bp were best for these data.  This is because any smaller of a window and 
there were often too few SNPs in a window to calculate properly, and any larger of a window 
and it made it much harder to narrow down specific SNPs that may be the ultimate target of 
selection.  Variscan then outputs a file giving the Tajima’s D value for every window of the 
specified bp size on the sliding scale (Hutter et al., 2006).  These values were then superimposed 
onto graphs of the regions. 
Integrated Haplotype Score.  iHS is a measure of whether a SNP is on an unusually 
long haplotype carrying the ancestral or derived allele.  In other words, it compares the rate of 
haplotype decay between haplotypes carrying either the ancestral or derived allele at a given site, 
called the core SNP.  The haplotype decay is calculated until the extended haplotype 
homozygosity (EHH) reaches 0.05.  EHH is defined as “the probability that two randomly 
chosen chromosomes carrying the core haplotype of interest are identical by descent for the 
entire interval from the core region to point x” (Sabeti et al., 2002).  This can be thought of as 
haplotype transmission with no recombination. Haplotypes whose core SNP is under selection 
will be unusually long compared to those evolving neutrally. Long haplotypes with derived 
alleles are indicated by negative iHS values and those with ancestral alleles are indicated by 
positive iHS values.  Under neutrality, extreme scores are distributed throughout the genome, 
however under selection, they are clustered across the selected region (Voight et al., 2006). iHS 
can be clearer than Tajima’s D, but also somewhat nuanced to work with because of the 
dependence on local recombination rate. However, it is a good method for detecting directional 
selection, especially a sweep that is in its early phases. We used the program WHAMM to 
calculate this statistic (Voight et al., 2006).   
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 First, we extracted the desired regions from the 1000 Genomes dataset.  We then selected 
known SNPs within each region, and extracted a region of plus or minus 2000 SNPs around that 
SNP, except in the case of CHRNB3-A6 where we selected plus or minus 2500 SNPs. We 
constructed recombination maps using cM maps provided by the SHAPEIT2 program (Delaneau 
et al., 2012).  Ancestral alleles were determined using the latest version of Seattleseq 
(http://snp.gs.washington.edu/SeattleSeqAnnotation137/). Phased haplotypes were coded as 
number of copies of the derived allele.  All positions in which the derived allele could not be 
determined unambiguously (i.e. C/G or A/T SNPs) as well as those without known chimp alleles 
were removed from further analyses.  All analyses were run on each population separately.  As 
iHS is greatly influenced by SNP allele frequency, iHS values from WHAMM were standardized 
using the average and standard deviation of all SNPs on chromosome 15 and 8 binned by allele 
frequency such that the average iHS value for each bin after standardization was identical.  We 
excluded SNPs with a minor allele frequency less than 5% because low frequency SNPs are 
difficult to normalize accurately.  After removing problematic SNPs discussed above, extracting 
just the desired gene regions, and removing those with MAF of <0.05, there were ~150-350 
SNPs per region, depending on the population.  Standardization was done separately for each 
population using population specific averages and standard deviations.  iHS values were then 
superimposed onto graphs of the regions.    
 The haplotype on which a beneficial allele resides tends to be significantly longer than 
the other haplotypes at the same frequency in the population when adjusted for the 
recombination background. However, long haplotypes tend to occur in regions with low 
recombination, and these can be confused with genuine genomic signals of positive selection 
(Liu et al., 2013). This is why WHAMM attempts to control for recombination by requiring the 
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input of a cM map.  The map we used here was the cM map for imputation available on the 
website for the program SHAPEIT2.   
 Candidate regions of positive selection were defined as genomic regions containing an 
uncharacteristic clustering of SNPs with high iHS statistics. This was quantified as the 
proportion of SNPs with |iHS| > 2 in the four regions of interest. Candidate regions of positive 
selection were identified as containing any SNP with an iHS score of |iHS| > 2, as this 
corresponds to the top ~5% of all scores. The iHS value at a SNP  “measures the strength of 
evidence for selection acting at or near that SNP” however does not provide a formal 
significance test (Voight et al. 2006). 
Ka/Ks_Calculator.  Nonsynonymous and synonymous substitution rates (denoted as Ka 
and Ks, respectively), or rather their ratio (Ka/Ks), is indicative of neutral evolution when the 
two are equal, negative (purifying) selection when Ka is less than Ks, and positive selection 
when Ka is greater than Ks (Zhang et al., 2006).  This is a way of comparing selective pressures 
at homologous genes.  However since not all datasets have the same degree of substitutions, 
having only one possible model is not optimal.  This is why the Ka/Ks_Calculator program 
(freely available at https://code.google.com/p/kaks-calculator/) provides a model selection step to 
choose a best-fit model. Here we have selected the Li-Wu-Luo (LWL) approximate method 
because unlike other similar methods such as the Jukes-Cantor (JC) method which makes the 
simplifying assumption that nucleotide substitution occurs randomly, the LWL method 
essentially weights Ka (number of nonsynonymous substitutions per nonsynonymous site) and 
Ks (number of synonymous substitutions per synonymous site) by whether or not the site is 
fourfold degenerate (always synonymous), twofold degenerate (one third synonymous and two-
thirds nonsynonymous), or nondegenerate (always nonsynonymous).   
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 A site is degenerate if all possible changes are nonsynonymous or nonsense.  A twofold 
degenerate site is one where one of the three possible changes is synonymous, and a fourfold 
degenerate site is one where all possible positions at the third codon result in a synonymous 
change. The purpose of this classification is to estimate nonsynonymous and synonymous rates 
of substitution separately (W. H. Li, Wu, & Luo, 1985).  The LWL method involves three steps: 
1) count the numbers of synonymous and nonsynonymous sites; 2) calculate the numbers of 
synonymous and nonsynonymous substitutions and 3) correct for multiple substitutions (Zhang 
et al., 2006). 
 Ka/Ks does not provide a measure of selective pressure at each nucleotide within a gene, 
but rather selective pressure on the gene as a whole.  Thus, it cannot give detailed information on 
which SNPs in the gene are associated with selection.  However, this statistic can give us 
information on selection events that have occurred in the more distant past than either Tajima’s 
D or iHS, such as changes that have occurred between species lineages.  This is somewhat 
intuitive because determining Ka/Ks for multiple sequences sampled from the same population 
will not yield information about fixation events along independent lineages, but rather 
polymorphisms segregating in a population (Kryazhimskiy & Plotkin, 2008).  Limitations to this 
approach are that only selection in protein coding regions can be calculated and since selective 
pressures are averaged over the region, it can take quite a strong selective signal to be detected. 
Also, since balancing selection does not cause an amino acid change, it cannot be detected (Yang 
& Bielawski, 2000).  Human and chimp sequences were aligned using ClustalW (Larkin et al., 
2007) and input into the Ka/Ks calculator as pairwise alignments.  The pairwise alignments for 
each gene analyzed were used to calculate Ka and Ks. 
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Association Analyses.  DNA samples were collected as part of the Collaborative Study 
of the Genetics of Alcoholism (COGA).  All members of the COGA sample underwent a semi-
structured interview, the SSAGA, which assessed alcohol, cocaine and nicotine use as well as 
comorbid psychiatric conditions.  The COGA sample utilized in this study consisted of family 
GWAS data from 2102 European-Americans. 
 COGA administered a variety of neuropsychological tests to its subjects including the 
three used here:  Wechsler Adult Intelligence Scale (WAIS) Block Design, WAIS Digit Symbol, 
and WAIS Information.  In total there were 1247 European-Americans with these 
neuropsychological phenotypes.   However, the overlap between this number and those with 
family GWAS data was 492.  Therefore, our analyses were done using 492 subjects. 
 SNPs in the region of the nicotinic receptor clusters on chromosomes 8 and 15 were 
tested for association with the neuropsychological phenotypes in European-Americans from the 
COGA study using linear regression as implemented in the GWAF package in R using age, sex 
and FTND score as covariates. 
 
RESULTS 
Tajima’s D Analyses.  Tajima's D is a method of addressing the frequencies of variant 
sites, based on the expectation that under neutrality, different estimates of expected diversity (θ) 
should be equal.  Tajima’s D tests for a skew in the frequency spectrum by comparing two 
estimates of θ – the number of segregating sites (S), and pairwise nucleotide diversity (π) 
(Tajima, 1989).  Extreme positive values can indicate either balancing selection or population 
subdivision, and extreme negative values can indicate positive selection or population growth 
(Jobling, 2004).  If the same skew is detected across the genome, the effect is likely due to 
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demography, whereas if the skew is localized to a few loci, selection is more likely to be 
occurring.  
  In a review, Garrigan & Hammer (Garrigan & Hammer, 2006) have combined published 
data for Tajima’s D values from 65 autosomal loci.  They find the mean value for Africans is 
slightly negative (-0.20) and for non-Africans is slightly positive (0.13).  Overall, the values 
range from -2 to 2.   As such, we have taken Tajima’s D values above 2 or below -2 to count as 
extreme values, as this represents the 95% confidence interval of values in our data.    
Figures 10 through 13 show histograms of the Tajima’s D values for our negative 
controls (Figure 10), our positive control (Figure 11), the chromosome 15 locus which contains 
the genes encoding the α3, ß4 and α5 subunits of the nicotinic receptor (Figure 12) and the 
chromosome 8 locus which contains the genes for the α6 and ß3 subunits of the nicotinic 
receptor (Figure 13).  Each figure shows the results for our three populations, AFR, ASN and 
EUR, in a separate histogram.  The positions of relevant SNPs demonstrated in GWAS studies to 
be associated with risk for (Bierut et al., 2008; N. L. Saccone et al., 2009; S. F. Saccone et al., 
2007; Spitz et al., 2008; Thorgeirsson et al., 2008; Weiss et al., 2008) or protection from (Hoft et 
al., 2009; Rice et al., 2012; S. F. Saccone et al., 2007; Zeiger et al., 2008) nicotine dependence 
are shown at the bottom of the histogram for the nicotinic receptor loci.  We have included on 
these figures rs1051730, a synonymous change, in CHRNA3 as it is in the same LD bin as 
rs16969968 and has in the past had significant p-values, although here it does not quite reach the 
cutoff threshold. 
 
Controls.  Ten 10 kb intergenic regions served as our controls.  As shown in Figure 10, 
most of the values fall between -1.5 to 1.5, with few exceptions, mostly in the ASN population.  
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Overall, the proportion of sliding windows with extreme Tajima’s D values in the control, 
intergenic regions was less than 2% in all our populations (Table 16).  The ASN population had 
the highest proportion of extreme Tajima’s D values with 1.7%, followed by EUR with 1.1% and 
AFR with 0%.  
 
Figure 10.  Histogram of the frequencies of Tajima’s D values in each population for the ten 10 
kb control regions. 
 
 For our positive control we used the LCT gene.  LCT encodes the protein, lactase, and 
mutations in the region give rise to lactase persistence.  The lactase persistence phenotype is 
actually due to changes in a regulatory region that enhances the expression of LCT.  This 
enhancer is located in intron 13 of the neighboring gene, MCM6 (Jones et al., 2013).  Multiple 
SNPs have been found to be enhancers in different populations.  We have marked the most 
common SNP, rs4988235, on the figures. Thus, we examined both genes in this region for 
evidence of selection.  As can be seen from Figure 11, both the ASN and EUR populations 
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proportion of windows with extreme values was 8.6 %.  The corresponding value for Asians was 
6.5 % (Table 16).  Essentially all of these values were extreme on the positive, rather than the 
negative, side.  These values are significantly different than the relevant negative controls 
(p=1.2x10-15 and p=4.2x10-8 for EUR and ASN, respectively) and are consistent with the 
occurrence of balancing selection or an ongoing sweep at the LCT locus in the EUR and ASN 
populations.   
 In contrast to what was seen with EUR and ASN, the histogram for AFR shows few 
windows with extreme Tajima’s D values.  Indeed, the proportion of windows with extreme 
values was <1% and was not significantly different from the negative controls.  This indicates a 
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CHRNA3-B4-A5.  We next applied the Tajima’s D test to the CHRNA3-B4-A5 gene 
cluster on chromosome 15.  In this region, we analyzed a 120 kb stretch of DNA from bp 
78,840,000 to 78,960,000, which includes the nicotinic receptor cluster as well as ~18 kb 
upstream.  This was done to ensure that we included the large region upstream of the cluster that 
has been associated with regulation of the level of expression of the receptors (J.-C. Wang et al., 
2013).  We refer to this as the CHRNA3-B4-A5 region even though it encompasses sequence 
outside of the nicotinic receptor genes proper. 
 Figure 12 shows the distribution of Tajima’s D values in the sliding windows in the 
CHRNA3-B4-A5 region in AFR, ASN and EUR.   As can be seen from the figure, all three 
populations showed numerous windows with extreme values, though the distribution of these 
windows differed somewhat among the different populations, reflecting population differences in 
LD.  Overall, 2.3% of the sliding windows in the AFR population showed extreme Tajima’s D 
values (Table 16), with all of them being positive.  This represents a significant difference from 
the negative control for the AFR population (p=2.8x10-8).  Noteworthy is the observation that in 
AFR, these extreme positive values were concentrated almost exclusively in CHRNA3 or the 
intergenic region between CHRNA3 and CHRNB4. This is interesting given the fact that 
rs1051730, a synonymous change in CHRNA3, has often had equally strong associations with 
nicotine dependence as rs16969968, leading some to wonder about the true importance of this 
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 The ASN population also had a significant concentration of extreme positive Tajima’s D 
values in the CHRNA3 and the intergenic region between CHRNA3 and CHRNB4.   In the ASN 
population, 7.1% of the windows overall exhibited extreme values (Table 16), which was again 
significantly different from the relevant negative controls (p=1.4x10-9). 
Table 16. 
Summary of extreme Tajima’s D values in Each Region in Comparison with Negative Controls 
P-values are from a Fisher’s Exact Test comparing each population for each genic region to the 
negative control values for that same population.  Significant p-values indicate a value that is 
significantly different than the negative controls.   
 
 In the EUR, 13.6% of the sliding windows had extreme Tajima’s D values (Table 16), 
again with the majority being extreme in the positive direction.  This is significantly different 
than the negative control for the EUR population (p=2x10-16) (Table 16).  Unlike AFR and ASN, 
in which the extreme Tajima’s D values were concentrated in CHRNA3 or the intergenic region 
between CHRNA3 and CHRNB4, EUR showed sliding windows with extreme positive Tajima’s 
D values more evenly distributed throughout the region examined, although some windows of 
extreme values were found in CHRNA3 that overlapped with similar blocks in AFR and ASN.   
 Two main LD bins in this region have previously been shown to be associated with risk 
for nicotine dependence.  The first is a large bin of ~86 kb that includes rs16969968, which has 
been shown in GWAS studies to exhibit the most significant association with risk of nicotine 
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dependence in the entire genome.  As previously mentioned, rs16969968 yields a non-
synonymous change in the gene encoding the α5 subunit of the nicotinic receptor on 
chromosome 15 that gives rise to a decrease in the binding affinity of the α5 receptor for nicotine 
and acetylcholine (J. C. Wang et al., 2009; J.-C. Wang et al., 2013).  This SNP is found at a 




Tajima’s D Statistics on SNPs in First LD Bin on Chromosome 15 
 
Tajima’s D ranges for all SNPs in the genome-wide significant LD bin on chromosome 15 
tagged by rs16969968 associated with increased risk of nicotine dependence.  Significant values 
are bolded and highlighted in yellow. 
 
As shown in Table 17, this SNP lies in a window of extreme Tajima’s D values for the  
EUR population.  A second SNP in this LD bin, rs12914385, is also located in a block of 
Tajima’s D values >2 in EUR.  An adjacent SNP in this same LD bin, rs1317286, is located in a 
block of sliding windows that show extreme positive Tajima’s D values in ASN.  No SNPs in 
this LD bin were in regions of extreme Tajima’s D values, consistent with the lower overall 
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signal for selection in this region in AFR.  Together, these data are consistent with the possibility 
that selection at these SNPs related to risk of nicotine dependence may contribute to the signal 
for selection seen at these locations in EUR and ASN.  Because the extreme Tajima’s D values in 
this bin are positive, we can conclude that at least in EUR, there has been recent balancing 
selection in the region of rs16969968.   
 A second LD bin in this cluster is tagged by rs588765 (see Figure 12).  The minor allele 
of rs588765 is associated with decreased mRNA expression of CHRNA5 and a decreased risk for 
nicotine addiction (J. C. Wang et al., 2009).  Other SNPs in this LD bin are listed in Table 18.  
Nearly all of them are in introns of either CHRNA5 or CHRNA3, suggesting they affect splicing 
or expression, not the function of these subunits. 
Within the EUR population, 5 SNPs in this bin, including 3 consecutive SNPs correlated 
to CHRNA5 were in windows with extreme Tajima’s D values (Table 18).  Two additional SNPs 
in this bin were also found in regions with high Tajima’s D values in EUR, specifically 
rs6115470 and rs2869546.  This latter SNP, rs2869546, which is in an intron of CHRNA3, had an 
extreme value in all three populations examined.   This SNP is classified as a DNase 
hypersensitivity site in B-lymphocyte, medulloblastoma and neuroblastoma cell types.  All 
Tajima’s D values were extreme in the positive direction, suggesting that balancing selection, 
focused on gene expression, may be occurring at this locus across all populations. 
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Table 18 
Tajima’s D Statistics on SNPs in Second LD Bin on Chromosome 15 
 
Tajima’s D ranges for all SNPs in the genome-wide significant LD bin on chromosome 15 
tagged by rs588765 and associated with decreased risk of nicotine dependence.  Significant 
values are bolded and highlighted in yellow. 
 
There is a third, smaller LD bin in this region, whose SNPs are also associated with 
CHRNA5 expression (J. C. Wang et al., 2009).  However, we did not explore this LD bin here 
due to the fact that after correcting for the first, larger bin associated with CHRNA5 expression, 
this third bin was no longer significant.   
CHRNB3-A6.  For the CHRNB3- A6 region, we examined a rather larger segment of the 
genome upstream of the gene cluster.  This was done so as to include several upstream SNPs that 
have previously been shown to exhibit associations with nicotine dependence or cocaine 
dependence (Sadler et al., 2014).  Thus, we have included from bp 42,520,000 to 42,630,000. 
 Figure 13 shows the histogram of Tajima’s D values across the sliding windows in the 
CHRNB3-A6 region.  In AFR, there were several windows with extreme Tajima’s D values 
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While the overall proportion of sliding windows with extreme values was only 2.1% in AFR 
(Table 16), this was nonetheless significantly different than the relevant negative control 
(p=2.4x10-7).   
 EUR also exhibit a cluster of sliding windows showing extreme positive Tajima’s D 
values just upstream of CHRNB3 and overlapping with that cluster in AFR.  There was also a 
cluster of positive iHS values in the same intergenic region between CHRNB3 and CHRNA6 as 
seen in AFR.  However, over the entire region, there was no significant difference from the EUR 
negative control (Table 16).  While ASN did have a region of positive Tajima’s D values 
upstream of CHRNB3, none of the sliding windows were in the “extreme” range and overall, 
there was no significant difference between this locus and the negative controls (Table 16). 
 Overall, the evidence for selection is weak in this cluster.  However, the concentration of 
windows with extreme Tajima’s D values upstream of CHRNB3 is noteworthy in the context of 
risk for nicotine addiction.  A GWAS study by Rice et al. (Rice et al., 2012) found that a SNP in 
this region, rs1451240, was associated at the genome-wide significant level with protection from 
nicotine dependence using the score on the Fagerstrom Test for Nicotine Dependence (FTND) as 
the phenotype.  The LD bin tagged by rs1451240 spans ~66 kb and several other SNPs in this 
bin have been associated with protection from nicotine dependence, although no others are 
significant at the genome-wide level (Rice et al., 2012).  The data in Table 19 show that in EUR 
and AFR, four adjacent SNPs from this LD bin, including rs1451240, were present in sliding 
windows with extreme Tajima’s D values.  These data suggest that these SNPs associated with a 
nicotine dependence phenotype may be undergoing balancing selection or positive selection in 
these two populations. 
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Table 19 
Tajima’s D Values for GWS LD bin on Chromosome 8 Associated with Nicotine Dependence 
 
Tajima’s D ranges for all SNPs in the genome-wide significant LD bin (r2 = 0.9) on 
chromosome 8 tagged by rs1451240 and associated with decreased risk of nicotine dependence.  
Significant values are bolded and highlighted in yellow. 
 
Integrated Haplotype Score (iHS) Analyses.  iHS is a measure of whether a SNP is on 
an unusually long haplotype carrying the ancestral or derived allele.  In other words, it compares 
the rate of haplotype decay between haplotypes carrying either the ancestral or derived allele at a 
given site, called the core SNP.  Haplotypes whose core SNP is under selection will be unusually 
long compared to those evolving neutrally. Long haplotypes with derived alleles are indicated by 
negative iHS values and those with ancestral alleles are indicated by positive iHS values.  Under 
neutrality, extreme scores are distributed throughout the genome, however under selection, they 
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are clustered across the selected region (Voight et al., 2006).  iHS can be clearer than Tajima’s 
D, but also somewhat nuanced to work with because of the dependence on local recombination 
rate.  However, it is a good method for detecting directional selection, especially in a sweep that 
is in its early phases. We used the program WHAMM to calculate this statistic (Voight et al., 2006).   
Candidate regions of positive selection were defined as genomic regions containing an 
uncharacteristic clustering of SNPs with high iHS statistics.  A high iHS score was defined as an 
|iHS| > 2, as this corresponds to the top ~5% of all scores.  This was quantified as the proportion 
of SNPs with |iHS| > 2 in the four regions of interest.  The iHS value at a SNP  “measures the 
strength of evidence for selection acting at or near that SNP”, however, it does not provide a 
formal significance test (Voight et al., 2006). 
Controls.  Our negative controls for the iHS analysis were the same 10 inter-genic 
regions used as negative controls in the Tajima’s D analyses.   The histograms for these regions 
are shown in Figure 14 and the data are summarized in Table 20.  For this analysis, AFR had the  
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Table 20 
Summary of Extreme iHS Values in Each Region in Comparison with Negative Controls 
Proportion of extreme his values within the three regions sampled, including intergenic regions, 
as well as the control regions.  P-values are from a Fisher’s Exact Test comparing each 
population for each genic region to the negative control values for that same population.  
Significant p-values indicate a value that is significantly different than the negative controls. 
 
 
We again used LCT/MCM6 as our positive control.   Figure 15 shows the histograms of 
iHS values in the LCT/MCM6 region for EUR, ASN and AFR populations.  The AFR population 
shows few extreme values (only 3.2%) and this does not differ significantly from the negative 
control.  Likewise, in ASN, there are few windows of extreme values although in total, the 
number is different from the negative control (Table 20).  In EUR, the overall average proportion 
of extreme values for this region is 80.4%.   This high proportion of extreme values in genic 
regions is evident from the histogram.  The clustering of extreme iHS values in the genic areas of  
this region is consistent with what is known about large-scale positive selection at this locus in 
the EUR population (Jones et al., 2013).  This demonstrates the validity of this approach for 
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CHRNA3-B4-A5.  Figure 16 shows the histogram of iHS values across the 
CHRNA3-B4-A5 locus on chromosome 15.  The summary statistics are given in Table 20.  
Among the 3 populations studied, none showed a proportion of extreme iHS values that 
was significantly different from the relevant negative control.  In addition, none of the 
windows with extreme values included any of the SNPs previously found to be associated 
with nicotine dependence (Tables 21 and 22). 
Table 21 
iHS Values for SNPs in First LD Bin on Chromosome 15 
iHS values for all SNPs in the genome-wide significant LD bin on chromosome 15 
associated with increased risk of nicotine dependence.  Significant values are bolded and 
highlighted in yellow. 
 
 Voight et al. (Voight et al., 2006) have previously shown that there is definite 
clustering of extreme iHS values in regions where SNPs show evidence of selection.  In 
our analyses, there was some clustering of extreme iHS values in CHRNA5 in the AFR 
population.  In this group, there are 5.6% extreme values when the entire CHRNA3-B4-
A5 cluster is considered but 18.7% extreme values for the CHRNA5 genic region.  The 
latter value is significantly different than the negative control, suggesting that this gene 
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may be undergoing selection.  Unfortunately, none of the SNPs previously associated 
with nicotine dependence were in windows that showed extreme iHS values so the data 
do not address the question of whether the selection is related to nicotine addiction 




iHS Values for SNPs in the Second LD Bin on Chromosome 15 
 
 
iHS values for all SNPs in the genome-wide significant LD bin on chromosome 15 
tagged by rs588765 and associated with decreased risk of nicotine dependence.  
Significant values are bolded and highlighted in yellow. 
 
CHRNB3-A6.  Figure 17 shows a histogram of the iHS values for the CHRNB3-
A6 cluster on chromosome 8.  The summary statistics are shown in Table 20.  As can be 
seen in the figure, the AFR population shows a cluster of extreme iHS values with a 
highly significant overall proportion of 26.1% extreme values in this genetic region 
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A6 locus on chromosome 8 shows evidence for ongoing selection in the AFR population.    
By contrast, in the ASN population, there were few windows of extreme iHS scores and 
the overall proportion was not significantly different from the negative control.   
Yet a third pattern was observed in the EUR population.  As in AFR, there was a highly 
significant overall proportion of extreme iHS values (23.6%) in EUR (Table 20).  Some 
clustering was observed in the region just upstream of CHRNB3, however, in EUR the 
extreme values were somewhat more dispersed throughout the CHRNB3-A6 region.  This 
clustering of extreme his values upstream of CHRNB3 is of high interest as this same 
region showed extreme values in the Tajima’s D analysis. 
As noted previously, an LD bin in this region tagged by rs1451240 has been 
shown in a GWAS study to be significantly associated with a decreased risk of nicotine 
addiction (Rice et al., 2012).  Table 23 lists the SNPs in this LD bin and provides the iHS 
value for the window that contains that SNP.    SNPs with an absolute value of iHS >2 
(and hence an extreme value) are in bold and highlighted in yellow.  In the EUR 
population, 13 SNPs in this LD bin, including the tag SNP, rs1451240, are in regions 
with an extreme iHS value.  All but one have positive values, indicating the presence of 
unusually long haplotypes containing the ancestral allele.  This suggests that the ancestral 
allele, which is associated with a greater risk of nicotine dependence, or one that is 
hitchhiking with it, is being favored by selection. 
 Several lines of evidence suggest that an increased risk for nicotine dependence 
is associated with a reduced risk of cocaine addiction and vice versa (Grucza et al., 2008; 
Levine et al., 2011; Sadler et al., 2014).  We therefore also examined an LD bin in the 
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Table 23 
iHS Values for GWS LD Bin on Chromosome 8 Associated with Nicotine Dependence 
 
iHS values for all SNPS in the genome-wide significant (GWS) LD bin (r2 = 0.9) on 
chromosome 8 tagged by rs1451240 and associated with a decreased risk of nicotine 
dependence.  Significant values are bolded and highlighted in yellow. 
 
CHRNB3-A6 region bin that has been shown to have SNPs significantly associated with 
increased risk for cocaine dependence (Sadler et al., 2014).  This bin is fairly large and 
spans the entire CHRNB3-A6 cluster.  It contains rs4952 and rs4953, two low frequency 
synonymous variants in CHRNB3 that have previously been reported to be associated 
with a reduced risk for nicotine dependence (S. F. Saccone et al., 2007).  All SNPs in the 
bin are present at around 10% in AFR and 4% in EUR but absent in ASN.   
We used the tag SNP from Sadler et al. (2014) - rs9298626 – and included all 
SNPs with a correlation (r2) of 0.9 or higher.  The data in Appendix C demonstrate that 
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although rs9298626 itself did not have an extreme iHS value, multiple SNPs in LD with 
rs9298626 do.  Overall, 40% of the SNPs in this bin showed extreme values in AFR and 
15% of the SNPs in this bin showed extreme values in EUR.   As these SNPs are absent 
from the ASN population, none showed extreme iHS values. The dense clustering of 
extreme iHS values in AFR and EUR is a definite indicator that this region is undergoing 
selection in these populations. 
In EUR, all 9 of the SNPs with extreme iHS values were extreme in the positive 
direction and all were shared with AFR.  Thus, in both populations, the ancestral allele 
with decreased risk for cocaine addiction is being favored.  This is consistent with the 
low frequency of these SNPs in these populations.  These data suggest that these SNPs 
were present in the population that traveled out of Africa to Europe and that both AFR 
and EUR have continued to select for the ancestral allele.   The absence of these SNPs 
from the ASN population is consistent with the possibility that the population that 
migrated to Asia either lacked the SNPs initially or underwent a bottleneck that removed 
the SNPs from the gene pool.  The AFR population exhibited an additional 13 SNPs with 
extreme iHS values, both positive and negative, suggesting that there are a variety of 
alleles, ancestral and derived, that tag the selected haplotype.  
Ka/Ks ratio.  The Ka/Ks ratio is a way of comparing selective pressures at 
homologous genes.   When non-synonymous (Ka) and synonymous (Ks) substitution 
rates are equal, their ratio = 1, and this is indicative of neutral evolution.  However, if the 
Ka/Ks ratio is less than one, this indicates purifying or stabilizing selection.  If the Ka/Ks 
ratio is greater than one, this is indicative of positive selection (Zhang et al., 2006).   
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Here we compare the human and chimpanzee sequences for the nicotinic 
receptors to test for evolution.  In this analysis, the null hypothesis is Ka=Ks.  We can 
reject the null hypothesis if Ka is significantly greater or less than Ks, as indicated by the 
p-value for the associated Fisher Exact test.   
Table 24 
Ka/Ks Ratio for all CHRN Genes Examined 
 
Ka/Ks ratio for all genes examined, including the LCT positive control and significance 
of the ratio according to Fisher Exact test. 
 
Table 24 shows the Ka/Ks ratio for all the nicotinic receptor genes (CHRNB3, 
CHRNA3, CHRNA6, CHRNB4 and CHRNA5) plus LCT as the positive control.  As 
Ka/Ks can only be calculated for protein coding regions, there are no data for the 
intergenic negative controls.  For all the genes examined, the Ka/Ks ratio was less than 1, 
indicating fixation of more synonymous than non-synonymous substitutions and thus 
describing a situation in which there is purifying or stabilizing selection.  Our positive 
control, LCT had the highest Ka/Ks ratio of 0.466, which was nonetheless still significant 
(p=2.29x10-2).  This relatively weak signal may be due to the fact that it is the expression 
of lactase that is under selection rather than the protein sequence itself.  
Among the nicotinic receptors, CHRNB3 appears to be under the strongest 
stabilizing selection, as its Ka/Ks ratio is nearly zero and the Fisher p-value (p=1.12x10-4) 
indicates this is highly significant.  CHRNA3 and CHRNA6 are similar with a Ka/Ks ratio 
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of 0.113 (p=7.20x10-4) and 0.134 (p=2.29x10-4), respectively.   CHRNB4 has a slightly 
higher ratio of 0.393 (p=6.79x10-3), but this still appears to be significant.  Of all the 
CHRN genes, only CHRNA5 has a Ka/Ks ratio that is not significantly different from 1 
(Ka/Ks =0.462, p=0.125).  
Thus, all but one of the nicotinic genes are undergoing stabilizing selection 
according to this metric.  As this comparison is between human and chimp, it is expected 
that some selection would have been occurring.  However, it is interesting that the 
selection is working to maintain the “ancestral” chimp sequence. 
Nicotine addiction and cognitive function.  The Tajima’s D analysis, integrated 
haplotype score and Ka/Ks ratio all indicate that the CHRNB3-A6 cluster is undergoing 
selection and in particular, the iHS scores suggest that it is the risk allele for nicotine 
dependence on chromosome 8 that is being selected for.  As it seems unlikely that risk of 
nicotine dependence is the phenotype undergoing selection, and because nicotinic 
receptors are involved in memory and learning, we hypothesized that a phenotype related 
to memory or learning, such as attention, might be the phenotype being selected. 
To test this possibility, we obtained data on genotype and cognitive phenotype 
from the Collaborative Study of the Genetics of Alcoholism (COGA).  Using this dataset, 
we tested the association between genotype and three of the most relevant phenotypes, 
namely scores on Wechsler Adult Intelligence Scale (WAIS) Block Design, WAIS Digit 
Symbol and WAIS Information tests.   
 In WAIS Block Design, the subject replicates models or pictures of two-color 
designs with blocks.  In WAIS Information, the subject answers a series of questions 
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about factual information.  In WAIS Digit Symbol, the subject writes down as quickly as 
possible the symbols that correspond to a series of numbers.   
 
Table 25 
SNP Association with Scores on WAIS Digit Symbol Test 
 
Beta, standard error and p-value for all SNPs in CHRNB3-A6 region of the COGA family 
GWAS and their association with scores on the WAIS Digit Symbol test.  Covariates 
used were age, sex and FTND score. 
 
Table 25 summarizes our findings.  Of the 17 SNPs in the CHRNB3-A6 region on 
chromosome 8, one SNP – rs7017612 - passed multiple test correction (p<0.003) for 
association with score on WAIS Digit Symbol (β=0.43, p=0.003).  Specifically, this test 
consists of nine pairs of digits and symbols (e.g. 1/-, 2/X….9/*). This is followed by a list 
of digits, under which the person must write the corresponding symbol as fast as they 
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can, and the number of correct responses within a time limit is measured (Salthouse, 
1992). After this, paired and free recall of the symbols is measured.  As shown in Figure 
17, rs7017612 lies in the intergenic region between CHRNB3 and CHRNA6.  This SNP 
has an r2 of 0.75 and a D’ of 0.95 with rs6474413, a SNP tagging the genome-wide 
significant bin for decreased risk for nicotine dependence.  These data suggest a modest 
association between genotype at these SNPs and cognitive function.  We also repeated 
the analysis using CPD as a covariate instead of FTND in order to measure consumption 
rather than case/control status.  The p-values were essentially the same. 
A second SNP in the CHRNB3-A6 region– rs6982753- had a nominal p-value 
with the WAIS Digit Symbol phenotype before multiple test correction and almost passed 
the multiple test correction (p=0.009).  Interestingly, this SNP has an r2 of 0.91 with 
rs892413 (β=0.39, p=0.008), a SNP that has previously been associated with increased 
risk for cocaine dependence (Sadler et al. 2014).   
No other neurocognitive phenotypes besides WAIS digit symbol had SNPs with 
significant values in the CHRNB3-A6 region and none of the three neurocognitive 
phenotypes had a significant association with SNPs in the region of CHRNA5-A3-B4 on 
chromosome 15 (not shown).   
DISCUSSION 
 It is clear from a variety of studies that the risk of nicotine addiction has a genetic 
component.  The question is why such a phenotype would exist and possibly be selected 
for in a population.  Selective pressures in our ancestral environments were likely not on 
addiction, but rather on behaviors that were biologically rewarding (i.e. mate or food 
finding, avoidance of harmful stimuli).  Given the role of nicotine in neurological 
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function, it is possible that, in the case of nicotine addiction, the phenotype on which 
natural selection was working was related to enhancements in memory or cognition.  The 
addiction phenotype would have hitchhiked along because it acts through the same or 
related mechanisms.  The addiction phenotype was likely not selected against in ancestral 
environments because the availability and opportunity for prolonged use of purified drugs 
was negligible. 
In this study, we sought to address this question of the evolution of nicotine 
addiction by first determining whether the genes for the nicotinic receptor subunits show 
evidence of ongoing selection and then by determining whether any SNPs in these genes 
might be associated with a phenotype associated with memory or cognition.  We 
performed three different tests of selection on chromosomal regions containing the genes 
for five subunits of the nicotinic receptor and all three of these analyses indicate that 
selection is occurring at the CHRNB3-A6 locus. 
ß3 and α6 are two of the 11 subunits (8 alphas and 3 betas) that combine to form 
the pentameric nicotinic cholinergic receptor.   There are two major subtypes containing 
these receptors: α6α4β2β3 and α6β2β3.  Almost all β3 receptor subunits occur in the 
presence of α6, forming the complex α6α4β2β3 subtype (Gotti et al., 2005).  However, 
α6β2β3 accounts for only ~ 40-60% of all α6-containing receptors (Gotti et al., 2007).    
ß3 mRNA has a limited expression pattern, with high levels being seen in the 
substantia nigra, medial habenula, ventral tegmental area and thalamus in the brain 
(Drago et al., 2003).  Interestingly β3-containing CHRNs appear to play a significant role 
in dopaminergic neurotransmission (Cui et al., 2003).  β3 null mice have altered 
locomotor activity and prepulse inhibition of acoustic startle (presentation of a tone prior 
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to an acoustic stimulus).   Both of these behaviors are partially mediated by dopaminergic 
pathways, suggesting a relationship between ß3 and the pathways known to mediate drug 
addiction. 
 α6 mRNA is mainly expressed in the substantia nigra, vental tegmental area and 
locus coeruleus, and to a lesser extent in the retina and thalamic reticular nucleus.  In all 
these regions, it co-localizes with β3 mRNA (Gotti et al., 2007).  CHRNA6 receptors are 
highly and selectively expressed by mesostriatal dopamine neurons that mediate the 
behavioral effects of nicotine such as habit learning and reinforcement (Gotti et al., 
2010).  Selective expression of α6* nAChRs in monkey striatum suggests that the 
α6β2β3, α6α4β2β3, and α3β2* nAChR subtypes are present on dopaminergic terminals 
(Quik et al., 2005). Thus, like ß3 subunits, the a6 subunits appear to be involved in the 
regulation of dopaminergic pathways associated with drug addiction. 
 Both the Tajima’s D test and iHS point to an ongoing sweep in humans on 
chromosome 8.  In the case of the CHRNB3-A6 locus, all of the extreme values in the 
Tajima’s D analysis were positive.  High positive Tajima’s D values occur when there is 
an excess of variants in a region with intermediate allele frequencies.  This can occur in 
either balancing selection or ongoing positive selection.   We also found extreme iHS 
values in the CHRNB3-A6 locus.  This is the only CHRN region to fulfill the criteria for a 
sweep laid out in Voight et al. (Voight et al., 2006), i.e. clustering of extreme iHS values.  
iHS values are only extreme in the presence of positive selection.   Together, these data 
imply that the Tajima’s D analysis is picking up on ongoing positive selection rather than 
balancing selection.   
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Several SNPs in the CHRNB3-A6 locus on chromosome 8 have previously been 
associated with a decreased risk of nicotine dependence (Rice et al., 2012).  One of these, 
rs1451240, was present in a window that showed extreme values in both the Tajima’s D 
test and iHS. The extreme positive iHS value in the window including rs1451240 
indicates that the haplotype containing the ancestral allele is being selected.  As the 
derived allele provides protection from nicotine addiction, this suggests that it is the allele 
that is associated with a greater risk of nicotine dependence that is being selected for.   
Since highly concentrated sources of nicotine were not present in the ancestral 
environment, it seems likely that this phenotype of nicotine dependence would have 
hitchhiked along with a more beneficial phenotype, such as improved memory or 
cognition. 
To test this possibility, we assessed the association of SNPs in the CHRNB3-A6 
locus with scores on WAIS tests of memory and cognitive function.  Our analysis of the 
individuals in the COGA dataset suggests that one SNP, rs7017612, that lies in the 
intergenic region between CHRNB3 and CHRNA6, is associated with increased score on 
the WAIS Digit Symbol test.  This test is thought to measure largely processing speed, 
but also, to some extent, memory.   rs7017612 itself has not been associated with nicotine 
dependence.  However, it is in reasonable LD (r2 = 0.75) with rs6474413, a SNP tagging 
the genome-wide significant bin for decreased risk for nicotine dependence.  Thus, our 
data are consistent with the possibility that improved performance on this particular 
cognitive test is modestly associated with a decreased risk for nicotine dependence. 
This conclusion is contrary to the bulk of our results relating to the direction of 
selection bias on the CHRNB3-A6 locus.  Our results largely suggest that positive 
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selective pressure is being exerted on the ancestral allele, which does not provide 
protection against nicotine dependence.  This suggests that another mechanism may exist 
to explain the apparent selection for SNPs that fail to confer an obvious selective 
advantage. 
 Genetic studies of nicotine addiction have identified an inverse relationship 
between the risk for nicotine addiction and the risk for cocaine addiction.  A variant in 
the gene for the α5 subunit of the nicotinic receptor, rs16969968, that enhances risk for 
the development of nicotine dependence, independently decreases risk for cocaine 
dependence as well (Grucza et al., 2008).  This finding was replicated in a subsequent 
study (Sherva et al., 2010).  My studies have identified a similar inverse relationship 
between the risk for nicotine and cocaine addiction conferred by SNPs in the CHRNA6-
B3 locus on chromosome 8 (Sadler et al., 2014).  
Consistent with a functional relationship between cocaine and nicotine, Levine et 
al. (Levine et al., 2011) showed that the use of cocaine among smokers increases the risk 
of becoming dependent on cocaine.  These workers further showed that pretreatment of 
mice with nicotine increased the response to cocaine, particularly in the striatum, a brain 
region involved in addiction-related reward, where α6ß3 containing nicotinic receptors 
are expressed.  Thus, an enhanced responsiveness to nicotine would prime the user to the 
potentiating effect of cocaine on addiction-related reward pathways.  Presumably, a 
decreased responsiveness to nicotine would limit the effect of cocaine on addiction-
related reward. 
Cocaine addiction is characterized by a dampened reward response to social 
interaction, meaning that it inhibits the positive emotions that accompany social 
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interaction or feelings of belonging.  A recent study demonstrated that cocaine users 
process social gaze (joint attention on an object) differently than controls, resulting in a 
reduced activation of the reward system during social interactions (Preller et al., 2014).   
Using fMRI, these authors showed that cocaine users had decreased activation of the 
medial orbitofrontal cortex, a region of the brain central for reward processing.  These 
observations could explain why alleles that protect against cocaine dependence could be 
under positive selection. 
Humans have an evolutionary need to form connections with each other, and as 
such, social bonding is adaptive and rewarding.   The opposite, social isolation, is 
maladaptive and painful (Verdejo-Garcia, 2014).   Selecting against the risk for cocaine 
addiction would maximize the likelihood that individuals would maintain their reward 
system for social interaction.  This would benefit both the individual and the group.  
Since nicotine sensitizes the animal to the effects of cocaine, which blunts the reward of 
social interactions, alleles that reduced the ability of nicotine to enhance the effects of 
cocaine would have undergone positive selection.  In this scenario, the nicotine 
dependence phenotype is not hitchhiking with memory or learning phenotypes, but rather 
with phenotypes protecting against antisocial and therefore maladaptive behavior. 
 Like nicotine, a source of highly concentrated cocaine was likely not present in 
the ancestral environment.  Coca, the most abundant source of cocaine, is native to South 
America and therefore would not have been available to our early hominid ancestors in 
Africa.  However, other stimulants, such as the amphetamine derivatives present in khat, 
would have been available in the ancestral environment and several lines of evidence 
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suggest that nicotine has a similar relationship with amphetamines as it does with 
cocaine.   
Work from several groups suggests that, as with cocaine, nicotine potentiates the 
behavioral effects of amphetamine (Jutkiewicz, Nicolazzo, Kim, & Gnegy, 2008; Santos, 
Marin, Cruz, Delucia, & Planeta, 2009). Furthermore, humans express an endogenous 
neuropeptide known as CART (cocaine- and amphetamine-regulated transcript) (Jaworski 
& Jones, 2006).  Expression of CART is highly upregulated in response to either cocaine 
or amphetamines and it acts to suppress the effects of both of these drugs, both of which 
act to enhance the levels of dopamine in the brain (Subhedar, Nakhate, Upadhya, & 
Kokare, 2014).  Finally, administration of either cocaine or amphetamines enhances the 
release of acetylcholine (Imperato et al. 1993).   The latter observation provides a 
physiological link between these drugs and nicotinic receptors.    
It is possible that there is a positively reinforcing cycle between nicotine and a 
variety of drugs, including but perhaps not limited to, cocaine and amphetamines.  Excess 
nicotinic receptor stimulation, either by nicotine or the endogenous ligand, acetylcholine, 
in a highly responsive receptor, would enhance the effects of cocaine or amphetamines.  
This would make the individuals more susceptible to addiction by drugs that impair the 
rewards of social interactions, a negative trait when survival depends on the entire group 
contributing to the procurement of food and defense against intruders.   Thus, SNPs that 
limit the efficacy of acetylcholine (or nicotine) for enhancing addiction to drugs that lead 
to anti-social behavior, without markedly diminishing cognitive function, could represent 
a trait for positive selection in a social group.  
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While not as compelling, there was nonetheless some evidence for selection at the 
CHRNA3-B4-A5 locus.  In particular, rs16969968, the SNP that encodes the missense 
mutation in α5 that is strongly associated with risk of nicotine dependence, lies in a 
sliding window exhibiting a high Tajima’s D score.   However, the iHS analysis of this 
locus did not provide evidence for selection.  Although the evidence for selection at the 
CHRN cluster on chromosome 15 was less convincing, it would be interesting to extend 
the integrated haplotype score (iHS) analyses another ~110 kb upstream from CHRNA5 
through IREB2.  SNPs in IREB2 are in the LD bin that contains rs16969968.   IREB2 is 
an iron-responsive element binding protein that regulates iron homeostasis.  Knockout of 
this gene in mice results in behavioral abnormalities and neurodegeneration.  IREB2 is of 
interest as Johnson/Sadler et al. (in preparation) find evidence for an association between 
IREB2 transcript levels and rs141518190, a SNP intronic to CHRNA3, in African-
Americans. The data suggest that rs141518190 acts as a cis-eQTL for IREB2, linking this 
SNP in CHRNA3 to an important neurological phenotype. 	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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
Evolutionary explanations of addiction have focused on the idea that addictive 
drugs are habit forming because they act on the dopaminergic brain circuits that mediate 
natural and biologically significant rewards of evolutionarily beneficial behaviors (Nesse 
& Berridge, 1997).  The hypothesis that drug use may be adaptive in specific cases is 
perhaps most plausible for the most commonly used drugs, nicotine and caffeine, since 
the use of these drugs is patterned in ways that would be predicted if adaptive use is 
assumed.   For example, groups under greater physical and emotional stress appear to use 
these drugs more often, just as the adaptive model would suggest.  Some have argued that 
humans and psychotropic plants, including tobacco, could have a co-evolutionary 
relationship that is millions of years old, and posited that humans have eaten plants to 
obtain neurochemicals directly to reduce foraging time (R. J. Sullivan & Hagen, 2002).  
Indeed, nicotine can suppress appetite and reduce fatigue (Pomerleau, 1997), allowing 
more effective foraging.  
While it is generally agreed that drug use must be adaptive in some way, to date 
there have been no attempts to uncover evidence for natural selection in genes 
specifically related to addiction.   And few studies have examined the relationship 
between SNPs in genes that correlate with addiction phenotype and any 
neuropsychological phenotypes that could be the true targets of natural selection.  The 
work reported in this thesis has addressed this gap in our knowledge by looking at two 
loci associated with risk for nicotine dependence to seek an answer to the question of the 
evolutionary basis for the existence of genes for nicotine addiction. 
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Because the few SNPs that have been associated with nicotine dependence are in 
genes encoding nicotinic receptors or nicotine metabolizing genes, we initially undertook 
a GWAS of imputed data from the Collaborative Study of the Genetics of Nicotine 
Dependence (COGEND) dataset to look for genetic associations outside of the 
cholinergic receptor loci.  This work identified SNPs in micro RNAs and GPC5 that 
represent the first non-nicotinic receptor SNPs that are associated with elevated risk of 
nicotine dependence.   
 Currently, the genotyping situation on the GWAS performed in this work is less 
than ideal.  With most of the controls genotyped on the 1M SNP chip and most of the 
cases on the 2.5M SNP chip, the logical and conservative choice was to only impute from 
the intersection of these two platforms, which was approximately 600,000 SNPs.  This 
approach discards data on nearly 2 million SNPs for some subjects.  Future studies 
should re-genotype all of the subjects from the GWAS of imputed data on the 2.5M SNP 
chip to increase the number of SNPs from which to impute.  This would lead to increased 
accuracy of imputation, and may lead to additional discoveries of loci associated with 
nicotine dependence.  In addition, the GPC5 finding needs to be replicated in other larger 
independent datasets. 
 Our studies described in chapter 3 identify the second example of a SNP within a 
CHRN locus (rs9298626 on chromosome 8) that has opposing effects on nicotine and 
cocaine dependencies.  Conditional and haplotype analyses discovered that this effect on 
cocaine dependence was independent of previous effects on nicotine dependence, 
meaning that when you control for the known nicotine association, the association with 
cocaine is still significant.  To strengthen our conclusion, it would be useful to replicate 
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the finding on chromosome 8 in other datasets that have assessed cocaine and nicotine 
dependence phenotypes.  In addition, it would be interesting to analyze datasets of other 
ethnicities to determine if these results are unique to European-Americans or are 
generally true across all populations.  Because no underlying functional mechanisms in 
this region have been discovered to account for the association with either nicotine or 
cocaine, it would be interesting to use functional tests to determine functionally why 
these SNPs may have been under selection. For example, in brain tissue, DNase-seq 
assays could be run on those SNPs predicted to be DNase hypersensitivity sites and 
ChIP-seq assays could be run on SNPs predicted to affect transcription factor binding or 
histone marks.  While SNPs in these genes have been tested for their effect on expression 
and methylation in different types of brain tissues, nothing was found for SNPs in or 
upstream of CHRNB3 (Jen Wang, personal communication).  Finally, it would be 
interesting to further investigate the possible inverse relationship between nicotine 
dependence and cocaine addiction by determining the nicotine-dependence phenotype 
and genotype in individuals harboring mutations in the CYFIP2 gene recently shown to 
be associated with response to cocaine (Kumar et al., 2013).   
To determine if any variants previously related to nicotine dependence showed 
evidence that they were undergoing natural selection, we examined the nicotinic receptor 
genes on chromosomes 8 and 15 using three statistical tests of selection: Tajima’s D; 
integrated haplotype score (iHS); and, Ka/Ks ratio.  Most interestingly, we discovered 
evidence for positive selection on the ancestral alleles within the CHRNB3 region on 
chromosome 8.  These ancestral alleles are associated with risk for nicotine dependence 
but protection from cocaine dependence.    
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Our analyses of the association between nicotine dependence and neurocognitive 
features reported in Chapter 4 was more limited than we would have liked.  Because of 
the discrepancy between the number of people in the Collaborative Study of the Genetics 
of Alcoholism (COGA) dataset with neurocognitive data and the number with GWAS 
data available, we conducted our analysis on 492 individuals.  Even with this small 
dataset, we found a significant association between a SNP linked to risk of nicotine 
dependence and score on WAIS digit symbol.  In the future, it would be of interest to 
genotype the rest of the individuals with phenotypes (but no genotypes) to increase the 
sample size for the association analysis from 492 to 1247.  This might increase the 
strength of the association at the SNPs discovered in my analysis, or possibly lead to 
associations at new SNPs either on chromosome 8 or 15 with WAIS digit symbol, block 
design or information. 
  Given the modest association between performance on WAIS digit symbol and 
nicotine dependence, it is not possible to draw a strong conclusion regarding whether this 
represents a phenotype upon which selection might act.  However, our findings regarding 
the inverse relationship between nicotine dependence and cocaine dependence offer 
another possible explanation for the presence of SNPs conferring risk for nicotine 
dependence.  This possibility could be addressed by additional genetic studies of nicotine 
and cocaine addiction as well as nicotine and amphetamine addiction.  Further, the 
possible role of CART, (cocaine- and amphetamine-regulated transcript) as a genetic basis 
for cocaine and amphetamine addiction and a possible relationship to nicotine addiction 
should be investigated.  This is particularly true as Gelernter et al. (2007) have previously 
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identified a nicotine dependence risk locus on chromosome 5 that includes the CART 
gene.  
 There is still much work to be done in determining both genetic and evolutionary 
explanations for phenotypes.  Behavioral phenotypes are especially difficult in this 
respect, particularly in humans, because of complex cultural variables.  However, I 
believe that evolutionary explanations must be increasingly considered as genomic 
information becomes cheaper and easier to obtain. It is my hope that this work has added 
valuable insight to this field and will inspire others to build on this work or investigate 
evolutionary explanations for other behaviors. 
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APPENDIX B  
ASSOCIATION RESULTS FOR DSM-5 COCAINE USE DISORDER, DSM-5 
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APPENDIX C  
IHS VALUES FOR LD BIN ASSOCIATED WITH COCAINE DEPENDENCE ON 
CHROMOSOME 8 
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